

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
6 December 2001 (06.12.2001)

PCT

(10) International Publication Number
WO 01/92877 A2

(51) International Patent Classification⁷: **G01N 33/48**

TN 38103 (US). **SCHUETZ, John** [US/US]; 1442 Carr Avenue, Memphis, TN 38105 (US).

(21) International Application Number: PCT/US01/17459

(74) Agent: **JACKSON, David, A.**; Klauber & Jackson, 411 Hackensack Avenue, Hackensack, NJ 07601 (US).

(22) International Filing Date: 30 May 2001 (30.05.2001)

(25) Filing Language: English

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(26) Publication Language: English

(30) Priority Data:
09/584,586 31 May 2000 (31.05.2000) US
09/866,866 29 May 2001 (29.05.2001) US

(84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

(63) Related by continuation (CON) or continuation-in-part (CIP) to earlier application:
US Not furnished (CON)
Filed on 29 May 2001 (29.05.2001)

(71) Applicant (*for all designated States except US*): **ST. JUDE CHILDREN'S RESEARCH HOSPITAL** [US/US]; 332 North Lauderdale Street, Memphis, TN 38105-2794 (US).

Published:

— *without international search report and to be republished upon receipt of that report*

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): **SORRENTINO, Brian** [US/US]; 6590 Quail Point Circle North, Memphis,

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: METHOD OF IDENTIFYING AND/OR ISOLATING STEM CELLS AND PROGNOSING RESPONSIVENESS TO LEUKEMIA TREATMENT

(57) Abstract: The present invention includes methods of identifying and/or isolating stem cells based on expression of BCRP. The present invention also describes methods of obtaining and/or using cell populations enriched for stem cells. In addition, methods are provided for diagnosing and/or prognosing leukemia, particularly human acute myelogenous leukemia (AML), through assaying for BCRP expression in leukemic cells.



WO 01/92877 A2

**METHOD OF IDENTIFYING AND/OR ISOLATING STEM CELLS AND
PROGNOSING RESPONSIVENESS TO LEUKEMIA TREATMENT**

5

RESEARCH SUPPORT

The research leading to the present invention was supported in part by the National
Institutes of Health Grant No: PO1 HL 53749-04 and the Cancer Center Support
10 Grant P30 CA21765. The government may have certain rights in the present
invention. Support for this invention was also provided by the AMERICAN
LEBANESE SYRIAN ASSOCIATED CHARITIES and the ASSISI FOUNDATION
OF MEMPHIS INC.

15

FIELD OF THE INVENTION

The present invention provides a method of identifying and/or isolating stem cells.
The present invention also provides methods of using cell populations enriched for
stem cells. In addition, the present invention provides methods for diagnosing and/or
20 prognosing human acute myelogenous leukemia (AML).

BACKGROUND OF THE INVENTION

All of the cells and cell types of an individual adult mammal are derived from a single
25 cell, the zygote. However, as cells mature and differentiate they lose their ability to be
converted into a different cell type. Thus, most adult cells are fully differentiated and
normally cannot be converted into another cell type. One particular exception is the
adult stem cell. Adult stem cells retain the ability to differentiate into other cell types,
though this differentiation is generally limited to forming cells of a single tissue type.
30 For example, hematopoietic stem cells (HSCs) are capable of differentiating into any
cell type of the blood and immune system, whereas brain stem cells can differentiate
into the different cell types of the brain. In recent years, therapies for treating
degenerative diseases and/or cancer (such as leukemia) have been designed which
employ stem cells. However, heretofore, isolating stem cells from the human donors
35 has proved to be extremely difficult since stem cells are relatively rare.

Hematopoietic stem cells are functionally defined based on their capacity for self-renewal divisions, which leads to the continuous generation of new HSCs over the lifetime of an animal, and by their potential for pluripotent hematopoietic differentiation. There are three possible general outcomes for the resulting daughter cells when a hematopoietic stem cell divides: (i) differentiation, (ii) self-renewal, or (iii) apoptosis. Despite the extensive study of HSCs, due to its relevance to bone marrow transplantation, gene therapy, and basic hematopoiesis, the mechanisms controlling these three tightly regulated outcomes are poorly understood.

10

Purification strategies for HSCs have been developed for both mouse [Spangrude *et al.*, *Science* **241**:58-62 (1988):(published erratum appears in *Science* **244**(4908):1030 (1989)); Uchida *et al.*, *J.Exp.Med.* **175**:175-184 (1992)] and humans HSCs [Zanjani *et al.*, *J.Clin.Invest.* **93**:1051-1055 (1994), *see comments*; Larochelle *et al.*, *Nat.Med.* **2**:1329-1337 (1996); Civin *et al.*, *Blood* **88**:4102-4109 (1996)]. Most of these strategies use antibodies directed against various cell surface antigens and multiparameter cell sorting to isolate phenotypically defined cell populations. This approach has allowed isolation of murine stem cell populations of sufficiently high purity to allow reconstitution of irradiated recipients with less than 10 cells [Morrison *et al.*, *Proc.Natl.Acad.Sci.USA* **92**:10302-10306 (1995); Osawa *et al.*, *Science* **273**:242-245 (1996)], while considerably greater numbers of sorted human cells have been required to reconstitute xenogeneic recipients [Larochelle *et al.*, *Nat.Med.* **2**:1329-1337 (1996); Zanjani *et al.*, *Exp.Hematol.* **26**:353-360 (1998), *see comments*]. The human MDR1 gene and its murine homologs were originally identified based on the ability of their expressed products, collectively referred to as P-glycoproteins (P-gps), to extrude a wide variety of cytotoxic drugs from the cell interior [Gros *et al.*, *Cell*, **47**:371-380 (1986) and Chen *et al.*, *Cell*, **47**:381-389 (1986)]. It is now known that the MDR1 gene belongs to a superfamily of transport proteins that contain a conserved ATP-binding cassette (ABC) which is necessary for pump function [Allikmets *et al.*, *Hum. Mol. Genet.* **5**:1649-1655 (1996)]. Numerous studies have clearly shown that P-gp expression plays an important role in the resistance of human tumor cells to cancer chemotherapy [Pastan and Gottesman, *Annu. Rev. Med.*, **42**:277-

286 (1991)]. Considering that P-gps are also expressed in a wide variety of normal tissues, more recent studies have examined the normal physiologic functions of MDR1-like genes. Murine gene disruption experiments have demonstrated that expression of various P-gps is necessary for biliary excretion [Smit *et al.*, *Cell*,
5 75:451-462 (1993)], maintenance of the blood-brain barrier [Schinkel *et al.*, *Cell*, 77:491-502 (1994)], and elimination of drugs [Schinkel *et al.*, *Proc.Natl.Acad.Sci. USA*, 94:4028-4033 (1997)]. P-gps can also mediate more general cellular functions including the translocation of lipids across the cell membrane [van Helvoort *et al.*, *Cell*, 87:507-517 (1996)] and modulation of specific apoptosis pathways [Johnstone *et al.*, *Blood*, 93:1075-1085 (1999) and Smyth *et al.*, *Proc.Natl.Acad.Sci.USA*, 95:7024-7029 (1998)].

P-gp is expressed in a variety of hematopoietic cell types [Drach *et al.*, *Blood*, 80:2729-2734 (1992)], including human CD34⁺ stem cells [Chaudhary and Roninson,
15 *Cell*, 66:85-94 (1991)] and murine c-kit⁺ stem cells [Sorrentino *et al.*, *Blood*, 86:491-501 (1995)]. Several lines of evidence suggest that P-gp expression is functionally conserved in hematopoietic stem cells.

Another ATP transport protein that contains a conserved ATP-binding cassette is the
20 gene product of the *Bcrp1/Mxr/Abcp/ABCG2* gene (referred to herein as BCRP when obtained from any mammalian source, but as mBCRP and huBCRP when the specific mouse or human gene or gene product(s) are being particularly referenced). The huBCRP cDNA was originally cloned from several different human tumor cell lines that were resistant to multiple drugs including doxorubicin, topotecan, and
25 mitoxantrone [Doyle *et al.*, *Proc.Natl.Acad.Sci.USA* 95:15665-15670 (1998):(published erratum appears in *Proc Natl Acad Sci U S A*; 96(5):2569 (1999)); Maliepaard *et al.*, *Cancer Res.* 59:4559-4563 (1999); Miyake *et al.*, *Cancer Res.* 59:8-13 (1999)]. A highly related mouse homologue (*mBcrp1*) was cloned from fibroblasts selected for multidrug resistance [Allen *et al.*, *Cancer Res.* 59:4237-4241
30 (1999)]. In contrast to the structure of the MDR1 gene, which consists of two duplicated halves, the predicted structure of BCRP is that of a "half transporter", with a single ATP binding cassette and transmembrane region. The expression pattern of

human BCRP (huBCRP) is highly restricted in normal human tissues, with the highest levels of mRNA detected in the placenta, and much lower levels detected in adult organs [Doyle *et al.*, *Proc.Natl.Acad.Sci.USA* **95**:15665-15670 (1998):(published erratum appears in *Proc.Natl.Acad.SciU S A.* **96**(5):2569 (1999)); Allikmets *et al.*,
5 *CancerRes.* **58**:5337-5339 (1998)].

Hematopoietic stem cells can be identified based on their ability to efflux fluorescent dyes that are substrates for P-gp, such as Rhodamine (Rho) 123 [Spangrude and Johnson, *Proc.Natl.Acad.Sci. SA*, **87**:7433-7437 (1990); Fleming *et al.*, *J. Cell Biol.*,
10 **122**:897-902 (1993); Orlic *et al.*, *Blood*, **82**:762-770 (1993); and Zijlmans *et al.*, *Proc.Natl.Acad.Sci.USA*, **92**:8901-8905 (1995)] and Hoechst 33342 [McAlister *et al.*, *Blood*, **75**:1240-1246 (1990); Wolf *et al.*, *Exp. Hematol.*, **21**:614-622 (1993); and Leemhuis *et al.*, *Exp. Hematol.*, **24**:1215-1224 (1996)]. One particular approach for
15 purifying stem cells is based on Hoechst dye-staining of bone marrow cells to identify a minor fraction of side population (SP) cells that are highly enriched for repopulating activity [Goodell *et al.*, *J. Exp. Med.*, **183**:1797-1806 (1996)]. This SP phenotype identifies a primitive subset of stem cells present in multiple mammalian species [Goodell *et al.*, *Nat. Med.*, **3**:1337-1345 (1997)], and based on verapamil inhibition studies, may be due to expression of P-gp or another ABC transporter [Goodell *et al.*,
20 *J. Exp. Med.*, **183**:1797-1806 (1996)].

Despite a recent report demonstrating that sorting for expression of the vascular endothelial growth factor receptor can enrich human stem cells to near purity [Ziegler *et al.*, *Science* **285**:1553-1558 (1999)], there still remains a general need for better and
25 more specific markers of human HSCs. In addition, there is a great need for new methodologies of isolating stem cells.

The citation of any reference herein should not be deemed as an admission that such reference is available as prior art to the instant invention.

SUMMARY OF THE INVENTION

The present invention provides methods of identifying and/or purifying stem cells by detecting and/or selecting for cells that express a specific transmembrane efflux pump.

5 More particularly the present invention discloses that BCRP expression is a more specific marker for stem cells than all currently available markers. Such stem cells include hematopoietic stem cells, and side population (SP) stem cells from other organs. The present invention therefore provides methods for isolating primitive stem cells based on the detection of BCRP expression, which as disclosed herein, is a
10 functional determinant for stem cells from a variety of tissues.

The present invention further provides methods of identifying cells that express BCRP. One such embodiment comprises obtaining a cell sample which contains (or is suspected to contain) stem cells and detecting the expression of BCRP by a cell in
15 the cell sample. A cell is identified as a stem cell if BCRP is expressed by the cell. The detection of the expression of BCRP can be performed *via* its specific pumping activity, *i.e.*, it can remove Hoechst 33342 dye but not Rhodamine 123 dye (*see* Example 1 below). Preferably detection of the expression of BCRP is performed with an anti-BCRP antibody which binds to BCRP (more preferably the extracellular
20 portion of BCRP). Stem cells can then be identified due to their binding to the anti-BCRP antibody. In one such embodiment the antibody is a polyclonal antibody. In another embodiment the antibody is a monoclonal antibody. Alternatively, the detection of the expression of BCRP is performed *via* PCR employing a PCR probe derived for a nucleic acid sequence that expresses BCRP (*see* Example 1 below).

25 In an alternative embodiment, the present invention provides a method for identifying a stem cell that further comprises detecting the expression of one or more additional stem cell markers, *i.e.*, a protein that is expressed by stem cells. A cell that expresses BCRP and expresses one or more of such stem cell markers is then confirmed as a
30 stem cell. In one such embodiment the stem cell marker is EM10. In another embodiment the stem cell marker is CD34. In a preferred embodiment of this type the

stem cell is also CD38⁻ (*i.e.*, does not express CD38). In still another embodiment the stem cell marker is Thy-1. In yet another embodiment the stem cell marker is P-gp. In still another embodiment the stem cell marker is c-kit. In yet another embodiment the stem cell marker is Ac133.

5

The present invention also provides methods of further enriching the stem cell population in a mixture of cells that have previously been enriched by selecting for an alternative stem cell marker. In a particular embodiment of this type, the cells have been previously selected for the expression of the CD34 marker. Such an enriched
10 stem cell population can then be further enriched by selecting for cells that also express BCRP. Any of the methods taught by the present invention for identifying/selecting cells that express BCRP can be used .

Alternatively, or in conjunction with detecting the expression of BCRP, the methods
15 for identifying a stem cell of the present invention can further comprise detecting the expression of one or more lineage specific markers. A cell that expresses BCRP (and preferably one or more additional stem cell markers) but does not express the lineage specific marker(s) is then identified as a stem cell.

20 In a particular embodiment the stem cell is a hematopoietic stem cell. In one such embodiment the lineage specific marker whose absence is used to confirm stem cell identification is CD14. In another embodiment the lineage specific marker is CD15. In yet another embodiment the lineage specific marker is CD38. In still another embodiment the lineage specific marker is HLA-DR. In yet another embodiment the
25 lineage specific marker is CD71. In still another embodiment the lineage specific marker is CD33. In yet another embodiment the lineage specific marker is CD2. In still another embodiment the lineage specific marker is CD16. In yet another embodiment the lineage specific marker is CD19. In still another embodiment the lineage specific marker is CD20. In yet another embodiment the lineage specific
30 marker is glycophorin A. In still another embodiment the lineage specific marker is CD3. In yet another embodiment the lineage specific marker is CD4. In still another

embodiment the lineage specific marker is CD8. In yet another embodiment the lineage specific marker is CD56.

The present invention therefore also provides methods of isolating stem cells. One
5 such embodiment comprises a method of isolating a cell that expresses BCRP that
comprises obtaining a cell sample which contains (or is suspected to contain) a cell
that expresses BCRP and detecting the expression of BCRP by a cell in the cell
sample. After being detected the cell that expresses BCRP is isolated. As indicated
above, the absence and/or presence of lineage specific markers and stem cell markers
10 respectively, can also be employed in the detection of the stem cells.

Cell samples can be obtained from any animal, but preferably a mammal and more
preferably a human. Preferably, these samples already have a cell population that has
been previously enriched in stem cells.

15 One particular embodiment comprises obtaining a cell sample which contains (or is
suspected to contain) stem cells and contacting them with an antibody that binds to
BCRP (preferably an extracellular portion BCRP). Cells that bind to the antibody are
then isolated. These isolated cells are identified as isolated stem cells due to their
20 binding to the anti-BCRP antibody. In a preferred embodiment of the present
invention the isolation of the stem cells is performed by flow cytometry. In one
particular embodiment, the antibody has a fluorescent label and the isolation of the
stem cells is performed by fluorescent-activated cell sorting (FACS).

25 In another embodiment, the anti-BCRP antibody is placed on a solid support. The
solid support can then be contacted/incubated with a sample of cells, such that the
cells can associate with the solid support by binding to the anti-BCRP antibody. The
solid support is then washed to remove cells that bind non-specifically. The
remaining cells are eluted from the solid support (by an excess of free antibody, for
30 example). Based on their ability to bind anti-BCRP antibody with specificity, the
eluted cells are identified as isolated stem cells.

In a particular embodiment, the solid support is an immunomagnetic bead (*e.g.*, MILTENYI MINIMACS™, DYNABEADS™). The anti-BCRP antibody is placed on the immunomagnetic beads which are then contacted/incubated with a sample of cells, as indicated above, such that the cells can associate with the beads by binding to the anti-BCRP antibody. Preferably after an appropriate incubation period, the immunomagnetic beads can then be separated from the sample of cells with a magnet. The immunomagnetic beads are then washed to remove cells that bind non-specifically. The remaining cells are eluted from the immunomagnetic beads as indicated above. Again, based on their ability to bind anti-BCRP antibody, the isolated cells are identified as stem cells.

In one embodiment the BCRP is a huBCRP gene product which is encoded by the nucleotide sequence of SEQ ID NO:9 and has the amino acid sequence of SEQ ID NO:10. In another embodiment the BCRP is a huBCRP gene product which is encoded by the nucleotide sequence of SEQ ID NO:26 and has the amino acid sequence of SEQ ID NO:27. In yet another embodiment the BCRP is a murine BCRP (mBCRP) which is encoded by the nucleotide sequence of SEQ ID NO:13 and has the amino acid sequence of SEQ ID NO:14. In still another embodiment the BCRP is a mBCRP which is encoded by a nucleotide sequence comprising SEQ ID NO:11 and has an amino acid sequence comprising SEQ ID NO:12.

Furthermore, any step in any method for isolating and/or identifying stem cells can be repeated to enhance the isolation/identification process. In addition, individual methods can also be combined in order to enhance the isolation/identification processes.

The purified/isolated stem cells obtained from the methodology of the present invention are also part of the present invention. In addition, cell populations enriched for stem cells obtained by a method of the present invention are also provided. One such enriched population is obtained from a mixed population of cells that comprises both stem cells and cells that are not stem cells. The cells of the mixed population of cells are then separated into two individual groups of cells based on whether or not

they express BCRP. The group of cells selected for expressing BCRP are a cell population enriched for stem cells. As indicated above, the selection process can be repeated one or more times to further enrich the population of cells for stem cells.

5 The identification and isolation of stem cells *via* the methods of the present invention extend beyond hematopoietic stem cells and comprises all stem cells, including but not limited to muscle stem cells, liver stem cells, gastrointestinal stem cells, brain stem cells, and embryonic stem cells. The present invention also provides methods of using these isolated stem cells including the use of muscle stem cells in the treatment
10 of diseases such as muscular dystrophy, degenerative liver disorder, myocardial infarction, Parkinson's disease, degenerative disorders of the brain, and for tissue regeneration/replacement. In addition, the hematopoietic stem cells can be used in bone marrow transplants (*e.g.*, for treatment of leukemia) as well as for *ex vivo* gene therapy for treatment of blood diseases such as sickle cell anemia and thalassemia.

15 The present invention also provides the antibodies and portions thereof that recognize an extracellular portion of a BCRP in its natural conformation. In a preferred embodiment an antibody of the present invention recognizes BCRP on the surface of a viable stem cell. In a particular embodiment the antibody is a polyclonal antibody. In
20 another embodiment the antibody is a monoclonal antibody. In another embodiment the antibody is a chimeric antibody. In a preferred embodiment of this type the chimeric antibody is a humanized antibody.

The present invention also provides a method of prognosing human leukemia,
25 particularly acute myelogenous leukemia (AML), through determination of BCRP expression in leukemic cells, *e.g.*, blast cells from individuals having or suspected of having AML. The effectiveness of chemotherapeutic agents which can be effluxed from the cell by BCRP is predictably decreased by the presence of BCRP on leukemic cells. Determination of the presence and level of BCRP expression in the leukemic
30 cells of an individual can therefore help the medical practitioner develop a therapeutic regimen which takes into account the predicted efficacy of such agents and allows

proper consideration of alternative therapies or agents which are not susceptible to the counter-effects of BCRP where BCRP expression is present.

Accordingly, it is a principal object of the present invention to provide a method of
5 obtaining purified stem cells.

It is a further object of the present invention to provide the purified stem cells.

It is a further object of the present invention to provide methods of using the purified
10 stem cells in the treatment of diseases in which one or more specific cell types are being adversely depleted and/or become dysfunctional.

It is a further object of the present invention to provide methods of using the purified stem cells for gene therapy.

15 It is a further object of the present invention to provide methods of identifying stem cells *in vitro*, *in situ*, and *in vivo* among mixed populations of cells and/or tissues.

It is a further object of the present invention to use BCRP as a marker for prognosing
20 the progression of AML.

These and other aspects of the present invention will be better appreciated by reference to the following drawings and Detailed Description.

25

BRIEF DESCRIPTION OF THE DRAWING

Figure 1 is a schematic representation of a method of producing anti-BCRP monoclonal antibodies that can be used to isolate living stem cells by cell sorting.

30

DETAILED DESCRIPTION OF THE INVENTION

The present invention provides the use of a specific ATP transporter, BCRP to identify and/or isolate a mammalian stem cell. Indeed, as shown herein, the BCRP gene is expressed at relatively high levels both in primitive CD34-murine HSCs and in SP cells from the bone marrow. In contrast, the expression of other known ABC transporters in the highly enriched CD34-stem cell population is low to absent. A retroviral vector expressing the huBCRP cDNA has been constructed as described below to study the functional properties of huBCRP. Fibroblasts expressing this vector gain the capacity to efflux Hoechst dye, a prerequisite property for establishment of the SP phenotype. Furthermore, when primary bone marrow cells are transduced with the BCRP vector, there is a large expansion of SP cells over time in culture. SP cells from the muscle also express BCRP at high levels. Indeed, BCRP mRNA expression is highly restricted in normal tissues. Furthermore, as disclosed herein, BCRP expression is relatively restricted to the hematopoietic stem cell compartment in mice. In accordance with these data BCRP expression is contemplated to be a universal marker for stem cells from various organs, and may well be the critical molecule for conferring the dye efflux phenotype to stem cells. Therefore, the present invention provides a method of identifying stem cells by their expression of BCRP. Such identification can then be used to isolate the stem cells.

Given the capacity of BCRP to confer resistance to anthracycline drugs [Miyake *et al.*, *Cancer Res.* **59**:8-13 (1999)], BCRP expression may directly confer resistance to AML induction chemotherapy. Indeed, BCRP expression in AML blasts appears to be associated with a drug resistant phenotype and thereby predict a poor prognosis. Therefore, the present invention also provides a method of prognostigating pediatric patients with AML, *e.g.*, by examining/monitoring blast cells from such pediatric patients.

As demonstrated in the Examples below, stem cells from the bone marrow, skeletal muscle, and other tissues can be identified by the "side population" (SP) phenotype. While heretofore it had been assumed that the expression of ABC transporters is

responsible for this phenotype, the specific molecules involved had not been defined. Herein, it is demonstrated that expression of the *Bcrp1* (mBCRP)/ABCG2 (huBCRP) gene is a conserved feature of stem cells from diverse tissue sources. Indeed, mBCRP mRNA is expressed at high levels in primitive murine hematopoietic stem cells, and is sharply downregulated with stem cell differentiation. Enforced expression of the huBCRP cDNA directly conferred the SP phenotype to bone marrow cells, and causes a block in differentiation using both *in vitro* and transplantation-based assays. These results identify BCRP gene expression as a novel stem cell marker, and that its observed expression reflects a functional role in inhibiting stem cell differentiation. Therefore, the present invention provides methods of identifying stem cells through assays that can detect the expression of the BCRP.

Thus the studies disclosed herein demonstrate that expression of the BCRP transporter is highly conserved in primitive stem cells from a variety of sources. Expression was noted in SP cells from murine bone marrow, skeletal muscle, cultured ES cells, and in Rhesus monkey bone marrow. Within the lineage negative compartment of murine bone marrow cells, BCRP expression was relatively restricted to primitive CD34-stem cells, and expression was sharply downregulated with differentiation. The link between BCRP expression and SP cells was further strengthened by the observation that enforced expression in bone marrow cells caused a significant expansion of cells bearing the SP phenotype, both *in vitro* and *in vivo*. Altogether, these findings support the idea that BCRP expression is a widely conserved and specific marker for stem cells, and indicate that this transporter plays a role in stem cell function and/or maintenance of stem cell phenotype. Cell sorting for BCRP expression using appropriate antibodies provides a new strategy for stem cell purification applicable to cells from different organ sources. BCRP expression is further contemplated as a marker for the recently described trans-differentiating stem cells found in murine bone marrow [Lagasse, E. *et al.*, *Nat. Med.* **6**:1229-1234 (2000)] and skeletal muscle [Jackson, K. A. *et al.*, *Proc. Natl. Acad. Sci. U. S. A* **96**:14482-14486 (1999); Gussoni, E. *et al.*, *Nature* **401**: 390-394 (1999)].

Therefore, if appearing herein, the following terms shall have the definitions set out below.

5 A "hematopoietic stem cell" is a pluripotent cell that is able to either replicate itself with self-renewal divisions or to differentiate along a number of pathways and thereby generate erythrocytes, granulocytes, monocytes, mast cells, lymphocytes, and megakaryocytes. These stem cells occur with a frequency of about 1 stem cell per 10^4 bone marrow cells.

10 A "heterologous gene" as used herein is a gene that is introduced into a stem cell (*e.g.*, a hematopoietic stem cell) through a molecular biological manipulation. As defined herein, this molecular biological manipulation is made such that the heterologous gene is inserted into the stem cell. The heterologous gene need not be expressed in the stem cell as long as it is expressed in the progeny of the stem cell. The coding
15 sequence of the heterologous gene is operatively linked to an expression control sequence. Generally a heterologous gene is first placed into a vector. The heterologous gene is not necessarily naturally contained by the vector, though a heterologous gene can encode a protein that is native to the stem cell. For example, the heterologous gene can encode a functional protein and be used in *ex vivo* gene
20 therapy to replace the corresponding defective gene in a stem cell, *e.g.*, an hematopoietic stem cell. The heterologous gene will usually be flanked by DNA that does not flank the genomic DNA in the genome of the source organism. Alternatively, the heterologous gene may not be naturally found in the stem cell, such as the gene for human MDR1 introduced into a murine hematopoietic stem cell.

25 A cell has been "transduced" by a heterologous gene such as the MDR1 gene (*i.e.*, a nucleic acid encoding MDR1), when the gene has been introduced inside the cell and the coding sequence of the gene is operatively linked to an expression control sequence. The transducing gene is carried by a vector and the gene may or may not be
30 integrated (covalently linked) into chromosomal DNA making up the genome of the cell. A stably transduced cell is one in which the transducing gene has become integrated into a chromosome so that it is inherited by daughter cells through

chromosome replication. This stability is demonstrated by the ability of the cell to establish cell lines or clones comprised of a population of daughter cells containing the transducing gene. A "clone" is a population of cells derived from a single cell or common ancestor by mitosis. A "cell line" is a clone of a primary cell that is capable
5 of stable growth *in vitro* for many generations.

As used herein a "gene-modified hematopoietic stem cell" is a hematopoietic stem cell that has been transduced by a heterologous gene.

10 As used herein the "expansion" of an hematopoietic stem cell indicates that there is an increase in the absolute number of hematopoietic stem cells, *i.e.*, during the culturing of the cells. Analogously, an hematopoietic cell that has undergone such expansion has been "expanded".

15 As used herein "engrafting" a stem cell, preferably an expanded hematopoietic stem cell, means placing the stem cell into an animal, *e.g.*, by injection, wherein the stem cell persists *in vivo*. This can be readily measured by the ability of the hematopoietic stem cell, for example, to contribute to the ongoing blood formation.

20 As used herein an "ABC transporter" is used in the conventional sense and is used to describe a protein that is a transport ATPase. ABC transporters are members of a large family of transport proteins that are ATP-dependent. The name is derived from a highly conserved ATP-binding cassette contained by all of the members. [See, Alberts *et al.*, *Molecular Biology of the Cell*, 3rd edition, Garland Publishing Inc.
25 (New York) Pages 519-522 (1994)]. MDR1 and BCRP are two transmembrane efflux pumps that are part of the family of ABC transporters.

The Breast Cancer Resistance Protein is an ATP transporter protein that contains a conserved ATP-binding cassette which has been isolated from a number of different
30 cell lines and mammalian tissues. Names in the literature of genes encoding this protein include *Bcrp1*, *Mxr*, *Abcp* and ABCG2 gene. Whereas, the murine gene is generally termed as the *Bcrp1* gene and the corresponding human gene has been

termed the ABCG2 gene, as used herein, "BCRP" is meant to include all of such ATP transport proteins obtained from any mammalian source. The murine protein is also referred to herein as mBCRP, whereas the human protein is termed herein, "huBCRP" when the specific mouse or human gene or gene product(s) are being particularly
5 referenced. One huBCRP gene product which is encoded by the nucleotide sequence of SEQ ID NO:9 and has the amino acid sequence of SEQ ID NO:10, whereas another variant is encoded by the nucleotide sequence of SEQ ID NO:26 and has the amino acid sequence of SEQ ID NO:27. One mBCRP is encoded by the nucleotide sequence of SEQ ID NO: 13 and has the amino acid sequence of SEQ ID NO: 14 and another
10 mBCRP is encoded by a nucleotide sequence comprising SEQ ID NO:11 and has an amino acid sequence comprising SEQ ID NO:12.

A "replicon" is any genetic element (e.g., plasmid, chromosome, virus) that functions as an autonomous unit of DNA replication *in vivo*; *i.e.*, capable of replication under its
15 own control.

A "vector" is a replicon, such as plasmid, phage or cosmid, to which another DNA segment may be attached so as to bring about the replication of the attached segment. The term "vector" can also refer to a recombinant virus or defective virus containing a
20 replicon to which another DNA segment may be attached.

A "DNA molecule" refers to the polymeric form of deoxyribonucleotides (adenine, guanine, thymine, or cytosine) in its either single stranded form, or a double-stranded helix. This term refers only to the primary and secondary structure of the molecule,
25 and does not limit it to any particular tertiary forms. Thus, this term includes double-stranded DNA found, *inter alia*, in linear DNA molecules (e.g., restriction fragments), viruses, plasmids, and chromosomes. In discussing the structure of particular double-stranded DNA molecules, sequences may be described herein according to the normal convention of giving only the sequence in the 5' to 3' direction along the
30 nontranscribed strand of DNA (*i.e.*, the strand having a sequence homologous to the mRNA).

A "coding sequence" is a nucleic acid sequence which can be reverse transcribed (*i.e.*, when part of a retroviral vector) and/or transcribed and then translated into a polypeptide *in vitro* and/or *in vivo* when placed under the control of appropriate regulatory sequences. The boundaries of the coding sequence are determined by a start codon at the 5' (amino) terminus and a translation stop codon at the 3' (carboxyl) terminus. A coding sequence can include, but is not limited to, prokaryotic sequences, cDNA from eukaryotic mRNA, genomic DNA sequences from eukaryotic (e.g., mammalian) DNA, and even synthetic DNA sequences. A polyadenylation signal and transcription termination sequence will usually be located 3' to the coding sequence.

10

A nucleic acid sequence is "operatively linked" to an expression control sequence when the expression control sequence controls and regulates the transcription and/or translation of that nucleic acid sequence. The term "operatively linked" includes having an appropriate start signal (*e.g.*, ATG) in front of the nucleic acid sequence to be expressed and maintaining the correct reading frame to permit expression of the nucleic acid sequence under the control of the expression control sequence and production of the desired product encoded by the nucleic acid sequence. If a gene that one desires to insert into a recombinant DNA molecule does not contain an appropriate start signal for example, such a start signal can be inserted in front of the gene.

20

Transcriptional and translational control sequences are DNA regulatory sequences, such as promoters, enhancers, polyadenylation signals, terminators, and the like, that provide for the expression of a coding sequence in a host cell.

25

A "promoter sequence" is a DNA regulatory region capable of binding RNA polymerase in a cell and initiating transcription of a downstream (3' direction) coding sequence. For purposes of defining the present invention, the promoter sequence is bounded at its 3' terminus by the transcription initiation site and extends upstream (5' direction) to include the minimum number of bases or elements necessary to initiate transcription at levels detectable above background. Within the promoter sequence will be found a transcription initiation site (conveniently defined for example, by

30

mapping with nuclease S1), as well as protein binding domains (consensus sequences) responsible for the binding of RNA polymerase. Eukaryotic promoters will often, but not always, contain "TATA" boxes and "CAT" boxes.

- 5 A coding sequence is "under the control" of transcriptional and translational control sequences in a cell when RNA polymerase transcribes the coding sequence into mRNA, which is then translated into the protein encoded by the coding sequence.

Any of a wide variety of expression control sequences -- sequences that control the
10 expression of a DNA sequence operatively linked to it -- may be used in these vectors to express the DNA sequences of this invention. Such useful expression control sequences include, for example, the early or late promoters of SV40, CMV, vaccinia, polyoma, adenovirus, herpes virus and other sequences known to control the expression of genes of mammalian cells, and various combinations thereof.

15 In selecting an expression control sequence, a variety of factors will normally be considered. These include, for example, the relative strength of the system, its controllability, and its compatibility with the particular DNA sequence or gene to be expressed, particularly as regards potential secondary structures. Considering these
20 and other factors a person skilled in the art will be able to construct a variety of vector/expression control sequence combinations that will express the heterologous genes used in the present invention.

The phrase "pharmaceutically acceptable" refers to molecular entities and
25 compositions that are physiologically tolerable and do not typically produce an allergic or similar untoward reaction, such as gastric upset, dizziness and the like, when administered to a human. Preferably, as used herein, the term "pharmaceutically acceptable" means approved by a regulatory agency of the Federal or a state government or listed in the U.S. Pharmacopeia or other generally recognized
30 pharmacopeia for use in animals, and more particularly in humans. The term "carrier" refers to a diluent, adjuvant, excipient, or vehicle with which the compound is administered. Such pharmaceutical carriers can be sterile liquids, such as water and

oils, including those of petroleum, animal, vegetable or synthetic origin, such as peanut oil, soybean oil, mineral oil, sesame oil and the like. Water or aqueous solution saline solutions and aqueous dextrose and glycerol solutions are preferably employed as carriers, particularly for injectable solutions.

5

The phrase "therapeutically effective amount" is used herein to mean an amount sufficient to reduce by at least about 15 percent, preferably by at least 50 percent, more preferably by at least 90 percent, and most preferably prevent and/or treat, a clinically significant deficit in the activity, function and response of the host.

10 Alternatively, a therapeutically effective amount is sufficient to cause an improvement in a clinically significant condition in the host.

Nucleic Acid Probes

A nucleic acid molecule is "hybridizable" to another nucleic acid molecule, such as a
15 cDNA, genomic DNA, or RNA, when a single stranded form of the nucleic acid molecule can anneal to the other nucleic acid molecule under the appropriate conditions of temperature and solution ionic strength [*see* Sambrook, Fritsch & Maniatis, *Molecular Cloning: A Laboratory Manual*, Second Edition (1989) Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York (herein "Sambrook
20 *et al.*, 1989" and Sambrook and Russell, *Molecular Cloning: A Laboratory Manual*, Third Edition (2001) Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York]. The conditions of temperature and ionic strength determine the "stringency" of the hybridization. Specific hybridization conditions, corresponding to a T_m of 55°, can be used, *e.g.*, 5x SSC, 0.1% SDS, 0.25% milk, and no formamide; or 30%
25 formamide, 5x SSC, 0.5% SDS. Moderate stringency hybridization conditions correspond to a higher T_m , *e.g.*, 40% formamide, with 5x or 6x SSC. High stringency hybridization conditions correspond to the highest T_m , *e.g.*, 50% formamide, 5x or 6x SSC. These conditions can be used for both annealing and wash steps. Hybridization requires that the two nucleic acids contain complementary sequences, although
30 depending on the stringency of the hybridization, mismatches between bases are possible. The appropriate stringency for hybridizing nucleic acids depends on the length of the nucleic acids and the degree of complementation, variables well known

in the art. The greater the degree of similarity or homology between two nucleotide sequences, the greater the value of T_m for hybrids of nucleic acids having those sequences. The relative stability (corresponding to higher T_m) of nucleic acid hybridizations decreases in the following order: RNA:RNA, DNA:RNA, DNA:DNA.

5 For hybrids of greater than 100 nucleotides in length, equations for calculating T_m have been derived [*see* Sambrook *et al.*, *supra*, 9.50-10.51]. For hybridization with shorter nucleic acids, *i.e.*, oligonucleotides, the position of mismatches becomes more important, and the length of the oligonucleotide determines its specificity [*see* Sambrook *et al.*, *supra*, 11.7-11.8]. Preferably a minimum length for a hybridizable
10 nucleic acid (probe and/or primer) is at least about 12 nucleotides; preferably at least about 18 nucleotides; and more preferably the length is at least about 27 nucleotides; and most preferably at least about 36 nucleotides. Particular primers for *BCRP*, and *mdr1a*, *mdr1b*, and *mdr2* are provided in Example 1 below.

15 Such nucleotide probes and primers can be labeled or used to label complementary DNA (where appropriate) by any number of ways well known in the art including using a radioactive label, such as ^3H , ^{14}C , ^{32}P , or ^{35}S , a fluorescent label, a boron label [U.S. Patent No: 5,595,878, Issued January 21, 1997 and U.S. Patent No: 5,876,938, Issued March 2, 1999 which are incorporated by reference in their entireties], and
20 enzymatic tags such as urease, alkaline phosphatase or peroxidase. In the case of enzyme tags, colorimetric indicator substrates are known which can be employed to provide a means visible to the human eye or spectrophotometrically, to identify specific hybridization with complementary nucleic acid-containing samples.

25 Antibodies to the ABC Transporters of the Present Invention

According to the present invention, ABC transporters as produced by a recombinant source, or through chemical synthesis, or an ABC transporter isolated from a natural source; and derivatives or analogs thereof, including fusion proteins, may be used as an immunogen to generate antibodies that recognize an ABC transporter such as
30 *BCRP*. Such antibodies include but are not limited to polyclonal, monoclonal, chimeric including humanized chimeric, single chain, Fab fragments, and a Fab expression library.

In a particular embodiment an antibody is raised to an external epitope of BCRP. In a particular embodiment the epitope is derived from the extracellular portion of BCRP. Such an antibody can be used to sort living cells on a flow cytometer. These
5 antibodies can be used, for example, to sort hematopoietic cells based on BCRP (*bcrp*) expression. Such antibodies also may be used to detect BCRP as a marker for repopulating activity.

The anti-BCRP antibodies of the invention may be cross reactive, that is, they may
10 recognize a BCRP derived from a different source, *e.g.*, an anti-human BCRP antibody may recognize both human and mouse BCRP. Polyclonal antibodies have greater likelihood of cross reactivity. Alternatively, an antibody of the invention may be specific for a single form of a BCRP, such as the huBCRP having the amino acid sequence of SEQ ID NO:10.

15 Various procedures known in the art may be used for the production of polyclonal antibodies to BCRP, for example, or derivative or analog thereof. For the production of antibody, various host animals can be immunized by injection with the BCRP, or a derivative (*e.g.*, or fusion protein) thereof, including but not limited to rabbits, mice,
20 rats, sheep, goats, etc. In one embodiment, the BCRP can be conjugated to an immunogenic carrier, *e.g.*, bovine serum albumin (BSA) or keyhole limpet hemocyanin (KLH). Various adjuvants may be used to increase the immunological response, depending on the host species, including but not limited to Freund's (complete and incomplete), mineral gels such as aluminum hydroxide, surface active
25 substances such as lysolecithin, pluronic polyols, polyanions, peptides, oil emulsions, keyhole limpet hemocyanins, dinitrophenol, and potentially useful human adjuvants such as BCG (*bacille Calmette-Guerin*) and *Corynebacterium parvum*.

For preparation of monoclonal antibodies directed toward the BCRP, or analog, or
30 derivative thereof, any technique that provides for the production of antibody molecules by continuous cell lines in culture may be used. These include but are not limited to the hybridoma technique originally developed by Kohler and Milstein

[*Nature*, **256**:495-497 (1975)], as well as the trioma technique, the human B-cell hybridoma technique [Kozbor *et al.*, *Immunology Today*, **4**:72 (1983); Cote *et al.*, *Proc. Natl. Acad. Sci. USA*, **80**:2026-2030 (1983)], and the EBV-hybridoma technique to produce human monoclonal antibodies [Cole *et al.*, in *Monoclonal Antibodies and Cancer Therapy*, Alan R. Liss, Inc., pp. 77-96 (1985)]. In an additional embodiment of the invention, monoclonal antibodies can be produced in germ-free animals utilizing recent technology [PCT/US90/02545]. In fact, according to the invention, techniques developed for the production of "chimeric antibodies" [Morrison *et al.*, *J. Bacteriol.*, **159**:870 (1984); Neuberger *et al.*, *Nature*, **312**:604-608 (1984); Takeda *et al.*, *Nature*, **314**:452-454 (1985)] by splicing the genes from a mouse antibody molecule specific for a BCRP together with genes from a human antibody molecule of appropriate biological activity can be used; such antibodies are within the scope of this invention. Such human or humanized chimeric antibodies are preferred for use in therapy of human diseases or disorders (described *infra*), since the human or humanized antibodies are much less likely than xenogeneic antibodies to induce an immune response, in particular an allergic response, themselves. In a particular embodiment, the BCRP-expressing cells of the present invention are used to raise monoclonal antibodies to external cell surface epitopes. Antibody producer clones can be screened for differential staining of producer cells versus their parental packaging cells (*see* Figure 1).

According to the invention, techniques described for the production of single chain antibodies [U.S. Patent Nos. 5,476,786 and 5,132,405 to Huston; U.S. Patent 4,946,778] can be adapted to produce for example, BCRP-specific single chain antibodies. An additional embodiment of the invention utilizes the techniques described for the construction of Fab expression libraries [Huse *et al.*, *Science*, **246**:1275-1281 (1989)] to allow rapid and easy identification of monoclonal Fab fragments with the desired specificity for a BCRP, or its derivatives, or analogs.

Antibody fragments which contain the idiotype of the antibody molecule can be generated by known techniques. For example, such fragments include but are not limited to: the F(ab')₂ fragment which can be produced by pepsin digestion of the

antibody molecule; the Fab' fragments which can be generated by reducing the disulfide bridges of the F(ab')₂ fragment, and the Fab fragments which can be generated by treating the antibody molecule with papain and a reducing agent.

- 5 In the production of antibodies, screening for the desired antibody can be accomplished by techniques known in the art, *e.g.*, radioimmunoassay, ELISA (enzyme-linked immunosorbant assay), "sandwich" immunoassays, immunoradiometric assays, gel diffusion precipitin reactions, immunodiffusion assays, *in situ* immunoassays (using colloidal gold, enzyme or radioisotope labels, for
10 example), Western blots, precipitation reactions, agglutination assays (*e.g.*, gel agglutination assays, hemagglutination assays), complement fixation assays, immunofluorescence assays, protein A assays, flow cytometry, and immunoelectrophoresis assays, etc. In one embodiment, antibody binding is detected by detecting a label on the primary antibody. In another embodiment, the primary
15 antibody is detected by detecting binding of a secondary antibody or reagent to the primary antibody. In a further embodiment, the secondary antibody is labeled. Many means are known in the art for detecting binding in an immunoassay and are within the scope of the present invention. For example, to select antibodies which recognize a specific epitope of BCRP, one may assay generated hybridomas for a product which
20 binds to the BCRP fragment containing such epitope and choose those which do not cross-react with BCRP. For selection of an antibody specific to a BCRP from a particular source, one can select on the basis of positive binding with BCRP expressed by or isolated from that specific source.
- 25 The present invention also provides methods for producing BCRP monoclonal antibodies that can be used to isolate living stem cells (*see* Figure 1). In a preferred embodiment of this type the living stem cells are isolated by a cell sorting technique. One initial step can be to obtain a cDNA sequence encoding a BCRP and then inserting it into a vector construct (preferably a retroviral vector). This construct can
30 then be introduced into packaging cells (*e.g.*, retroviral packaging cells) to produce transducing vector particles. When GPE86 packaging cells are used, ecotropic ABCG2 (*i.e.*, huBCRP) vector is produced in the supernatant, and can be used to

transduce murine 3T3 cells. After applying the supernatant to logarithmically growing cells, transduced 3T3 cells that express the huBCRP can be isolated by flow cytometry based on their capacity to efflux the fluorescent dye Hoechst 33342. The 3T3 cells which express huBCRP (oval cell, *see* Figure 1), can then be injected into
5 the intraperitoneal space in mice. The strategy of using living cells transduced with the vector increases the probability that the immune system will detect external huBCRP epitopes in their native configuration, rather than epitopes that are internally located in the cells, or epitopes only present in denatured protein.

10 After several rounds of immunization, mice that show anti-huBCRP activity in the peripheral serum can be killed. Their spleens are then isolated and about 500 hybridoma clones are obtained by fusion with myeloma cells using standard techniques. Supernatants from these growing fusion clones are then screened for the presence of anti-huBCRP antibodies. This screening process involves transducing
15 human MCF7 breast cancer cells with the huBCRP vector.

As depicted in Figure 1, the reason that human breast cancer cells are preferred is that unwanted monoclonal antibodies (small cell #3) that react to native 3T3 cell proteins (squares and triangles) are not likely to bind to the human proteins present on MCF7
20 cells. Supernatants are then incubated with the transduced MCF7 cells which express huBCRP. These cells are then stained with a phycoerythrin (PE) conjugated secondary antibody that recognize mouse immunoglobulins. Flow cytometry is then used to detect cell samples that have PE-fluorescence, *i.e.*, cells that bind the murine antibodies from the hybridoma supernatants. These supernatants are likely to contain
25 anti-huBCRP antibodies from their respective monoclonal hybridomas (cell #1). However, it is also possible that the reactivity observed is not due to anti-huBCRP activity, but rather to a murine antibody that cross-reacts with a surface protein found on the MCF7 cell (hybridoma clone 2). To identify and eliminate such clones, all positive supernatants can be back-screened with the parental (non-transduced) MCF7
30 cells. These cells do not express huBCRP, but do express all of the native surface proteins present on the transduced MCF7 cells. Therefore, all clones found to react with the parental (non-transduced) MCF7 cells are discarded.

Hybridoma clones that pass this screening process are then expanded, resubcloned, and reanalyzed. Subclones that pass a second round of screening are then used to make monoclonal antibody containing supernatant in an *ex vivo* roller-bottle
5 production system. The antibody can then be purified on an affinity column, the isotype can be determined, and the concentration of the antibody measured. This preparation can then be used to identify native stem cells that express the huBCRP gene product on their surface, and to isolate such cells by methods including but not limited to flow cytometry, immunoaffinity columns, or magnetic bead procedures.

10

The foregoing antibodies can be used in methods known in the art relating to the localization and activity of the BCRP, *e.g.*, for Western blotting, imaging BCRP *in situ*, measuring levels thereof in appropriate physiological samples, etc. using any of the detection techniques mentioned herein or known in the art. In a specific
15 embodiment, antibodies that agonize or antagonize the activity of BCRP can be generated. Such antibodies can be tested using the assays that measure the drug pumping ability of BCRP, for example.

The antibodies to the ABC transporters can be labeled. Suitable labels include
20 enzymes, fluorophores (*e.g.*, fluorescein isothiocyanate (FITC), phycoerythrin (PE), Texas red (TR), rhodamine, free or chelated lanthanide series salts, especially Eu^{3+} , to name a few fluorophores), chromophores, radioisotopes, chelating agents, dyes, colloidal gold, latex particles, ligands (*e.g.*, biotin), and chemiluminescent agents. In the instance where a radioactive label, such as the isotopes ^3H , ^{14}C , ^{32}P , ^{35}S , ^{125}I , and
25 ^{131}I , are used, known currently available counting procedures may be utilized. In the instance where the label is an enzyme, detection may be accomplished by any of the presently utilized colorimetric, spectrophotometric, fluorospectrophotometric, amperometric or gasometric techniques known in the art.

30 Direct labels are one example of labels which can be used according to the present invention. A direct label has been defined as an entity, which in its natural state, is readily visible, either to the naked eye, or with the aid of an optical filter and/or

applied stimulation, *e.g.* ultraviolet light to promote fluorescence. Among examples of colored labels, which can be used according to the present invention, include metallic sol particles, for example, gold sol particles such as those described by Leuving (U.S. Patent 4,313,734); dye sol particles such as described by Gribnau *et al.* (U.S. Patent 4,373,932) and May *et al.* (WO 88/08534); dyed latex such as described by May, *supra*, Snyder (EP-A 0 280 559 and 0 281 327); or dyes encapsulated in liposomes as described by Campbell *et al.* (U.S. Patent 4,703,017). Other direct labels include a radionucleotide, a fluorescent moiety or a luminescent moiety. In addition to these direct labeling devices, indirect labels comprising enzymes can also be used according to the present invention. Various types of enzyme linked immunoassays are well known in the art, for example, alkaline phosphatase and horseradish peroxidase, lysozyme, glucose-6-phosphate dehydrogenase, lactate dehydrogenase, urease, these and others have been discussed in detail by Eva Engvall in Enzyme Immunoassay ELISA and EMIT in *Methods in Enzymology*, **70**:419-439 (1980) and in U.S. Patent 4,857,453.

Suitable enzymes include, but are not limited to, alkaline phosphatase and horseradish peroxidase. In addition, an antibody can be modified to contain a marker protein such as green fluorescent protein as described in U.S. Patent No. 5,625,048 filed April 29, 1997, WO 97/26333, published July 24, 1997 and WO 99/64592 all of which are hereby incorporated by reference in their entireties. Other labels for use in the invention include magnetic beads or magnetic resonance imaging labels.

In another embodiment, a phosphorylation site can be created on an antibody of the invention for labeling with ^{32}P , *e.g.*, as described in European Patent No. 0372707 (application No. 89311108.8) by Sidney Pestka, or U.S. Patent No. 5,459,240, issued October 17, 1995 to Foxwell *et al.*

Antibodies also can be labeled by metabolic labeling. Metabolic labeling occurs during *in vitro* incubation of the cells that express the protein in the presence of culture medium supplemented with a metabolic label, such as [^{35}S]-methionine or [^{32}P]-orthophosphate. In addition to metabolic (or biosynthetic) labeling with [^{35}S]-

methionine, the invention further contemplates labeling with [^{14}C]-amino acids and [^3H]-amino acids (with the tritium substituted at non-labile positions).

Stem Cell Purification

5 After an appropriate antibody is identified, mouse bone marrow cells, for example, can be depleted of lineage positive cells, and the lin^- cells can be sorted for BCRP expression. Competitive repopulation assays can then be used to demonstrate the enrichment of stem cell activity in the BCRP-expressing fraction. BCRP sorting experiments can also be performed in lin^- , ckit^+ , sca1^+ cells, and in CD34-cells to
10 determine if these populations can be further enriched for stem cell activity. An analogous procedure can be performed using an alternative cell source, *e.g.*, human cord blood cells.

Thus, BCRP sorting experiments can be performed using lin^- , CD34-cells, as well as
15 CD34 $^+$, CD38 $^-$ cells to determine the amount that BCRP expression enriches for repopulating activity in these stem cell populations. Sorted cells then can be injected into NOD/SCID mice in limiting dilution analyses to quantify the stem cell frequencies in these populations. This procedure can be repeated using bone marrow cells and cytokine-mobilized peripheral blood stem cells to demonstrate the utility of
20 the procedure in various clinical stem cell sources. For example, SP cells were isolated from mouse muscle satellite cells and RT-PCR and FACS analysis was used to demonstrate that BCRP is also expressed in these cells (*see* Example 1 below). Reconstitution studies can also be performed using sorted BCRP-expressing muscle cells. Sorted donor cells can be identified after transplant using a GFP-transgenic
25 mouse line for donor cells, for example, and analyzing recipients for GFP $^+$ SP cells in the muscle.

Therefore, the present invention provides a functional basis for identifying SP stem cells, and furthermore, provides a new way to isolate stem cells both for research and
30 clinical applications. For example, the present invention provides a method of isolating stem cells using an anti-BCRP antibody. These stem cells can originate from any tissue that contains stem cells including from bone marrow cells, muscle cells and

even brain cells. Any method that allows the separation of cells that can be distinguished by their ability to bind a particular antibody can be employed. For example, to isolate hematopoietic stem cells, bone marrow cells can be obtained from an animal subject, (preferably a human). Single cell suspensions can then be
5 prepared. An anti-BCRP antibody can be incubated with the cells and the cells can be isolated using standard cell sorting methodology *e.g.*, by fluorescent cell sorting [Bhatia *et al.*, *Nat. Med.* 4:1038-1045 (1998)]. In a related embodiment, muscle stem cells can be isolated from a muscle cell sample [Gussoni *et al.*, *Nature* 401:390 (1999)]. Alternatively, stem cells can be distinguished from non-stem cells by the
10 specificity of the drug-pumping activity of BCRP.

Bone marrow cells can be obtained from any number of sources from an animal, including a human subject. For example, the cells can be harvested from iliac bone marrow from laboratory animals. Alternatively, hematopoietic stem cells can be
15 obtained from umbilical chord cells. Another source for hematopoietic stem cells is from circulating fetal blood cells. In addition, a human subject, for example, can be treated with a cytotoxic drug and/or a hematopoietic stem cell stimulating cytokine (*e.g.*, G-CSF). Mononuclear cells can then be collected by leukaphoresis and the hematopoietic stem cells can be isolated from the peripheral blood cells by their
20 selective binding to an antibody raised against CD34. One source of embryonic stem cells is embryonic/fetal tissue. Sources for obtaining stem cells from a particular tissue type (such as brain or liver) include but are not limited to biopsy samples and cadavers.

25 BCRP enriched stem cells can be used in the same way, and for the same purposes, as the enriched stem cells that are currently available, *e.g.*, CD34 enriched stem cells. Indeed, the embryonic stem cells provided can be used generally, whereas specific adult stem cells obtained by the methods of the present invention can be used for specific stem cell transplantation *e.g.*, hemopoietic stem cells for bone marrow
30 transplantation, pancreatic stem cells to treat type II diabetes, and brain stem cells to treat Parkinson's disease. The stem cells provided by the present invention can also be used as cell targets in gene therapy protocols. Importantly, cell samples that are

identified/selected to be enriched for BCRP expression by the methods disclosed herein comprise a more highly purified population of stem cells than any of the other currently available sources of stem cells that have been isolated based on any alternative stem cell marker (*e.g.*, cell samples selected for expression of CD34).

5 Thus, the enriched stem cell preparations provided by the present invention comprise fewer deleterious anti-host reacting cells and thereby their use significantly lowers the risk of graft *versus* host disease, and/or transplant rejection and may broaden the number of available donors for a given patient.

10 Therefore, the BCRP enriched cell samples of the present invention provide a preferred source of purified stem cells for therapeutic applications. These more highly enriched stem cell samples also allow therapeutic applications of stem cells such as allogeneic transplantation, that heretofore, could not be reliably performed due to the relatively higher level of contaminating non-stem cells in prior stem cell preparations.

15

Furthermore, these highly enriched stem cells are preferred for gene therapy because their use leads to an increase in transduction efficiency and reduces the amount of vector needed for transduction.

20

BCRP Expression and Leukemia

A significant number of leukemic cells, particularly Acute Myelogenous Leukemia (AML) blasts, can efflux fluorescent dyes and certain chemotherapeutic agents such as mitoxantrone and duanomycin, despite the absence of MDR1 and MRP1 expression.

A substantial proportion of these cases are contemplated to be due to the expression of

25 BCRP. AML blasts from newly diagnosed pediatric patients can be assayed for BCRP expression using a variety of techniques as described herein in the context of stem cell **identification** and purification. Suitable techniques particularly include the use of flow cytometry after staining with a specific anti-BCRP antibody, immunocytochemistry, staining protein lysates with BCRP antibody in Western Blot
30 analyses, and methods that measure BCRP mRNA levels such as PCR, real time PCR, Northern Blot analyses, and ribonuclease protection assays. In cases where significant levels of BCRP expression is found, it can be determined whether the expression of

BCRP is due to mutations in the promoter, hypomethylation of promoter sequences, or due to changes in the transcription factor environment.

Determination of BCRP expression in leukemic cells, particularly AML blasts, provides useful information to the medical practitioner with regard to predicting the efficacy of administration of chemotherapeutic agents which are susceptible to efflux via BCRP. Such information may be used by the medical practitioner to determine the optimal course of treatment for a patient suffering from leukemia, particularly AML. For example, in those cases where the leukemic cells of a patient are determined to be expressing significant levels of BCRP, a course of treatment which does not rely upon agents susceptible to reduced efficacy via BCRP efflux such as bone marrow transplant or immunotherapy may be used. Furthermore, in cases where BCRP expression predicts poor prognosis with standard treatment, more aggressive treatment plans can be implemented at the outset including more aggressive chemotherapy, or bone marrow transplantation approaches.

The present invention may be better understood by reference to the following non-limiting Examples, which are provided as exemplary of the invention. These examples are presented in order to more fully illustrate the preferred embodiments of the invention. They should in no way be construed, however, as limiting the broad scope of the invention.

EXAMPLES

EXAMPLE 1

BCRP IS EXPRESSED IN A WIDE VARIETY OF SIDE POPULATION STEM CELLS, BLOCKS DIFFERENTIATION OF TRANSDUCED HEMATOPOIETIC STEM CELLS AND CAN BE USED AS A MARKER FOR PURIFICATION OF STEM CELLS

Introduction

Hematopoietic stem cells (HSCs) can be identified by staining with fluorescent dyes such as Rhodamine (Rho) 123 and purified based on efflux of such dyes [Orlic *et al.*, *Blood* **82**:762-770 (1993); Fleming *et al.*, *J. Cell Biol.* **122**:897-902 (1993); Spangrude and Johnson, *Proc. Natl. Acad. Sci. USA* **87**:7433-7437 (1990); Zijlmans *et al.*, *Proc*

Natl Acad Sci USA **92**:8901-8905 (1995)] and Hoechst 33342 [McAlister *et al.*, *Blood* **75**:1240-1246 (1990); Leemhuis *et al.*, *Exp.Hematol.* **24**:1215-1224 (1996); Wolf *et al.*, *Exp.Hematol.* **21**:614-622 (1993)]. The most primitive HSCs are characterized by low degrees of fluorescence after staining with these dyes, a property ascribed to both
5 their capacity for dye efflux, and to relatively low degrees of mitochondrial staining [Kim *et al.*, *Blood* **91**:4106-4117 (1998)]. A related method for stem cell identification has been based on Hoechst dye-staining of whole bone marrow cells, followed by dual emission wavelength analysis by flow cytometry. This technique identifies a small fraction of side population (SP) cells that are highly enriched for
10 repopulating activity [Goodell *et al.*, *J.Exp.Med.* **183**:1797-1806 (1996)].

This SP population is highly enriched for repopulating cells and is present in the bone marrow of all species examined [Goodell, M.A. *et al.*, *Nat. Med.* **3**:1337-1345 (1997)]. The SP phenotype can be blocked by drugs which inhibit cellular dye efflux
15 mechanisms. It has been thought that the efflux activity responsible for the SP phenotype may be due to expression of P-glycoproteins (P-gps), the products of the mammalian multidrug resistance genes (MDR1 in humans and *mdr1a* and *1b* in mice) [Sorrentino, B.P. *et al.*, *Blood* **86**: 491-501 (1995)]. This possibility is suggested by the facts that: (i) Rho123 and Hoechst 33342 are substrates for P-gp, (ii) primitive
20 human hematopoietic cells express high levels of P-gp [Chaudhary and Roninson, *Cell* **66**:85-94 (1991)], and (iii) the phenotype of SP cells can be blocked by verapamil, a competitive inhibitor of P-gp [Goodell *et al.*, *J.Exp.Med.* **183**:1797-1806 (1996)].

25 More recent evidence shows that the muscle contains reconstituting cells that can be identified by the SP phenotype [Gussoni *et al.*, *Nature* **401**:390-394 (1999); Jackson *et al.*, *Proc.Natl.Acad.Sci.U.S.A* **96**:14482-14486 (1999), *see comments*] suggesting that expression of ABC transporters may be a general stem cell property [Orkin, S.H., *Nat. Med.* **6**:1212-1213 (2000)]. Indeed whatever their exact function, it appears that
30 expression of ABC transporters has been evolutionarily conserved in stem cells. The conservation of transporter expression in a wide variety of stem cells is consistent with an important functional role in stem cells.

Although many of the genes encoding ABC transporters were first identified based on their ability to confer drug resistance in tumor cells, it has recently become apparent that they can exert more general effects on cellular function. For example, MDR1
5 gene expression has been shown to inhibit caspase-dependent apoptosis in a variety of cells [Smyth *et al.*, *Proc.Natl.Acad.Sci.USA* **95**:7024-7029 (1998)] including hematopoietic cells [Johnstone *et al.*, *Blood* **93**:1075-1085 (1999)]. P-gps can also function as lipid translocases by redistributing membrane phospholipids from the inner to outer leaflet of the cell membrane [van Helvoort *et al.*, *Cell* **87**:507-517
10 (1996)].

Direct evidence that ABC transporters can have a functional effect in HSCs comes from studies of MDR1 gene transfer in mice [Bunting *et al.*, *Blood* **92**:2269-2279 (1998); Example 1 of U.S. Serial No. 09/584,586 filed May 31, 2000, the disclosure
15 of which are hereby incorporated by reference in their entireties]. When murine bone marrow cells were transduced with an MDR1-expressing retroviral vector, dramatic expansion of repopulating stem cells was noted during a 12-day culture period [Bunting *et al.*, *Blood* **92**:2269-2279 (1998); Example 1 of U.S. Serial No. 09/584,586 filed May 31, 2000, the disclosure of which are hereby incorporated by reference in
20 their entireties]. In contrast, repopulating activity was lost over time in control cultures [Bunting *et al.*, *Blood* **96**:902-909 (2000); Example 2 of U.S. Serial No. 09/584,586 filed May 31, 2000, the disclosure of which is hereby incorporated by reference in its entirety]. These results demonstrate that enforced expression of MDR1 results in stem cell self-renewal and expansion during extended culture
25 periods. This expansion of repopulating cells was associated with a parallel increase in SP cells, while SP cells were lost over time in control cultures. These results directly link ABC transporter expression, or at least MDR1 expression, with the SP stem cell phenotype.

30 One possible mechanism for the stem cell expansion was that P-gp expression could result in the efflux of toxic media components from HSCs during the *ex vivo* culture period. This possibility was ruled out by the observation that MDR1-transduced stem

cells had a direct proliferative advantage *in vivo* [Example 2 of U.S. Serial No. 09/584,586 filed May 31, 2000, the disclosure of which is hereby incorporated by reference in its entirety]. When transduced bone marrow cells were directly transplanted in irradiated mice, without an *ex vivo* expansion phase, there was a progressive outgrowth of MDR1-transduced cells relative to a control graft. These results show that MDR1 expression was conferring a more general effect on stem cell division, and not simply acting through a detoxification mechanism specific to *ex vivo* culture. Experiments with a mutant P-gp construct demonstrated that HSC expansion required the molecular pump function of P-gp, suggesting that the mechanism of expansion involved modulation of some endogenous molecular substrate within HSCs [Example 2 of U.S. Serial No. 09/584,586 filed May 31, 2000, the disclosure of which is hereby incorporated by reference in its entirety]. Collectively, these studies show that MDR1 gene expression can promote HSC self-renewal and amplification. Heretofore, it was not known if this property is unique to the MDR1 gene, or whether other ABC transporters can exert a similar function.

Results

The regulated expression of endogenous P-gps in HSCs appears to be important in facilitating the self-renewal divisions that maintain the stem cell compartment over time [see Examples 1 and 2 of U.S. Serial No. 09/584,586 filed May 31, 2000, the disclosure of which is hereby incorporated by reference in its entirety] and indeed, one or more naturally occurring endogenous ABC transporters apparently plays a critical functional role in stem cell homeostasis. This premise is consistent with two observations: (i) HSCs universally express dye-effluxing transporters; and (ii) enforced expression of MDR1 leads to stem cell amplification and myeloproliferation [see Example 1 of U.S. Serial No. 09/584,586 filed May 31, 2000, the disclosure of which is hereby incorporated by reference in its entirety].

As disclosed herein, an alternate ABC transporter(s) is expressed in SP stem cells derived from the *mdr1a/1b* knockout mouse. The analyses of mRNA from sorted SP stem cells have identified several newly cloned transporters that are expressed in SP HSCs, that may possibly have a role in the self-renewal process of HSCs. The most

highly expressed is the *Bcrp1/Mxr/Abcp/ABCG2* gene product, BCRP. Importantly, there is no detectable expression of BCRP in peripheral blood leukocytes, spleen, or thymus at the level of Northern blot analysis, while small but detectable amounts of BCRP mRNA were expressed in human fetal liver.

5

An ABC transporter other than P-gp is expressed in murine SP HSCs: Quantitative repopulation assays were performed using commercially available *mdr1a/ab* $-/-$ mice as donors because it is well known that severe quantitative stem cell abnormalities can coexist with relatively normal peripheral blood counts such as in *W/W_v* mice. Normal
10 numbers of repopulating cells were found to be present in the bone marrow. Bone marrow cells were then analyzed for the content of SP cells after staining with Hoechst dye. To confirm that the knockout mice had the expected phenotype, it was verified that the capacity for Rho 123 efflux had been lost in peripheral blood leukocytes as has been previously described [Schinkel *et al.*, *Proc Natl Acad Sci USA*
15 **94**:4028-4033 (1997)]. Despite this loss of P-gp related transporter function, SP cells were present in normal numbers in the bone marrow when compared to wild type mice of the same strain. This indicates that another ABC transporter is likely being expressed, potentially compensating for the loss of P-gp function.

20 To further test this possibility, biochemical studies were performed on knockout bone marrow cells using known inhibitors of ABC transporter efflux function. Cells were treated with either verapamil or 2-deoxyglucose. Verapamil is a competitive inhibitor of several known ABC transporters including MDR1, whereas 2-deoxyglucose is an inhibitor of ATP synthesis that depletes cellular ATP levels required for ABC
25 transporter function. Treatment with either of these compounds before and during Hoechst 33342 staining eliminated phenotypically identifiable SP cells. These results conclusively demonstrate that another ABC transporter(s) is being expressed in SP cells from the bone marrow of *mdr1a/1b* knockout mice and is (are) responsible for the SP phenotype.

30

Identification of Bcrp as an expressed ABC transporter in hematopoietic stem cells:

An RT-PCR assay was developed to detect mRNA expression of other known ABC transporters in murine bone marrow SP cells. Based on the published human sequences for MRP1 [Cole *et al.*, *Science* **258**:1650-1654 (1992), *see comments*],
5 MRP2, 3, 4 [Kool *et al.*, *Cancer Res.* **57**:3537-3547 (1997)], and BCRP [Doyle *et al.*, *Proc.Natl.Acad.Sci.U.S.A* **95**:15665-15670 (1998):published erratum appears in *Proc Natl Acad Sci U S A*; **96**(5):2569 (1999)] homologous sequences from the murine EST database were identified to design PCR primers for cDNA amplification. Multiple primer sets were tested using mouse liver cDNA as a template, and primer
10 sets were chosen that gave specific bands of the expected size. Using FACS, bone marrow SP cells were sorted from both normal mice and the *mdr1a/1b* knockout mouse. Total cellular RNA was prepared from 50,000 and 100,000 purified SP cells, and then used for RT-PCR analysis. These experiments showed that the *Bcrp1* (mBCRP) mRNA was the most highly expressed of all the transporters studied.
15 Moderate expression levels were observed for *mrp4* and *mrp1*, while *mrp3* was expressed at very low levels, and no detectable expression of *mrp2* was observed. The low levels of expression of *mrp1* in the liver correlated with previously described low levels of expression of MRP1 in human liver [Kool *et al.*, *Cancer Res.* **57**:3537-3547 (1997)]. Virtually identical results were obtained using sorted SP cells from normal
20 mice.

It is important to note that while SP cells are highly enriched for repopulating cells, at least 250 SP cells are required to achieve significant repopulation in mice [Goodell *et al.*, *J.Exp.Med.* **183**:1797-1806 (1996)] indicating that most SP cells are not true stem
25 cells. In contrast, it has previously been shown that CD34⁺, c-kit⁺, Sca1⁺, lineage negative (CD34-KSL) cells from the bone marrow are a relatively pure subset of repopulating cells, with repopulation in about 20% of mice that are transplanted with single sorted cells [Osawa *et al.*, *Science* **273**:242-245 (1996)]. Therefore, transporter expression was studied in the highly purified CD34-KSL population, as well as from a
30 number of other different sorted populations.

Like SP cells, the CD34-KSL cells expressed relatively high levels of mBCRP mRNA, however in contrast to SP cells, there were little to no expression of the other ABC transporters. In the more differentiated CD34⁺ KSL cell fraction, there was marked downregulation of mBCRP expression with the appearance of significant
5 expression of *mrp1*, 2, and 4. The S⁺K⁺Lin⁻ population is a mixture of CD34⁻ and + cells, and gave results that were intermediate between the CD34⁺ and - subfractions. mBCRP expression was not detectable in granulocytes, macrophages, B cells, or thymocytes. The only other cell populations with detectable mBCRP expression were erythroid progenitors (Ter119⁺) and natural killer cells (NK1.1⁺). These results
10 suggest that mBCRP expression is highly specific for repopulating stem cells in the lineage negative compartment of the bone marrow, and that expression of other transporters in the sorted SP cell population were likely due to the presence of more differentiated cells with lesser degrees of repopulation potential. These data indicate that BCRP expression should be a useful marker for stem cell identification and
15 purification. The expression data are also consistent with a necessary functional role for BCRP gene expression in repopulating hematopoietic stem cells, and perhaps in SP stem cells from muscle and other tissues.

High levels of expression of BCRP mRNA in sorted SP cells from Rhesus Monkey
20 *bone marrow:* To determine if primate SP cells were expressing BCRP, a bone marrow aspirate sample was obtained from a normal Rhesus Monkey. After lysis of the red blood cells, the leukocyte population was stained with Hoechst dye and analyzed by flow cytometry for SP cells. The flow pattern was very similar to that obtained with mouse bone marrow, with about 0.05% of cells falling into the SP gate
25 (*see above*). Sorting was performed and resulted in isolation of 2000 SP cells, and 10,000 cells from a distinct gate outside of the SP region (non-SP cells). RNA was extracted, and a RT-PCR cycle curve using β -actin primers as an internal control showed roughly equivalent signals at 35 cycles for non-SP cells versus 60 cycles for SP cells. These PCR conditions were repeated using BCRP-specific primers in place
30 of the β -actin primers. A strong signal was obtained with BCRP primers at 60 cycles in the SP cells sample, and a much fainter signal was detected at 50 cycles. No BCRP signal was detected at 35 cycles in the non-SP sample, which was the highest cycle

number used for this sample. These results demonstrate relatively specific, high level expression of BCRP mRNA in monkey SP cells since the β -actin signal for non-SP cells at 35 cycles was actually greater than the signal for SP cells at 60 cycles. Taken together with the mouse data, (above) these results show that the expression of a
5 BCRP transporter ortholog is conserved in SP stem cells from diverse species. In addition, these results further confirm that human stem cells can be identified and/or purified by monitoring/exploiting their unique BCRP expression .

Expression of Bcrp1 in murine myoblast SP cells and murine ES cells: Stem cells
10 bearing the SP phenotype have also been identified in murine muscle, and appear to be related to the satellite cells that are located on the periphery of the muscle fiber. Consistently, these cells also appear to be associated with muscle regeneration.

SP cells were therefore isolated from the murine muscle, and assayed for mBCRP
15 expression by RT-PCR to further correlate *Bcrp1* (mBCRP) expression with the SP phenotype. Muscle tissue was dissected, minced, digested with collagenase, and a single cell suspension was stained with Hoechst dye for SP cell analysis. An SP population of cells was observed with FACS analysis that bears a striking resemblance to the profile seen with bone marrow cells. Gated myoblast SP cells
20 were sorted, and RNA was prepared from a fraction of 20,000 cells. RT-PCR analysis showed relatively high levels of mBCRP expression. However, unlike the results with monkey bone marrow, a distinct non-SP cell fraction was not available for analysis. These results further support the conclusion that mBCRP expression can be used to identify SP stem cells from a variety of organs.

25 In contrast to the results described above, the non-SP population from murine ES cells expressed *mBCRP* at equivalent levels to the SP fraction. This is not surprising because ES cells are clonally derived and are expected to be homogenous with regard to gene expression. These results show that *mBCRP* expression is conserved in all SP
30 populations that were studied, and suggests a possible required role for mBCRP in stem cell function.

Vector-mediated expression of ABCG2 (huBCRP) directly confers the SP phenotype.

A pcDNA-based BCRP vector was used to transfect Soas2 cells, which were then analyzed for their dye efflux properties. Transfected clones readily effluxed Hoechst dye but not rho, and the efflux activity was fully inhibited by reserpine. Furthermore,
5 an inactivating mutation in the Walker A motif abolished the Hoechst dye efflux activity, showing the requirement for transporter pump function in dye efflux. These findings are fully consistent with the Hoechst low, rho bright phenotype of bone marrow SP cells from *mdr1a/1b*^{-/-} mice.

10 A retroviral producer cell line was then used based on the Harvey murine sarcoma virus backbone (HaBCRP) to transduce normal murine bone marrow cells. After culture in myeloid cytokines for 12 days, vector-transduced cells showed a large increase in the number of SP cells, with greater than 60% of the cells falling within the SP region. By comparison, only 0.05% of cells that were mock-transduced
15 showed the SP phenotype. HaBCRP-transduced bone marrow cells were also transplanted into lethally irradiated recipients to determine if SP expansion could be directly obtained *in vivo*. Three mice were killed 5 weeks after transplant, and all showed increased proportions of SP cells in the bone marrow ranging between 1.4 to 11.4 % SP cells. Altogether, these results show that expression of HuBCRP
20 transporter can directly confer the SP phenotype in transduced primary bone marrow cells.

Enforced expression of HuBCRP in murine bone marrow cells blocks differentiation.

To determine the functional effects of enforced HuBCRP expression,
25 HaBCRP-transduced bone marrow cells were assayed for their ability to generate myeloid progenitor colonies. In cells that were analyzed directly after transduction, a significant decrease in CFU-C and CFU-S formation was seen in HaBCRP-transduced populations. The plating efficiency of CFU-C was decreased between 4-6 fold in 2 independent experiments. Control cells gave confluent CFU-S at a dose of 1×10^5
30 cells, while HaBCRP-transduced cells gave only a few discrete colonies. To control for non-specific effects of HuBCRP expression in the producer cells during the coculture phase of transduction, bone marrow cells were also co-cultured with

HaBCRP-transduced 3T3 cells. No effects on progenitor content were seen with this control.

Lethally irradiated C57Bl/6J mice were then transplanted with HaBCRP-transduced
5 cells and the effects on hematopoietic reconstitution were studied. Despite
amplification of SP cells in the bone marrow in all 3 cases, transduction with
HaBCRP was associated with a significant decrease in the peripheral white blood cell
count at 5 weeks, and a parallel decrease in the CFU-C content in the bone marrow.
Competitive repopulation assays were next performed to more precisely quantify the
10 effects of vector expression on myeloid maturation. Mock-transduced bone marrow
cells were competed in equal ratios with either HaBCRP-transduced cells, or with
cells transduced with a control MSCV-GFP vector. At 9 weeks after transplant,
peripheral contributions to the erythrocyte compartment were measured using an
electrophoresis assay that distinguishes between donor specific hemoglobin
15 polymorphisms [Bunting, K.D. *et al.*, *Blood* **96**: 902-909 (2000); U.S. Serial No.
09/584,586 filed May 31, 2000, the disclosures of which are hereby incorporated by
reference in their entireties]. These studies showed that the HaBCRP vector caused a
marked inhibition of erythroid repopulation that was not seen in mock controls.
Altogether, these results show that enforced expression of HuBCRP can block
20 hematopoietic differentiation, and suggest that endogenously expressed *BCRP*
HuBCRP may function to maintain stem cells in a primitive, pluripotent state.

*Derivation of murine monoclonal antibodies against the human ABCG2 (huBCRP)
gene product:* A human BCRP cDNA was obtained as a full length EST from
25 Genome Systems in St. Louis, MO (*see* Methods above). This cDNA was cloned into
the Harvey murine sarcoma virus backbone to create the HaBCRP retroviral vector, as
described above. This vector was next introduced into the ecotropic packaging cell
line GPE86, and vector-containing supernatant was used to transduce NIH 3T3 cells. A
polyclonal population of cells (designated 3T3-BCRP) was isolated by flow
30 cytometry, gating on cells that efflux the fluorescent dye Hoechst 33342. Expression
of the HuBCRP gene product in these cells was confirmed by Western blot analysis
using a polyclonal serum raised in rabbits to an internal peptide epitope.

The 3T3-BCRP cells were used to immunize mice. Twenty BALB-C mice were immunized with whole, living 3T3-BCRP cells by injecting 4 million cells directly into the peritoneal space. Fourteen days later, these cells were reinjected as an immunization boost. Individual mice that showed antibody reactivity in the serum were killed and hybridoma clones were isolated after cell fusion and selection with HAT media. Supernatants from each hybridoma clone were screened by flow cytometry using a human breast cancer cell line (MCF-7) that had been transduced with an amphotrophic HaBCRP vector. Any supernatant that showed reactivity in this assay was then back-screened on the parental MCF-7 line, and clones that reacted with the MCF-7 HaBCRP cells but not with the parental MCF-7 line were scored as positive and specific. These cells were then subcloned, and re-screened based on the indicator cell lines (*see* Figure 1).

Independent subclones that show relatively large shifts with the MCF-7 HaBCRP cells, but not with the parental control cells are then isolated. Clones that can detect expression of the HaBCRP vector in bone marrow cells from previously transplanted mice are then expanded to produce larger quantities of supernatant *ex vivo* with a rollerbottle production system. The antibodies are then purified on an affinity column. These antibodies can then be tested for their ability to detect the endogenously expressed huBCRP gene product in human umbilical cord blood samples. Antibodies that detect the endogenously expressed ABCG2 gene product in human umbilical cord blood samples can then be used to identify and/or isolate stem cells.

25

Discussion

While Hoechst and rho dye staining have long served as methods for hematopoietic stem cell purification, the molecular basis for this phenotype has not been defined. The results provided herein show that both *Bcrp1* and MDR1 homologues are expressed in a relatively restricted manner in primitive stem cells. The fact that SP cells are not diminished in *mdr1a/b*^{-/-} mice is explained by the compensatory Hoechst efflux activity provided by *Bcrp1* expression. The lack of rho dull SP cells in

30

mdr1a/b^{-/-} mice is similarly explained by the fact that Pgp can efflux rho but the BCRP pump cannot. The finding that these dye efflux activities are molecularly distinguishable has significant implications for stem cell purification strategies. For instance, murine ES cells do not efflux rho, implying that Hoechst dye efflux
5 (mBCRP expression) is a more specific stem cell marker.

Several aspects of the data disclosed herein indicate that BCRP plays an important functional role in stem cells. The conserved expression of this transporter in SP stem cells from a wide variety of sources is consistent with a required function. Secondly,
10 the tightly regulated expression pattern of *Bcrp1* in murine hematopoiesis, where expression is markedly decreased in early stages of differentiation, is consistent with a stem cell-specific role. Further evidence is provided by overexpression studies, where enforced huBCRP expression leads to a defect in hematopoietic differentiation. *In vivo*, the HaBCRP vector caused an accumulation of SP cells in the bone marrow, but
15 mature progeny from these cells were significantly decreased in the bone marrow and peripheral blood, and a direct inhibitory effect on CFU-C and CFU-S formation was observed. Altogether, these results are best explained by a model where *Bcrp1* expression in stem cells confers relative resistance to commitment and differentiation and thereby contributes to maintaining a primitive, pluripotent state. This potential
20 anti-differentiative effect would then be alleviated with the observed decrease in expression that occurs during early commitment. Along these lines, the results of enforced expression can now be explained by promiscuous expression of *Bcrp1* in more mature compartments where endogenous expression does not normally occur. The block to development could occur in these compartments as the result of
25 deregulated *Bcrp1* expression.

In considering the mechanism for these effects, it is notable that the normal physiologic functions of BCRP have not yet been defined. The gene was first isolated from human tumor cell lines and shown to be involved in drug resistance [Doyle, L.A.
30 *et al.*, *Proc. Natl. Acad. Sci. U. S. A* **95**:15665-15670 (1998); Miyake, K. *et al.*, *Cancer Res.* **59**:8-13 (1999); Maliepaard, M. *et al.*, *Cancer Res.* **59**: 4559-4563 (1999)]. The primary structure of huBCRP shares the highest homology with the *Drosophila white*

gene product. These “half transporters” have only one ATP binding cassette, and are thought to require homo- or heterodimerization for ATP hydrolysis and function. The *white* gene product heterodimerizes with two other half transporters, and these interactions specifically define eye color in *Drosophila* [Ewart, G.D. *et al.*, *J. Biol. Chem.* **269**, 10370-10377 (1994)]. BCRP may also form heterodimers in mammalian cells with other as yet undefined partners, and these interactions could affect substrate specificity.

While the mechanism for the effects of huBCRP expression on hematopoietic differentiation is not known, several general possibilities can be proposed. There is a precedent for the ability of ABC transporters to maintain stem cell primitivity in lower organisms. *Dictyostelium* cells express a transport activity defined by rho efflux that maintains cells in a primitive undifferentiated state [Good, J.R. & Kuspa, A., *Dev. Biol.* **220**: 53-61 (2000)]. This effect is conferred by efflux of a differentiation-inducing factor, DIF-1, from the interior of prespore cells. It is possible that *Bcrp1* is modulating an analogous substrate in mammalian cells. A second possibility is that the *Bcrp1* pump may play a role in mediating extracellular signals that dictate stem cell interactions with the microenvironment. This type of effect on extracellular signaling has recently been demonstrated in *mrp1*^{-/-} mice, where this transporter has been shown to be required for normal dendritic cell migration via transport of leukotrienes to the extracellular space [Robbani, D.R. *et al.*, *Cell* **103**: 757-768 (2000)]. A third possibility is that *Bcrp1* may be providing a function that is redundant with *mdr1a*, so that the loss of a potential anti-apoptotic signal in stem cells in the *mdr1a/1b*^{-/-} knockout mice could be compensated by *Bcrp1* expression.

25

Methods

Retroviral-mediated gene transfer into murine hematopoietic stem cells: Bone marrow cells can be harvested from C57BL/6 or B6.Ch-1/By (referred to as “HW80”) congenic mouse strains (Jackson Laboratories, Bar Harbor, ME) by standard methods. Following isolation, cells are placed into liquid suspension culture in Dulbecco’s Modified Eagle’s Medium (DMEM) (BioWhittaker, Walkersville, MD) with 1% penicillin/ streptomycin (Gibco/BRL, Grand Island, NY), 15% fetal bovine

30

serum (FBS; Hyclone, Logan UT), 20 ng/ml murine interleukin (IL)-3 R & D Systems, Minneapolis, MN), 50 ng/ml human IL-6 (Amgen, Thousand Oaks, CA), and 50 ng/ml murine stem cell factor R & D Systems). The cells are initially plated at 1×10^6 cells/ml in 10 mls of medium. Following pre-stimulation for 48 hours, cells
5 are replated onto confluent monolayers of irradiated ecotropic producer cell lines. The bone marrow cells were plated at the same density used in the pre-stimulation phase and in the same medium with 6 μ g/ml polybrene added. Co-culture with producer cells is continued for 48 hours followed by harvest of bone marrow cells. A small sample of bone marrow cells are plated into methylcellulose to score
10 drug-resistant myeloid progenitors.

Southern Blot Analysis: DNA can be prepared as previously described [Sorrentino *et al.*, Science **257**:99-103 (1992)]. Typically 10 to 20 mg of genomic DNA is restriction digested with either EcoR1 or NheI, and separated on a 1% agarose gel.
15 Gels can be blotted overnight onto Hybond N⁺ nylon membrane (Amersham), UV crosslinked, and hybridized with either MDR1 or hemoglobin-specific [³²P]-labeled probes. Blots are washed extensively at 65°C, exposed overnight, and can be analyzed on a phosphorimager (Molecular Dynamics).

20 *Rhodamine 123 (Rho123) staining:* Rho123 staining can be performed by trypsinizing cells, resuspending the cells in DMEM medium containing 10% FCS at a concentration of 1×10^6 cells/ml, and adding Rho123 (Sigma) at a final concentration of 1 μ g/ml. The cells are then incubated at 37°C for one hour in the dark, washed once with 10 mls of PBS, and resuspended in DMEM/10% FCS. The cells are next
25 incubated at 37°C for one hour to allow for efflux, spun down, and then resuspended in 1 ml of PBS for FACS analysis.

4E3 antibody and Rhodamine 123 staining: Producer cells can be analyzed for an ABC transporter, *e.g.*, P-gp expression by staining with a monoclonal mouse
30 anti-human P-glycoprotein antibody (clone 4E3, DAKO, Carpinteria, CA). Adherent cells are trypsinized, and resuspended in 50 μ l PBS containing 2% BSA and 0.1% NaN₃. 5 μ l of the 4E3 antibody are then added, incubated at room temp (RT) for 30

minutes, washed twice with phosphate buffered saline (PBS), and then resuspended in 50 ul PBS containing 2% BSA and 0.1% NaN₃. After the primary antibody staining, 5 ul of PE-conjugated, rabbit anti-mouse antibody (DAKO) is added as a secondary stain. The cells are then incubated at RT for 30 minutes, washed twice with PBS,
5 resuspended in PBS for FACS analysis.

Hoechst 33342 SP cell assay: Murine bone marrow cells are collected and resuspended at 1×10^6 cells/ml in DMEM plus 10 mM HEPES and 2% FBS. In a water bath, the cells are allowed to equilibrate at 37°C, followed by addition of 5
10 µg/ml Hoechst 33342 (Fisher Scientific, Pittsburgh, PA) for 90 minutes as previously described [Goodell *et al.*, *J. Exp. Med.*, **183**:1797-1806 (1996)]. Cells are then centrifuged at 4°C and resuspended in ice cold HBSS plus 10 mM HEPES and 2% FBS at 1×10^7 cells/ml. For flow cytometric analysis or sorting, a Becton Dickinson FACS Vantage flow cytometer (Becton Dickinson, San Jose, CA) can be configured
15 for dual emission wavelength analysis as previously described [Goodell *et al.*, *J. Exp. Med.*, **183**:1797-1806 (1996)]. Cells are gated based on forward and side light scatter to exclude debris. Propidium iodide staining (2 µg/ml) can be utilized to derive a gate excluding dead cells. Cells are analyzed at approximately 5,000 cells/second until data from 1×10^6 cells are collected. The SP cell gate can be defined based on normal
20 fresh bone marrow cells,(C57BL/6 for example).

Mice: Both male and female *mdr1a/1b*^{-/-} mice, backcrossed onto the FVB background, were purchased from Taconic Labs (Germantown, NY). For transplant studies, female C57BL/6J and B6.C-H1b/ByJ mice (referred to as HW80) were purchased
25 from Jackson Laboratories (Bar Harbor, ME), and used between 8 and 14 weeks of age.

SP cell analysis. Murine and Rhesus monkey SP cell analyses was performed exactly as previously described [Goodell, M.A. *et al.*, *J. Exp. Med.* **183**:1797-1806 (1996);
30 Goodell, M.A. *et al.*, *Nat. Med.* **3**:1337-1345 (1997)]. For the inhibitor experiments, 2-deoxyglucose and sodium azide (Sigma, St. Louis), or reserpine (Sigma) were added to cells at a final concentration of 50 and 15 mM, or 5 µM respectively. Cells were

then incubated at 37°C for 15 minutes prior to adding Hoechst 33342 dye. In other experiments, bone marrow cells were incubated in the presence of 0.1 µg/ml rhodamine 123 (Sigma) at 37°C for 20 minutes, then resuspended in medium containing Hoechst 33342 for SP analysis.

5

Cell sorting and RNA extraction. Using a FACS Vantage (Becton Dickinson, San Jose, CA) for flow cytometric sorting, approximately 300,000 and 160,000 SP cells were isolated from the bone marrow of *mdr1a/1b^{-/-}* and wildtype mice respectively. Rhesus monkey bone marrow cells from a 2 ml aspirate were sorted by flow cytometry, and approximately 2,000 SP and 10,000 non-SP cells were isolated. Single cell suspensions of murine skeletal muscle cells were prepared for SP analysis as previously described [Gussoni, E. *et al.*, *Nature* **401**:390-394 (1999)], and 10,000 SP and non-SP cells were sorted. The procedure for purifying murine CD34⁺ stem cells has been previously described [Osawa, M. *et al.*, *Science* **273**:242-245 (1996)]. In all cases, total RNA from the sorted cells was isolated using RNA STAT-60 (Tel-Test, INC. Friendswood, TX) according to the manufacture's recommendations.

15

RT-PCR assays. The primers used for PCR amplification are as follows:

20 murine bcrp1: 5'-CCATAGCCACAGGCCAAAGT-3', SEQ ID NO:17 and
5'-GGGCCACATGATTCTTCCAC-3', SEQ ID NO:18 for a 327bp fragment;

Rhesus BCRP: 5'-GGCCTCAGGAAGACTTATGT-3', SEQ ID NO:19 and
5'-AAGGAGGTGGTGTAGCTGAT-3', SEQ ID NO:20 for a 342bp fragment.

25

Multiplex PCR for MDR1 like genes utilized a forward primer for *mdr1a* and *mdr2*
5'-AGCTGGAGAGATCCTCACC-3', SEQ ID NO:21,
a forward primer for *mdr1b*

5'-AGCCGGAGAGATCCTCACC-3', SEQ ID NO:22 and

30 reverse primers for *mdr1a*, *mdr1b*, and *mdr2* respectively:
5'-CTGTAGCTGTCAATCTCGGG-3', SEQ ID NO:23,

5'-CTGTAGCTGTCAATCTCAGG-3', SEQ ID NO:24, and

5'-CTGTAGCTGTCAATCAGAGG-3', SEQ ID NO:25 .

These primers amplify a 730bp fragment for all 3 cDNAs.

- 5 PCR products were digested with a mixture of BstXI, BglII, and EcoRI at 37°C to distinguish the relative contributions from each cDNA species (*mdr1a* BstXI digestion: 619 + 111bp, *mdr1b* BglII digestion: 305 + 425bp, *mdr2* EcoRI digestion: 452 + 278bp).
- 10 RNA was treated with RQ1 RNase-free Dnase (Promega, Madison, WI) and reverse transcribed into cDNA by using Superscript II RT (Gibco-BRL, Gaithersburg, MD) and a mixture of oligo dT primers and random hexamers, according to the manufacturers instructions. All cDNAs were first normalized using GAPDH as a standard. In the experiments involving murine SP populations, ABC transporter
- 15 amplification were performed using 32 cycles. In CD34⁺ experiments, GAPDH normalized cDNA aliquots were amplified with mBCRP primers for 35 cycles. In the Rhesus monkey experiments, RNA from 2000 SP cells was amplified for HuBCRP or β -actin using 60 cycles, while RNA from 10,000 non-SP cells was amplified using 35 cycles, based on the observation that these different conditions gave equivalent β -actin
- 20 signals from each sample. All PCR reactions were performed using 0.2 μ L P³²-labeled CTP at 800 μ Ci/mmol/L in the reaction mix. After amplification, 20 μ L of the reaction mix was electrophoresed on a 5% nondenaturing polyacrylamide gel. HuBCRP expression vectors, transduction, and transplants.
- 25 The human BCRP cDNA was obtained (Genome Systems, St. Louis, MO) as a full length EST # 52176, SEQ ID NO:26. This cDNA was cloned either into the pcDNA₃ expression vector (Invitrogen, Palo Alto, CA), or used to replace the MDR1 cDNA in the HaMDR1sc vector [Bunting, K.D. *et al.*, *Blood* **92**: 2269-2279 (1998); Bunting, K.D. *et al.*, *Blood* **96**: 902-909 (2000); U.S. Serial No. 09/584,586 filed May
- 30 31, 2000, the disclosures of which are hereby incorporated by reference in their entireties]. Polyclonal populations of ecotropic producer cells were generated by transducing GP⁺E86 packaging cells [Markowitz, D. *et al.*, *J. Virol.* **62**:1120-1124

(1988)] with a transient supernatant derived from transfected 293T cells, as previously described [Persons,D.A. *et al.*, *Blood Cells Mol. Dis.* **24**: 167-182 (1998)].

Vector-transduced producer cells were then isolated by cell sorting for Hoechst 33342 dim cells. The methods for transduction of bone marrow cells, *in vitro* expansion of
5 cells, murine transplants, and competitive repopulation assays has been previously described [Allay,J.A. *et al.*, *Nat. Med.* **4**:1136-1143 (1998)]. CFU-C and CFU-S assays were done as previously described [Allay,J.A. *et al.*, *Blood* **90**: 3546-3554 (1997); Persons,D.A. *et al.*, *Blood* **90**:1777-1786 (1997)].

10

EXAMPLE 2

BCRP EXPRESSION IN BLASTS FROM PEDIATRIC ACUTE MYELOGENOUS LEUKEMIA (AML)

Clinical evidence shows an association between dysregulated ABC transporter
15 expression and human leukemia. In chronic myelogenous leukemia, about 60% of chronic phase patients exhibit P-gp expression in leukemic cells from the bone marrow [Giles *et al.*, *Cancer* **86**:805-813 (1999)]. In patients with acute myelogenous leukemia (AML), between 35 and 70% of cases demonstrate P-gp expression in leukemic blasts at diagnosis, and P-gp expression was a strongly negative prognostic
20 factor [Leith *et al.*, *Blood* **94**:1086-1099 (1999)]. In contrast, normal late myeloid cells in humans do not express P-gp [Drach *et al.*, *Blood* **80**:2729-2734 (1992), *see* comments]. In some cases, increased P-gp expression in blast cells was due to hypomethylation of sequences in the MDR1 promoter [Nakayama *et al.*, *Blood* **92**:4296-4307 (1998)]. Expression of other ABC transporters can occur in human
25 AML, as has been documented for the multidrug resistance protein (MRP1), and the lung resistance protein (LRP) [Leith *et al.*, *Blood* **94**:1086-1099 (1999); Michieli *et al.*, *Br.J.Haematol.* **104**:328-335 (1999)]. Importantly, a significant number of AML cases showed inhibitable dye efflux activity that was not associated with MDR1, MRP1, or LRP [Michieli *et al.*, *Br.J.Haematol.* **104**:328-335 (1999); Leith *et al.*,
30 *Blood* **86**:2329-2342 (1995)].

To determine if BCRP expression could be detected in leukemia cells from pediatric patients with AML, RT-PCR analysis was performed on RNAs derived from leukemic bone marrow from four individual cases. Two cases were strongly positive for BCRP mRNA, with BCRP-amplified fragments detected at 25 cycles of amplification.

5 Interestingly both of these “high-expressing” cases were associated with the M1 FAB phenotype. Two other cases with an M5 phenotype did not show any detectable signal at 25 cycles, but BCRP could be detected at 30 cycles. β -actin controls demonstrated that this variation was not due to differences in mRNA loading. The low level signal
10 seen in the M5 cases could have been due to contaminating erythroid progenitors which may be expressing BCRP, or due to low level BCRP expression in the blast cells. These data confirm that BCRP mRNA expression can be detected in at least some primary AML samples. Furthermore, these results provide further impetus for using an anti-BCRP antibody to probe blast cell samples in the diagnosis/prognosis of AML.

15

While the invention has been described and illustrated herein by references to the specific embodiments, various specific material, procedures and examples, it is understood that the invention is not restricted to the particular material combinations of material, and procedures selected for that purpose. Indeed, various modifications
20 of the invention in addition to those described herein will become apparent to those skilled in the art from the foregoing description. Such modifications are intended to fall within the scope of the appended claims.

It is further to be understood that all base sizes or amino acid sizes, and all molecular
25 weight or molecular mass values, given for nucleic acids or polypeptides are approximate, and are provided for description.

Various publications, patent applications and patents are cited herein, the disclosures of which are incorporated by reference in their entireties.

WHAT IS CLAIMED IS:

1. A method of identifying a stem cell comprising:
 - (a) obtaining a cell sample which contains a stem cell; and
 - 5 (b) detecting the expression of BCRP by a cell in the cell sample; wherein a cell that expresses BCRP is identified as a stem cell.
2. The method of Claim 1 wherein said detecting is performed with an antibody that binds to BCRP; and wherein a stem cell is identified if it binds to said antibody.
10
3. The method of Claim 1 wherein said detecting is performed with a PCR probe for the nucleic acid that expresses BCRP.
4. The method of Claim 1 wherein said detecting is performed by measuring the
15 pumping activity of the cell; wherein a stem cell is identified if it can remove Hoechst 33342 dye, but not Rhodamine 123 dye.
5. The method of Claim 1 further comprising:
 - (c) detecting the expression of a cell marker associated with stem cells;
 - 20 wherein a cell that expresses BCRP and expresses the cell marker is identified as a stem cell.
6. The method of Claim 5 wherein said cell marker is selected from the group consisting of EM10, CD34, Thy-1, P-gp, Ac133, and c-kit.
25
7. The method of Claim 5 wherein said cell marker is CD34 and wherein the cell is also CD38⁺.
8. The method of Claim 1 further comprising
30 (c) detecting the expression of a lineage specific marker; wherein a cell that expresses BCRP but does not express the lineage specific marker is identified as a stem cell.

9. The method of Claim 8 wherein said stem cell is a hematopoietic stem cell and the lineage specific marker is selected from the group consisting of CD2, CD3, CD4, CD8, CD14, CD15, CD16, CD19, CD20, CD33, CD38, CD56, CD71, HLA-DR, and glycophorin A.

5

10. A method of isolating a cell that expresses BCRP comprising:
(a) obtaining a cell sample which contains a cell that expresses BCRP;
(b) detecting the expression of BCRP by a cell in the cell sample; and
(c) isolating the cell that expresses BCRP.

10

11. A method of isolating a cell that expresses BCRP comprising:
(a) obtaining a cell sample which contains a cell that expresses BCRP;
(b) contacting the cell sample with an antibody that binds to BCRP; and
(c) isolating a cell from the cell sample that binds to said antibody;

15 wherein the isolated cell is a cell that expresses BCRP.

12. The method of Claim 11, wherein said isolating is performed by flow cytometry.

20 13. The method of Claim 12, wherein said antibody has a fluorescent label and said isolating is performed by fluorescence-activated cell sorting.

14. An isolated stem cell obtained by the method of Claim 11.

25 15. A cell population enriched for stem cells obtained by a method comprising:
(a) obtaining a mixed population of cells which comprises both stem cells and cells that are not stem cells; and
(b) separating the cells of the mixed population of cells into two individual groups of cells based on whether they do or do not express BCRP; wherein the group
30 of cells that express BCRP is a cell population enriched for stem cells.

16. An antibody that recognizes an extracellular portion of a BCRP; wherein said extracellular portion of the BCRP is in its natural conformation.
17. The antibody of Claim 16 wherein the BCRP is on the surface of a viable stem
5 cell.
18. A method for determining the amount of BCRP expressed in a human subject having or suspected of having leukemia comprising:
- 10 (a) obtaining a leukemic cell from the subject; and
- (b) determining the amount of BCRP expressed in the leukemic cell.
19. The method of Claim 18, wherein the leukemia is acute myelogenous leukemia (AML).
- 15 20. The method of claim 19 wherein the leukemic cell is a blast cell.

I340-1-021 CIP2 (Sheet 1 of 1)




Figure 1

SEQUENCE LISTING

<110> Sorrentino, Brian
 Schuetz, John
 <120> A Method of Identifying and/or Isolating Stem Cells
 <130> 1340-1-021CPCT
 <140> Unassigned
 <141> 2001-05-30
 <150> 09/584,586
 <151> 2000-05-31
 <150> Unassigned
 <151> 2001-05-29
 <160> 27
 <170> PatentIn version 3.0
 <210> 1
 <211> 3860
 <212> DNA
 <213> Homo sapiens
 <400> 1
 atggatcttg aaggggaccg caatggagga gcaaagaaga agaacttttt taaactgaac 60
 aataaaagtg aaaaagataa gaaggaaaag aaaccaactg tcagtgtatt ttcaatgttt 120
 cgctattcaa attggcttga caagttgtat atggtggtgg gaactttggc tgccatcatc 180
 catggggctg gacttcctct catgatgctg gtgtttggag aaatgacaga tatctttgca 240
 aatgcaggaa atttagaaga tctgatgtca aacatcacta atagaagtga tatcaatgat 300
 acagggttct tcatgaatct ggaggaagac atgaccagat atgcctatta ttacagtggg 360
 attggtgctg ggggtgctgg tgcctgttac attcaggttt catttttggtg cctggcagct 420
 ggaagacaaa tacacaaaat tagaaaacag ttttttcatg ctataatgcg acaggagata 480
 ggctggtttg atgtgcacga tgttggggag cttaacaccc gacttacaga tgatgtctct 540
 aagattaatg aaggtattgg tgacaaaatt ggaatgttct ttcagtcaat ggcaacattt 600
 ttcactgggt ttatagtagg atttacacgt ggttgggaagc taacccttgt gattttggcc 660
 atcagtcctg ttcttggact gtcagctgct gtctgggcaa agatactatc ttcatttact 720
 gataaagaac tcttagcgta tgcaaaagct ggagcagtag ctgaagaggt cttggcagca 780
 attagaactg tgattgcatt tggaggacaa aagaaagaac ttgaaaggta caacaaaaat 840
 ttagaagaag ctaaaagaat tgggataaag aaagctatta cagccaatat ttctataggt 900
 gctgctttcc tgctgatcta tgcattctat gctctggcct tctggtatgg gaccaccttg 960
 gtcctctcag gggaatattc tattggacaa gtactcactg tattcttttc tgtattaatt 1020
 ggggctttta gtgttggaca ggcatctcca agcattgaag catttgcaaa tgcaagagga 1080
 gcagcttatg aaatcttcaa gataattgat aataagccaa gtattgacag ctattcgaag 1140
 agtgggcaca aaccagataa tattaaggga aatttggaaat tcagaaatgt tcaattcagt 1200
 taccatctc gaaaagaagt taagatcttg aagggcctga acctgaaggt gcagagtggg 1260
 cagacggtgg ccctggttgg aaacagtggc tgtgggaaga gcacaacagt ccagctgatg 1320
 cagaggctct atgacccac agaggggatg gtcagtgttg atggacagga tattaggacc 1380
 ataaatgtaa ggtttctacg ggaaatcatt ggtgtggtga gtcaggaacc tgtattgttt 1440

gccaccacga tagctgaaaa cattcgctat ggccgtgaaa atgtcaccat ggatgagatt 1500
gagaaagctg tcaaggaagc caatgcctat gactttatca tgaaactgcc tcataaattt 1560
gacaccctgg ttggagagag agggggcccag ttgagtgggtg ggcagaagca gaggatcgcc 1620
attgcacgtg ccctggttcg caaccccaag atcctcctgc tggatgaggc cacgtcagcc 1680
ttggacacag aaagcgaagc agtgggttcag gtggctcttg ataaggccag aaaaggtcgg 1740
accaccattg tgatagctca tcgtttgtct acagttcgta atgctgacgt catcgctgggt 1800
ttcgatgatg gagtcattgt ggagaaagga aatcatgatg aactcatgaa agagaaaggc 1860
atttacttca aacttgtcac aatgcagaca gcaggaaatg aagttgaatt agaaaatgca 1920
gctgatgaat ccaaaagtga aattgatgcc ttggaaatgt cttcaaataa ttcaagatcc 1980
agtctaataa gaaaaagatc aactcgtagg agtgtccgtg gatcacaagc ccaagacaga 2040
aagcttagta ccaaagaggc tctggatgaa agtatacctc cagtttcctt ttggaggatt 2100
atgaagctaa atttaactga atggccttat tttgttgttg gtgtattttg tgccattata 2160
aatggaggcc tgcaaccagc atttgcaata atattttcaa agattatagg ggtttttaca 2220
agaattgatg atcctgaaac aaaacgacag aatagtaact tgttttcact attgtttcta 2280
gcccttgaa ttattttctt tattacattt ttccctcaag gtttcacatt tggcaaagct 2340
ggagagatcc tcaccaagcg gctccgatac atggttttcc gatccatgct cagacaggat 2400
gtgagttgggt ttgatgacc taaaaacacc actggagcat tgactaccag gctcgccaat 2460
gatgctgctc aagttaaagg ggctataggt tccaggcttg ctgtaattac ccagaatata 2520
gcaaactcttg ggacaggaat aattatatcc ttcattctatg gttggcaact aacactgtta 2580
ctcttagcaa ttgtacccat cattgcaata gcaggagttg ttgaaatgaa aatgttgtct 2640
ggacaagcac tgaaagataa gaaagaacta gaagggtgctg ggaagatcgc tactgaagca 2700
atagaaaact tccgaaccgt tgtttctttg actcaggagc agaagtttga acatatgtat 2760
gctcagagtt tgcaggatcc atacagaaac tctttgagga aagcacacat ctttggaatt 2820
acattttcct tcaccaggc aatgatgtat ttttcctatg ctggatgttt ccggtttgga 2880
gcctacttgg tggcacataa actcatgagc tttgaggatg ttctgttagt attttcagct 2940
gttgtctttg gtgccatggc cgtggggcaa gtcagttcat ttgctcctga ctatgccaaa 3000
gccaaaatat cagcagccca catcatcatg atcattgaaa aaacccttt gattgacagc 3060
tacagcacgg aaggccta at gccgaacaca ttggaaggaa atgtcacatt tggatgaagt 3120
gtattcaact atcccacccg accggacatc ccagtgcctc agggactgag cctggagggtg 3180
aagaagggcc agacgctggc tctgggtggc agcagtggtg gtgggaagag cacagtggtc 3240
cagctcctgg agcggttcta cgacccttg gcagggaag tgctgcttga tggcaaagaa 3300
ataaagcgac tgaatgttca gtggctccga gcacacctgg gcatcgtgtc ccaggagccc 3360
atcctgtttg actgcagcat tgctgagaac attgcctatg gagacaacag ccgggtgggtg 3420

```

tcacaggaag agatcgtgag ggcagcaaag gaggccaaca tacatgcctt catcgagtca 3480
ctgcctaata aatatagcac taaagtagga gacaaaggaa ctcagctctc tgggtggccag 3540
aaacaacgca ttgccatagc tcgtgccctt gttagacagc ctcataatattt gcttttggat 3600
gaagccacgt cagctctgga tacagaaagt gaaaagggtg tccaagaagc cctggacaaa 3660
gccagagaag gccgcacctg cattgtgatt gctcacgcc tgtccaccat ccagaatgca 3720
gacttaatag tgggtgttca gaatggcaga gtcaaggagc atggcacgca tcagcagctg 3780
ctggcacaga aaggcatcta tttttcaatg gtcagtgtcc aggctggaac aaagcgccag 3840
tgaactctgg ttaactccac 3860

```

```

<210> 2 <211> 1280 <212> PRT <213> Homo sapiens <400> 2
Met Asp Leu Glu Gly Asp Arg Asn Gly Gly Ala Lys Lys Lys Asn Phe
1 5 10 15
Phe Lys Leu Asn Asn Lys Ser Glu Lys Asp Lys Lys Glu Lys Lys Pro
20 25 30
Thr Val Ser Val Phe Ser Met Phe Arg Tyr Ser Asn Trp Leu Asp Lys
35 40 45
Leu Tyr Met Val Val Gly Thr Leu Ala Ala Ile Ile His Gly Ala Gly
50 55 60
Leu Pro Leu Met Met Leu Val Phe Gly Glu Met Thr Asp Ile Phe Ala
65 70 75 80
Asn Ala Gly Asn Leu Glu Asp Leu Met Ser Asn Ile Thr Asn Arg Ser
85 90 95
Asp Ile Asn Asp Thr Gly Phe Phe Met Asn Leu Glu Glu Asp Met Thr
100 105 110
Arg Tyr Ala Tyr Tyr Tyr Ser Gly Ile Gly Ala Gly Val Leu Val Ala
115 120 125
Ala Tyr Ile Gln Val Ser Phe Trp Cys Leu Ala Ala Gly Arg Gln Ile
130 135 140
His Lys Ile Arg Lys Gln Phe Phe His Ala Ile Met Arg Gln Glu Ile
145 150 155 160
Gly Trp Phe Asp Val His Asp Val Gly Glu Leu Asn Thr Arg Leu Thr
165 170 175
Asp Asp Val Ser Lys Ile Asn Glu Gly Ile Gly Asp Lys Ile Gly Met
180 185 190
Phe Phe Gln Ser Met Ala Thr Phe Phe Thr Gly Phe Ile Val Gly Phe
195 200 205
Thr Arg Gly Trp Lys Leu Thr Leu Val Ile Leu Ala Ile Ser Pro Val
210 215 220
Leu Gly Leu Ser Ala Ala Val Trp Ala Lys Ile Leu Ser Ser Phe Thr
225 230 235 240
Asp Lys Glu Leu Leu Ala Tyr Ala Lys Ala Gly Ala Val Ala Glu Glu

```

245										250					255				
Val	Leu	Ala	Ala	Ile	Arg	Thr	Val	Ile	Ala	Phe	Gly	Gly	Gln	Lys	Lys				
		260						265					270						
Glu	Leu	Glu	Arg	Tyr	Asn	Lys	Asn	Leu	Glu	Glu	Ala	Lys	Arg	Ile	Gly				
		275					280					285							
Ile	Lys	Lys	Ala	Ile	Thr	Ala	Asn	Ile	Ser	Ile	Gly	Ala	Ala	Phe	Leu				
		290				295					300								
Leu	Ile	Tyr	Ala	Ser	Tyr	Ala	Leu	Ala	Phe	Trp	Tyr	Gly	Thr	Thr	Leu				
305					310					315					320				
Val	Leu	Ser	Gly	Glu	Tyr	Ser	Ile	Gly	Gln	Val	Leu	Thr	Val	Phe	Phe				
				325					330					335					
Ser	Val	Leu	Ile	Gly	Ala	Phe	Ser	Val	Gly	Gln	Ala	Ser	Pro	Ser	Ile				
		340						345					350						
Glu	Ala	Phe	Ala	Asn	Ala	Arg	Gly	Ala	Ala	Tyr	Glu	Ile	Phe	Lys	Ile				
		355					360					365							
Ile	Asp	Asn	Lys	Pro	Ser	Ile	Asp	Ser	Tyr	Ser	Lys	Ser	Gly	His	Lys				
	370					375					380								
Pro	Asp	Asn	Ile	Lys	Gly	Asn	Leu	Glu	Phe	Arg	Asn	Val	His	Phe	Ser				
385					390					395					400				
Tyr	Pro	Ser	Arg	Lys	Glu	Val	Lys	Ile	Leu	Lys	Gly	Leu	Asn	Leu	Lys				
				405					410					415					
Val	Gln	Ser	Gly	Gln	Thr	Val	Ala	Leu	Val	Gly	Asn	Ser	Gly	Cys	Gly				
			420					425					430						
Lys	Ser	Thr	Thr	Val	Gln	Leu	Met	Gln	Arg	Leu	Tyr	Asp	Pro	Thr	Glu				
		435					440					445							
Gly	Met	Val	Ser	Val	Asp	Gly	Gln	Asp	Ile	Arg	Thr	Ile	Asn	Val	Arg				
	450					455					460								
Phe	Leu	Arg	Glu	Ile	Ile	Gly	Val	Val	Ser	Gln	Glu	Pro	Val	Leu	Phe				
465					470					475					480				
Ala	Thr	Thr	Ile	Ala	Glu	Asn	Ile	Arg	Tyr	Gly	Arg	Glu	Asn	Val	Thr				
				485					490					495					
Met	Asp	Glu	Ile	Glu	Lys	Ala	Val	Lys	Glu	Ala	Asn	Ala	Tyr	Asp	Phe				
			500					505					510						
Ile	Met	Lys	Leu	Pro	His	Lys	Phe	Asp	Thr	Leu	Val	Gly	Glu	Arg	Gly				
		515					520					525							
Ala	Gln	Leu	Ser	Gly	Gly	Gln	Lys	Gln	Arg	Ile	Ala	Ile	Ala	Arg	Ala				
		530				535					540								
Leu	Val	Arg	Asn	Pro	Lys	Ile	Leu	Leu	Leu	Asp	Glu	Ala	Thr	Ser	Ala				
545					550					555					560				
Leu	Asp	Thr	Glu	Ser	Glu	Ala	Val	Val	Gln	Val	Ala	Leu	Asp	Lys	Ala				
				565					570					575					
Arg	Lys	Gly	Arg	Thr	Thr	Ile	Val	Ile	Ala	His	Arg	Leu	Ser	Thr	Val				
			580					585					590						
Arg	Asn	Ala	Asp	Val	Ile	Ala	Gly	Phe	Asp	Asp	Gly	Val	Ile	Val	Glu				

595					600					605					
Lys	Gly	Asn	His	Asp	Glu	Leu	Met	Lys	Glu	Lys	Gly	Ile	Tyr	Phe	Lys
	610					615					620				
Leu	Val	Thr	Met	Gln	Thr	Ala	Gly	Asn	Glu	Val	Glu	Leu	Glu	Asn	Ala
625					630					635					640
Ala	Asp	Glu	Ser	Lys	Ser	Glu	Ile	Asp	Ala	Leu	Glu	Met	Ser	Ser	Asn
				645					650					655	
Asp	Ser	Arg	Ser	Ser	Leu	Ile	Arg	Lys	Arg	Ser	Thr	Arg	Arg	Ser	Val
			660					665					670		
Arg	Gly	Ser	Gln	Ala	Gln	Asp	Arg	Lys	Leu	Ser	Thr	Lys	Glu	Ala	Leu
		675				680						685			
Asp	Glu	Ser	Ile	Pro	Pro	Val	Ser	Phe	Trp	Arg	Ile	Met	Lys	Leu	Asn
	690					695					700				
Leu	Thr	Glu	Trp	Pro	Tyr	Phe	Val	Val	Gly	Val	Phe	Cys	Ala	Ile	Ile
705					710					715					720
Asn	Gly	Gly	Leu	Gln	Pro	Ala	Phe	Ala	Ile	Ile	Phe	Ser	Lys	Ile	Ile
				725					730					735	
Gly	Val	Phe	Thr	Arg	Ile	Asp	Asp	Pro	Glu	Thr	Lys	Arg	Gln	Asn	Ser
			740					745					750		
Asn	Leu	Phe	Ser	Leu	Leu	Phe	Leu	Ala	Leu	Gly	Ile	Ile	Ser	Phe	Ile
		755					760					765			
Thr	Phe	Phe	Leu	Gln	Gly	Phe	Thr	Phe	Gly	Lys	Ala	Gly	Glu	Ile	Leu
	770					775					780				
Thr	Lys	Arg	Leu	Arg	Tyr	Met	Val	Phe	Arg	Ser	Met	Leu	Arg	Gln	Asp
785					790					795					800
Val	Ser	Trp	Phe	Asp	Asp	Pro	Lys	Asn	Thr	Thr	Gly	Ala	Leu	Thr	Thr
				805					810					815	
Arg	Leu	Ala	Asn	Asp	Ala	Ala	Gln	Val	Lys	Gly	Ala	Ile	Gly	Ser	Arg
			820					825					830		
Leu	Ala	Val	Ile	Thr	Gln	Asn	Ile	Ala	Asn	Leu	Gly	Thr	Gly	Ile	Ile
		835					840					845			
Ile	Ser	Phe	Ile	Tyr	Gly	Trp	Gln	Leu	Thr	Leu	Leu	Leu	Leu	Ala	Ile
	850					855					860				
Val	Pro	Ile	Ile	Ala	Ile	Ala	Gly	Val	Val	Glu	Met	Lys	Met	Leu	Ser
865					870					875					880
Gly	Gln	Ala	Leu	Lys	Asp	Lys	Lys	Glu	Leu	Glu	Gly	Ala	Gly	Lys	Ile
				885					890					895	
Ala	Thr	Glu	Ala	Ile	Glu	Asn	Phe	Arg	Thr	Val	Val	Ser	Leu	Thr	Gln
			900					905					910		
Glu	Gln	Lys	Phe	Glu	His	Met	Tyr	Ala	Gln	Ser	Leu	Gln	Val	Pro	Tyr
		915					920					925			
Arg	Asn	Ser	Leu	Arg	Lys	Ala	His	Ile	Phe	Gly	Ile	Thr	Phe	Ser	Phe
	930					935					940				
Thr	Gln	Ala	Met	Met	Tyr	Phe	Ser	Tyr	Ala	Gly	Cys	Phe	Arg	Phe	Gly

945	950	955	960
Ala Tyr Leu Val	Ala His Lys Leu Met	Ser Phe Glu Asp Val	Leu Leu
	965	970	975
Val Phe Ser Ala	Val Val Phe Gly Ala Met	Ala Val Gly Gln	Val Ser
	980	985	990
Ser Phe Ala Pro	Asp Tyr Ala Lys	Ala Lys Ile Ser	Ala His Ile
	995	1000	1005
Ile Met	Ile Ile Glu Lys Thr	Pro Leu Ile Asp	Ser Tyr Ser Thr
1010	1015		1020
Glu Gly	Leu Met Pro Asn Thr	Leu Glu Gly Asn	Val Thr Phe Gly
1025	1030		1035
Glu Val	Val Phe Asn Tyr Pro	Thr Arg Pro Asp	Ile Pro Val Leu
1040	1045		1050
Gln Gly	Leu Ser Leu Glu Val	Lys Lys Gly Gln	Thr Leu Ala Leu
1055	1060		1065
Val Gly	Ser Ser Gly Cys Gly	Lys Ser Thr Val	Val Gln Leu Leu
1070	1075		1080
Glu Arg	Phe Tyr Asp Pro Leu	Ala Gly Lys Val	Leu Leu Asp Gly
1085	1090		1095
Lys Glu	Ile Lys Arg Leu Asn	Val Gln Trp Leu	Arg Ala His Leu
1100	1105		1110
Gly Ile	Val Ser Gln Glu Pro	Ile Leu Phe Asp	Cys Ser Ile Ala
1115	1120		1125
Glu Asn	Ile Ala Tyr Gly Asp	Asn Ser Arg Val	Val Ser Gln Glu
1130	1135		1140
Glu Ile	Val Arg Ala Ala Lys	Glu Ala Asn Ile	His Ala Phe Ile
1145	1150		1155
Glu Ser	Leu Pro Asn Lys Tyr	Ser Thr Lys Val	Gly Asp Lys Gly
1160	1165		1170
Thr Gln	Leu Ser Gly Gly Gln	Lys Gln Arg Ile	Ala Ile Ala Arg
1175	1180		1185
Ala Leu	Val Arg Gln Pro His	Ile Leu Leu Leu	Asp Glu Ala Thr
1190	1195		1200
Ser Ala	Leu Asp Thr Glu Ser	Glu Lys Val Val	Gln Glu Ala Leu
1205	1210		1215
Asp Lys	Ala Arg Glu Gly Arg	Thr Cys Ile Val	Ile Ala His Arg
1220	1225		1230
Leu Ser	Thr Ile Gln Asn Ala	Asp Leu Ile Val	Val Phe Gln Asn
1235	1240		1245
Gly Arg	Val Lys Glu His Gly	Thr His Gln Gln	Leu Leu Ala Gln
1250	1255		1260
Lys Gly	Ile Tyr Phe Ser Met	Val Ser Val Gln	Ala Gly Thr Lys
1265	1270		1275
Arg Gln			

1280

<210> 3 <211> 3860 <212> DNA <213> homo sapiens <400> 3'
 atggatcttg aaggggaccg caatggagga gcaaagaaga agaacttttt taaactgaac 60
 aataaaagtg aaaaagataa gaaggaaaag aaaccaactg tcagtgtatt ttcaatgttt 120
 cgctattcaa attggcttga caagttgtat atgggtgggtg gaactttggc tgccatcatc 180
 catggggctg gacttcctct catgatgctg gtgtttggag aaatgacaga tatctttgca 240
 aatgcaggaa atttgaaga tctgatgtca aacatcacta atagaagtga tatcaatgat 300
 acagggttct tcatgaatct ggaggaagac atgaccagat atgcctatta ttacagtgga 360
 attggtgctg ggggtgctggt tgctgcttac attcaggttt cattttggtg cctggcagct 420
 ggaagacaaa tacacaaaat tagaaaacag ttttttcatg ctataatgcg acaggagata 480
 ggctggtttg atgtgcacga tgttggggag cttaacaccc gacttacaga tgatgtctct 540
 aagattaatg aagttattgg tgacaaaatt ggaatgttct ttcagtcaat ggcaacattt 600
 ttcactgggt ttatagtagg atttacacgt ggttgggaagc taacccttgt gatcttggcc 660
 atcagtcttg ttcttggact gtcagctgct gtctgggcaa agatactatc ttcatttact 720
 gataaagaac tcttagcgta tgcaaaagct ggagcagtag ctgaagaggt cttggcagca 780
 attagaactg tgattgcatt tggaggacaa aagaaagaac ttgaaaggta caacaaaaat 840
 ttagaagaag ctaaaagaat tgggataaag aaagctatta cagccaatat ttctataggt 900
 gctgctttcc tgctgatcta tgcactttat gctctggcct tctggtatgg gaccaccttg 960
 gtctctctcag gggaatattc tattggacaa gtactcactg tattcttttc tgtattaatt 1020
 ggggctttta gtgttggaca ggcatctcca agcattgaag catttgcaa tgcaagagga 1080
 gcagcttatg aaatcttcaa gataattgat aataagccaa gtattgacag ctattcgaag 1140
 agtgggcaca aaccagataa tattaagga aatttggaa tcagaaatgt tcaattcagt 1200
 taccatctc gaaaagaagt taagatcttg aagggcctga acctgaagggt gcagagtggg 1260
 cagacggtgg ccctggtttg aaacagtggc tgtgggaaga gcacaacagt ccagctgatg 1320
 cagaggctct atgacccac agaggggatg gtcagtgttg atggacagga tattaggacc 1380
 ataatgtaa ggtttctacg ggaaatcatt ggtgtggtga gtcaggaacc tgtattgttt 1440
 gccaccacga tagctgaaaa cattcgctat ggccgtgaaa atgtcaccat ggatgagatt 1500
 gagaaagctg tcaaggaagc caatgcctat gactttatca tgaaactgcc tcataaattt 1560
 gacaccttg ttggagagag agggggccag ttgagtgggtg ggcagaagca gaggatcgcc 1620
 attgcacgtg ccctggttcg caaccccaag atcctcctgc tggatgaggc cacgtcagcc 1680
 ttggacacag aaagcgaagc agtggttcag gtggctctgg ataaggccag aaaaggctcg 1740
 accaccattg tgatagctca tcgtttgtct acagttcgta atgctgacgt catcgctggt 1800
 ttcgatgatg gagtcattgt ggagaaagga aatcatgatg aactcatgaa agagaaaggc 1860
 atttacttca aacttgtcac aatgcagaca gcaggaaatg aagttgaatt agaaaatgca 1920

gctgatgaat ccaaaagtga aattgatgcc ttggaaatgt cttcaaataa ttcaagatcc	1980
agtctaataa gaaaaagatc aactcgtagg agtgtccgtg gatcacaaagc ccaagacaga	2040
aagcttagta ccaagaggc tctggatgaa agtataacct cagtttcctt ttggaggatt	2100
atgaagctaa atttaactga atggccttat tttgttggtg gtgtattttg tgccattata	2160
aatggaggcc tgcaaccagc atttgcaata atattttcaa agattatagg ggtttttaca	2220
agaattgatg atcctgaaac aaaacgacag aatagtaact tgttttctact attgtttcta	2280
gcccttgga ttattttctt tattacattt ttccttcaag gtttcacatt tggcaaagct	2340
ggagagatcc tcaccaagcg gctccgatac atggttttcc gatccatgct cagacaggat	2400
gtgagttggt ttgatgacct taaaaacacc actggagcat tgactaccag gctcgccaat	2460
gatgctgctc aagttaaagg ggctataggt tccaggcttg ctgtaattac ccagaatata	2520
gcaaatcttg ggacaggaat aattatatcc ttcattctat gttggcaact aacactgtta	2580
ctcttagcaa ttgtacccat cattgcaata gcaggagttg ttgaaatgaa aatgttgtct	2640
ggacaagcac tgaaagataa gaaagaacta gaagggtgctg ggaagatcgc tactgaagca	2700
atagaaaact tccgaaccgt tgtttctttg actcaggagc agaagtttga acatatgtat	2760
gctcagagtt tgcaggtagc atacagaaac tctttgagga aagcacacat ctttggaatt	2820
acattttcct tcaccaggc aatgatgtat ttttcctatg ctggatgttt ccggtttgga	2880
gcctacttgg tggcacataa actcatgagc tttgaggatg ttctgttagt attttcagct	2940
gttgtctttg gtgccatggc cgtggggcaa gtcagttcat ttgctcctga ctatgccaaa	3000
gccaaaatat cagcagccca catcatcatg atcattgaaa aaacccttt gattgacagc	3060
tacagcacgg aaggcctaata gccgaacaca ttggaaggaa atgtcacatt tggatgaagt	3120
gtattcaact atcccaccg accggacatc ccagtgttc agggactgag cctggagggtg	3180
aagaagggcc agacgctggc tctggtggc agcagtggct gtgggaagag cacagtggctc	3240
cagctcctgg agcgtttcta cgacccttg gcagggaag tgctgcttga tggcaaagaa	3300
ataaagcgac tgaatgttca gtggctccga gcacacctgg gcatcgtgtc ccaggagccc	3360
atcctgtttg actgcagcat tgctgagaac attgcctatg gagacaacag ccgggtggtg	3420
tcacaggaag agatcgtgag ggcagcaaag gaggccaaca tacatgcctt catcgagtca	3480
ctgcctaata aatatagcac taaagtagga gacaaaggaa ctcagctctc tgggtggccag	3540
aaacaacgca ttgcatagc tcgtgccctt gttagacagc ctcatatttt gcttttggat	3600
gaagccacgt cagctctgga tacagaaagt gaaaagggtg tccaagaagc cctggacaaa	3660
gccagagaag gccgcacctg cattgtgatt gtcaccgcc tgtccaccat ccagaatgca	3720
gacttaatag tgggtgtttca gaatggcaga gtcaaggagc atggcacgca tcagcagctg	3780
ctggcacaga aaggcatcta tttttcaatg gtcagtgtcc aggctggaac aaagcgccag	3840
tgaactctgg ttaactccac	3860

```

<210> 4 <211> 1280 <212> PRT <213> Homo sapiens <400> 4
Met Asp Leu Glu Gly Asp Arg Asn Gly Gly Ala Lys Lys Lys Asn Phe
1          5          10          15
Phe Lys Leu Asn Asn Lys Ser Glu Lys Asp Lys Lys Glu Lys Lys Pro
          20          25          30
Thr Val Ser Val Phe Ser Met Phe Arg Tyr Ser Asn Trp Leu Asp Lys
          35          40          45
Leu Tyr Met Val Val Gly Thr Leu Ala Ala Ile Ile His Gly Ala Gly
          50          55          60
Leu Pro Leu Met Met Leu Val Phe Gly Glu Met Thr Asp Ile Phe Ala
65          70          75          80
Asn Ala Gly Asn Leu Glu Asp Leu Met Ser Asn Ile Thr Asn Arg Ser
          85          90          95
Asp Ile Asn Asp Thr Gly Phe Phe Met Asn Leu Glu Glu Asp Met Thr
          100          105          110
Arg Tyr Ala Tyr Tyr Tyr Ser Gly Ile Gly Ala Gly Val Leu Val Ala
          115          120          125
Ala Tyr Ile Gln Val Ser Phe Trp Cys Leu Ala Ala Gly Arg Gln Ile
          130          135          140
His Lys Ile Arg Lys Gln Phe Phe His Ala Ile Met Arg Gln Glu Ile
145          150          155          160
Gly Trp Phe Asp Val His Asp Val Gly Glu Leu Asn Thr Arg Leu Thr
          165          170          175
Asp Asp Val Ser Lys Ile Asn Glu Val Ile Gly Asp Lys Ile Gly Met
          180          185          190
Phe Phe Gln Ser Met Ala Thr Phe Phe Thr Gly Phe Ile Val Gly Phe
          195          200          205
Thr Arg Gly Trp Lys Leu Thr Leu Val Ile Leu Ala Ile Ser Pro Val
          210          215          220
Leu Gly Leu Ser Ala Ala Val Trp Ala Lys Ile Leu Ser Ser Phe Thr
225          230          235          240
Asp Lys Glu Leu Leu Ala Tyr Ala Lys Ala Gly Ala Val Ala Glu Glu
          245          250          255
Val Leu Ala Ala Ile Arg Thr Val Ile Ala Phe Gly Gly Gln Lys Lys
          260          265          270
Glu Leu Glu Arg Tyr Asn Lys Asn Leu Glu Glu Ala Lys Arg Ile Gly
          275          280          285
Ile Lys Lys Ala Ile Thr Ala Asn Ile Ser Ile Gly Ala Ala Phe Leu
          290          295          300
Leu Ile Tyr Ala Ser Tyr Ala Leu Ala Phe Trp Tyr Gly Thr Thr Leu
305          310          315          320
Val Leu Ser Gly Glu Tyr Ser Ile Gly Gln Val Leu Thr Val Phe Phe
          325          330          335

```

Ser Val Leu Ile Gly Ala Phe Ser Val Gly Gln Ala Ser Pro Ser Ile
 340 345 350
 Glu Ala Phe Ala Asn Ala Arg Gly Ala Ala Tyr Glu Ile Phe Lys Ile
 355 360 365
 Ile Asp Asn Lys Pro Ser Ile Asp Ser Tyr Ser Lys Ser Gly His Lys
 370 375 380
 Pro Asp Asn Ile Lys Gly Asn Leu Glu Phe Arg Asn Val His Phe Ser
 385 390 395 400
 Tyr Pro Ser Arg Lys Glu Val Lys Ile Leu Lys Gly Leu Asn Leu Lys
 405 410 415
 Val Gln Ser Gly Gln Thr Val Ala Leu Val Gly Asn Ser Gly Cys Gly
 420 425 430
 Lys Ser Thr Thr Val Gln Leu Met Gln Arg Leu Tyr Asp Pro Thr Glu
 435 440 445
 Gly Met Val Ser Val Asp Gly Gln Asp Ile Arg Thr Ile Asn Val Arg
 450 455 460
 Phe Leu Arg Glu Ile Ile Gly Val Val Ser Gln Glu Pro Val Leu Phe
 465 470 475 480
 Ala Thr Thr Ile Ala Glu Asn Ile Arg Tyr Gly Arg Glu Asn Val Thr
 485 490 495
 Met Asp Glu Ile Glu Lys Ala Val Lys Glu Ala Asn Ala Tyr Asp Phe
 500 505 510
 Ile Met Lys Leu Pro His Lys Phe Asp Thr Leu Val Gly Glu Arg Gly
 515 520 525
 Ala Gln Leu Ser Gly Gly Gln Lys Gln Arg Ile Ala Ile Ala Arg Ala
 530 535 540
 Leu Val Arg Asn Pro Lys Ile Leu Leu Leu Asp Glu Ala Thr Ser Ala
 545 550 555 560
 Leu Asp Thr Glu Ser Glu Ala Val Val Gln Val Ala Leu Asp Lys Ala
 565 570 575
 Arg Lys Gly Arg Thr Thr Ile Val Ile Ala His Arg Leu Ser Thr Val
 580 585 590
 Arg Asn Ala Asp Val Ile Ala Gly Phe Asp Asp Gly Val Ile Val Glu
 595 600 605
 Lys Gly Asn His Asp Glu Leu Met Lys Glu Lys Gly Ile Tyr Phe Lys
 610 615 620
 Leu Val Thr Met Gln Thr Ala Gly Asn Glu Val Glu Leu Glu Asn Ala
 625 630 635 640
 Ala Asp Glu Ser Lys Ser Glu Ile Asp Ala Leu Glu Met Ser Ser Asn
 645 650 655
 Asp Ser Arg Ser Ser Leu Ile Arg Lys Arg Ser Thr Arg Arg Ser Val
 660 665 670
 Arg Gly Ser Gln Ala Gln Asp Arg Lys Leu Ser Thr Lys Glu Ala Leu
 675 680 685

Asp	Glu	Ser	Ile	Pro	Pro	Val	Ser	Phe	Trp	Arg	Ile	Met	Lys	Leu	Asn	690	695	700
Leu	Thr	Glu	Trp	Pro	Tyr	Phe	Val	Val	Gly	Val	Phe	Cys	Ala	Ile	Ile	705	710	715
Asn	Gly	Gly	Leu	Gln	Pro	Ala	Phe	Ala	Ile	Ile	Phe	Ser	Lys	Ile	Ile	725	730	735
Gly	Val	Phe	Thr	Arg	Ile	Asp	Asp	Pro	Glu	Thr	Lys	Arg	Gln	Asn	Ser	740	745	750
Asn	Leu	Phe	Ser	Leu	Leu	Phe	Leu	Ala	Leu	Gly	Ile	Ile	Ser	Phe	Ile	755	760	765
Thr	Phe	Phe	Leu	Gln	Gly	Phe	Thr	Phe	Gly	Lys	Ala	Gly	Glu	Ile	Leu	770	775	780
Thr	Lys	Arg	Leu	Arg	Tyr	Met	Val	Phe	Arg	Ser	Met	Leu	Arg	Gln	Asp	785	790	795
Val	Ser	Trp	Phe	Asp	Asp	Pro	Lys	Asn	Thr	Thr	Gly	Ala	Leu	Thr	Thr	805	810	815
Arg	Leu	Ala	Asn	Asp	Ala	Ala	Gln	Val	Lys	Gly	Ala	Ile	Gly	Ser	Arg	820	825	830
Leu	Ala	Val	Ile	Thr	Gln	Asn	Ile	Ala	Asn	Leu	Gly	Thr	Gly	Ile	Ile	835	840	845
Ile	Ser	Phe	Ile	Tyr	Gly	Trp	Gln	Leu	Thr	Leu	Leu	Leu	Leu	Ala	Ile	850	855	860
Val	Pro	Ile	Ile	Ala	Ile	Ala	Gly	Val	Val	Glu	Met	Lys	Met	Leu	Ser	865	870	875
Gly	Gln	Ala	Leu	Lys	Asp	Lys	Lys	Glu	Leu	Glu	Gly	Ala	Gly	Lys	Ile	885	890	895
Ala	Thr	Glu	Ala	Ile	Glu	Asn	Phe	Arg	Thr	Val	Val	Ser	Leu	Thr	Gln	900	905	910
Glu	Gln	Lys	Phe	Glu	His	Met	Tyr	Ala	Gln	Ser	Leu	Gln	Val	Pro	Tyr	915	920	925
Arg	Asn	Ser	Leu	Arg	Lys	Ala	His	Ile	Phe	Gly	Ile	Thr	Phe	Ser	Phe	930	935	940
Thr	Gln	Ala	Met	Met	Tyr	Phe	Ser	Tyr	Ala	Gly	Cys	Phe	Arg	Phe	Gly	945	950	955
Ala	Tyr	Leu	Val	Ala	His	Lys	Leu	Met	Ser	Phe	Glu	Asp	Val	Leu	Leu	965	970	975
Val	Phe	Ser	Ala	Val	Val	Phe	Gly	Ala	Met	Ala	Val	Gly	Gln	Val	Ser	980	985	990
Ser	Phe	Ala	Pro	Asp	Tyr	Ala	Lys	Ala	Lys	Ile	Ser	Ala	Ala	His	Ile	995	1000	1005
Ile	Met	Ile	Ile	Glu	Lys	Thr	Pro	Leu	Ile	Asp	Ser	Tyr	Ser	Thr		1010	1015	1020
Glu	Gly	Leu	Met	Pro	Asn	Thr	Leu	Glu	Gly	Asn	Val	Thr	Phe	Gly		1025	1030	1035

Glu Val Val Phe Asn Tyr Pro Thr Arg Pro Asp Ile Pro Val Leu
 1040 1045 1050
 Gln Gly Leu Ser Leu Glu Val Lys Lys Gly Gln Thr Leu Ala Leu
 1055 1060 1065
 Val Gly Ser Ser Gly Cys Gly Lys Ser Thr Val Val Gln Leu Leu
 1070 1075 1080
 Glu Arg Phe Tyr Asp Pro Leu Ala Gly Lys Val Leu Leu Asp Gly
 1085 1090 1095
 Lys Glu Ile Lys Arg Leu Asn Val Gln Trp Leu Arg Ala His Leu
 1100 1105 1110
 Gly Ile Val Ser Gln Glu Pro Ile Leu Phe Asp Cys Ser Ile Ala
 1115 1120 1125
 Glu Asn Ile Ala Tyr Gly Asp Asn Ser Arg Val Val Ser Gln Glu
 1130 1135 1140
 Glu Ile Val Arg Ala Ala Lys Glu Ala Asn Ile His Ala Phe Ile
 1145 1150 1155
 Glu Ser Leu Pro Asn Lys Tyr Ser Thr Lys Val Gly Asp Lys Gly
 1160 1165 1170
 Thr Gln Leu Ser Gly Gly Gln Lys Gln Arg Ile Ala Ile Ala Arg
 1175 1180 1185
 Ala Leu Val Arg Gln Pro His Ile Leu Leu Leu Asp Glu Ala Thr
 1190 1195 1200
 Ser Ala Leu Asp Thr Glu Ser Glu Lys Val Val Gln Glu Ala Leu
 1205 1210 1215
 Asp Lys Ala Arg Glu Gly Arg Thr Cys Ile Val Ile Ala His Arg
 1220 1225 1230
 Leu Ser Thr Ile Gln Asn Ala Asp Leu Ile Val Val Phe Gln Asn
 1235 1240 1245
 Gly Arg Val Lys Glu His Gly Thr His Gln Gln Leu Leu Ala Gln
 1250 1255 1260
 Lys Gly Ile Tyr Phe Ser Met Val Ser Val Gln Ala Gly Thr Lys
 1265 1270 1275
 Arg Gln
 1280

<210> 5 <211> 4189 <212> DNA <213> Mus musculus <400> 5
 atggagtttg aagagaacct taagggaaga gcagacaaga acttctcgaa gatgggcaaa 60
 aagagtaaaa aggagaagaa agaaaagaaa cctgctgttg gcgtatttgg gatgtttcgc 120
 tatgcagatt ggctggacaa gctgtgcatg attctgggaa ctctcgctgc tattatccat 180
 ggaacattac ttccctcttt gatgctggtg tttggaaaca tgacagatag ttttcaaaaa 240
 gcagaagcca gtattctgcc aagcattact aatcaaagtg gaccaaacag tactctgatc 300
 atcagcaaca gcagtctgga ggaagagatg gccatatacg cctactatta caccgggatt 360
 ggtgctggtg tgctcatagt tgcctacatc caggtttcac tttggtgcct ggcagctgga 420

agacagatac acaagattag gcagaagttt ttccatgcta taatgaatca ggagataggc	480
tggttttagtg tgcattgatgt tggggagctc aacacccggc tcacagatga tgtctccaaa	540
attaatgacg gaattggtga caaaattggg atgttttttc agtccataac cacattttta	600
gccggtttta tcataggatt tataagtggg tggaagctaa cccttgatcat tttggctgtc	660
agccctctta ttggattgtc atctgctttg tgggcaaagg tattgacttc atttactaat	720
aaggaactcc aggccttatgc aaaagctgga gcagttgctg aagaagtctt agcagccatc	780
agaactgtga ttgccttttg aggacaacag aaggaacttg aaaggtacaa taaaaattta	840
gaagaagcta aaaatgttgg cataaagaaa gctatcacag ccagcatttc gataggcatt	900
gcctacctgt tggcttatgc atcatatgca ctggcattct ggtatgggac atccttggtc	960
ctctcaaagt aatattctat tggagaagtg cttactgtct tcttctctat tttgttgggg	1020
acttttagta ttggacactt ggccccaac atagaagcct ttgcaaagc acgaggggca	1080
gcctttgaaa tcttcaagat aattgataac gagccaagca ttgacagctt ctcaacaag	1140
ggctacaaac cagacagtat aatgggaaac ttagagttta aaaatgttca cttcaactac	1200
ccatcgagaa gcgaagttca gatcttgaag ggcctcaatc tgaaggtgaa gagcggacag	1260
acggtggcct tggttggcaa cagtggctgt ggaaaaagca caactgtcca gctgatgcag	1320
aggctctacg acccctgga gggcgtggc agtatcgacg gacaagacat cagaaccatc	1380
aatgtgaggt atctgagga gatcattggt gtggtgagtc aggaacctgt gctgtttgcc	1440
accacgatcg ccgagaacat tcgctatggc cgagaagatg tcaccatgga tgagattgag	1500
aaagctgtca aggaagccaa tgcctatgac ttcattcatga aactgcccc ccaatttgac	1560
accctgggtg gtgagagagg ggcgcagctg agtgggggac agaaacagag aatcgccatt	1620
gcccgggccc tgggtccgaa tccaagatc cttttgttgg acgaggccac ctacgccctg	1680
gatacagaaa gtgaagctgt ggtgcaggcc gcactggata aggctagaga aggccggacc	1740
accattgtga tagctcatcg cttgtctaca gttcgtaatg ctgacgtcat tgctggtttt	1800
gatggtggtg tcattgtgga gcaaggaaat catgatgagc tcatgagaga aaagggcatt	1860
tacttcaaac ttgtcatgac acagactaga ggaaatgaaa ttgaaccagg aaataatgct	1920
tatggatccc agagtgcac tgatgcttct gaactgactt cagaagaatc caaatcacct	1980
ttaataagga gatcaattta cagaagtgtc cacagaaagc aagaccaaga gagaagactt	2040
agtatgaaag aggcctgtgga tgaagatgtg cctctggttt ctttttggcg gatcctaaat	2100
ctaaatctaa gtgaatggcc ttatttactt gttggcgtag tttgcgctgt tataaatggg	2160
tgcatacaac cagtgtttgc catagtattt tcaaggattg taggggtttt ttcaagagat	2220
gatgaccatg aaactaaacg acagaattgt aatttgtttt ccctgttctt tctggttatg	2280
gggctgattt cttttgttac atatttcttt cagggttca catttggcaa agccggagag	2340
atcctcacca agcgagtccg atacatgggt ttcaaatacca tgctgagaca ggatataagc	2400

tggttc gatg accataagaa cagcactggc t cactgacca ccaggctcgc cagt gatgct 2460
 tctagtgtta aagggg cgat gggcgccagg cttgctgtag ttaccagaa tgtagcaaac 2520
 ctctgggacag gagtcacct ctccttagtc tatggctggc agctgacact tctacttgta 2580
 gtaattatac cgctcattgt attgggcgga attattgaaa tgaagctgtt gtctggccaa 2640
 gccttgaagg acaagaaaca gcttgagatc tctgggaaga ttgctacaga agcaattgaa 2700
 aacttccgca ctattgtctc tttgactcgg gagcagaagt ttgaaacat gtatgccag 2760
 agcttg cagg taccatacag aaatgcgatg aagaaagcac acgtgtttgg gatcacgttc 2820
 tccttcaccc aggccatgat gtatttttct tatgtctgctt gtttccggtt cgggtgcctac 2880
 ttggtggcac aacaactcat gacttttgaa aatgttatgt tggatatttc tgctgttgctc 2940
 tttggtgcc a tggcagctgg gaatactagt tcat ttgctc ctgactatgc gaaagccaaa 3000
 gtatcagcat ctcatatcat caggatcatt gagaaaaccc ctgagattga cagctacagc 3060
 acagagggct tgaagcctac tctgttagaa ggaaatgtaa aatttaatgg agtccagttt 3120
 aactatccca cccgacccaa catcccagtg cttcaggggc tgagcctcga ggtgaagaag 3180
 ggccagacgt tggccctggg gggcagcagt ggctgtggga agagcacagt ggtccagctg 3240
 ctctgagcgt tctacgaccc catggctgga tcagtgtttc tagatggcaa agaaataaag 3300
 caactgaatg tccagtggct ccgagctcac cttggcattg tgtcccagga gccattctc 3360
 tttgactgca gcattgcaga gaacatcgcc tatggagaca acagccgggc cgtgtctcat 3420
 gaggagattg tgagggcagc caaggaggcc aacatccacc agttcatcga ctactgcct 3480
 gataaatata acaccagagt aggagacaaa ggcactcagc tgtcgggtgg gcagaagcag 3540
 cgcacgcca tcgcacgtgc cctcgtcaga cagcctcaca ttttacttct ggacgaagca 3600
 acatcagctc tggatacaga aagtga aaag gttgtccagg aagcgctgga caaagccagg 3660
 gaaggccgca cctgcattgt gatcgctcac cgcctgtcca ccatccagaa cgcggacttg 3720
 atcgtgggtga ttgagaacgg caaagtcaag gagcacggca cccaccagca gctgctggcg 3780
 cagaagggca tctacttctc aatgggtccag gctggagcaa agcgctcatg agctgtgact 3840
 atctgaggtg ctaagtattt ttaatatattg tgttttaaca tggcaccaaa ccaaagttaa 3900
 aaggcaagg ctgttaaagg taactccatc aagatgagaa gccttccgag actttgtaat 3960
 taaatgaacc aaaatcggaa acaacaaac aaacaaacaa acaagccata gttaaacagg 4020
 gccatgtttt taattgcatt acgtgattca taagagaaca tatagttttt taaaataaaa 4080
 tgtataattt tgtttcagtt ttttaatttct accctacttt cttaaagat tataaagatt 4140
 gtaaaaagca ctattttctta aattgcctat aaaaattaaa ttttcatat 4189

<210> 6 <211> 1276 <212> PRT <213> Mus musculus <400> 6

Met Glu Phe Glu Glu Asn Leu Lys Gly Arg Ala Asp Lys Asn Phe Ser
 1 5 10 15

Lys Met Gly Lys Lys Ser Lys Lys Glu Lys Lys Glu Lys Lys Pro Ala
 20 25 30
 Val Gly Val Phe Gly Met Phe Arg Tyr Ala Asp Trp Leu Asp Lys Leu
 35 40 45
 Cys Met Ile Leu Gly Thr Leu Ala Ala Ile Ile His Gly Thr Leu Leu
 50 55 60
 Pro Leu Leu Met Leu Val Phe Gly Asn Met Thr Asp Ser Phe Thr Lys
 65 70 75 80
 Ala Glu Ala Ser Ile Leu Pro Ser Ile Thr Asn Gln Ser Gly Pro Asn
 85 90 95
 Ser Thr Leu Ile Ile Ser Asn Ser Ser Leu Glu Glu Glu Met Ala Ile
 100 105 110
 Tyr Ala Tyr Tyr Tyr Thr Gly Ile Gly Ala Gly Val Leu Ile Val Ala
 115 120 125
 Tyr Ile Gln Val Ser Leu Trp Cys Leu Ala Ala Gly Arg Gln Ile His
 130 135 140
 Lys Ile Arg Gln Lys Phe Phe His Ala Ile Met Asn Gln Glu Ile Gly
 145 150 155 160
 Trp Phe Asp Val His Asp Val Gly Glu Leu Asn Thr Arg Leu Thr Asp
 165 170 175
 Asp Val Ser Lys Ile Asn Asp Gly Ile Gly Asp Lys Ile Gly Met Phe
 180 185 190
 Phe Gln Ser Ile Thr Thr Phe Leu Ala Gly Phe Ile Ile Gly Phe Ile
 195 200 205
 Ser Gly Trp Lys Leu Thr Leu Val Ile Leu Ala Val Ser Pro Leu Ile
 210 215 220
 Gly Leu Ser Ser Ala Leu Trp Ala Lys Val Leu Thr Ser Phe Thr Asn
 225 230 235 240
 Lys Glu Leu Gln Ala Tyr Ala Lys Ala Gly Ala Val Ala Glu Glu Val
 245 250 255
 Leu Ala Ala Ile Arg Thr Val Ile Ala Phe Gly Gly Gln Gln Lys Glu
 260 265 270
 Leu Glu Arg Tyr Asn Lys Asn Leu Glu Glu Ala Lys Asn Val Gly Ile
 275 280 285
 Lys Lys Ala Ile Thr Ala Ser Ile Ser Ile Gly Ile Ala Tyr Leu Leu
 290 295 300
 Val Tyr Ala Ser Tyr Ala Leu Ala Phe Trp Tyr Gly Thr Ser Leu Val
 305 310 315 320
 Leu Ser Asn Glu Tyr Ser Ile Gly Glu Val Leu Thr Val Phe Phe Ser
 325 330 335
 Ile Leu Leu Gly Thr Phe Ser Ile Gly His Leu Ala Pro Asn Ile Glu
 340 345 350
 Ala Phe Ala Asn Ala Arg Gly Ala Ala Phe Glu Ile Phe Lys Ile Ile
 355 360 365

Asp	Asn	Glu	Pro	Ser	Ile	Asp	Ser	Phe	Ser	Thr	Lys	Gly	Tyr	Lys	Pro
370						375					380				
Asp	Ser	Ile	Met	Gly	Asn	Leu	Glu	Phe	Lys	Asn	Val	His	Phe	Asn	Tyr
385					390					395					400
Pro	Ser	Arg	Ser	Glu	Val	Gln	Ile	Leu	Lys	Gly	Leu	Asn	Leu	Lys	Val
				405					410					415	
Lys	Ser	Gly	Gln	Thr	Val	Ala	Leu	Val	Gly	Asn	Ser	Gly	Cys	Gly	Lys
			420					425					430		
Ser	Thr	Thr	Val	Gln	Leu	Met	Gln	Arg	Leu	Tyr	Asp	Pro	Leu	Glu	Gly
		435					440					445			
Val	Val	Ser	Ile	Asp	Gly	Gln	Asp	Ile	Arg	Thr	Ile	Asn	Val	Arg	Tyr
	450					455					460				
Leu	Arg	Glu	Ile	Ile	Gly	Val	Val	Ser	Gln	Glu	Pro	Val	Leu	Phe	Ala
465					470					475					480
Thr	Thr	Ile	Ala	Glu	Asn	Ile	Arg	Tyr	Gly	Arg	Glu	Asp	Val	Thr	Met
				485					490					495	
Asp	Glu	Ile	Glu	Lys	Ala	Val	Lys	Glu	Ala	Asn	Ala	Tyr	Asp	Phe	Ile
			500					505					510		
Met	Lys	Leu	Pro	His	Gln	Phe	Asp	Thr	Leu	Val	Gly	Glu	Arg	Gly	Ala
		515					520					525			
Gln	Leu	Ser	Gly	Gly	Gln	Lys	Gln	Arg	Ile	Ala	Ile	Ala	Arg	Ala	Leu
	530					535					540				
Val	Arg	Asn	Pro	Lys	Ile	Leu	Leu	Leu	Asp	Glu	Ala	Thr	Ser	Ala	Leu
545					550					555					560
Asp	Thr	Glu	Ser	Glu	Ala	Val	Val	Gln	Ala	Ala	Leu	Asp	Lys	Ala	Arg
				565					570					575	
Glu	Gly	Arg	Thr	Thr	Ile	Val	Ile	Ala	His	Arg	Leu	Ser	Thr	Val	Arg
			580					585					590		
Asn	Ala	Asp	Val	Ile	Ala	Gly	Phe	Asp	Gly	Gly	Val	Ile	Val	Glu	Gln
		595					600					605			
Gly	Asn	His	Asp	Glu	Leu	Met	Arg	Glu	Lys	Gly	Ile	Tyr	Phe	Lys	Leu
	610					615					620				
Val	Met	Thr	Gln	Thr	Arg	Gly	Asn	Glu	Ile	Glu	Pro	Gly	Asn	Asn	Ala
625					630					635					640
Tyr	Gly	Ser	Gln	Ser	Asp	Thr	Asp	Ala	Ser	Glu	Leu	Thr	Ser	Glu	Glu
				645					650					655	
Ser	Lys	Ser	Pro	Leu	Ile	Arg	Arg	Ser	Ile	Tyr	Arg	Ser	Val	His	Arg
			660					665					670		
Lys	Gln	Asp	Gln	Glu	Arg	Arg	Leu	Ser	Met	Lys	Glu	Ala	Val	Asp	Glu
		675					680					685			
Asp	Val	Pro	Leu	Val	Ser	Phe	Trp	Arg	Ile	Leu	Asn	Leu	Asn	Leu	Ser
	690					695					700				
Glu	Trp	Pro	Tyr	Leu	Leu	Val	Gly	Val	Leu	Cys	Ala	Val	Ile	Asn	Gly
705					710					715					720

Cys Ile Gln Pro Val Phe Ala Ile Val Phe Ser Arg Ile Val Gly Val
 725 730 735
 Phe Ser Arg Asp Asp Asp His Glu Thr Lys Arg Gln Asn Cys Asn Leu
 740 745 750
 Phe Ser Leu Phe Phe Leu Val Met Gly Leu Ile Ser Phe Val Thr Tyr
 755 760 765
 Phe Phe Gln Gly Phe Thr Phe Gly Lys Ala Gly Glu Ile Leu Thr Lys
 770 775 780
 Arg Val Arg Tyr Met Val Phe Lys Ser Met Leu Arg Gln Asp Ile Ser
 785 790 795 800
 Trp Phe Asp Asp His Lys Asn Ser Thr Gly Ser Leu Thr Thr Arg Leu
 805 810 815
 Ala Ser Asp Ala Ser Ser Val Lys Gly Ala Met Gly Ala Arg Leu Ala
 820 825 830
 Val Val Thr Gln Asn Val Ala Asn Leu Gly Thr Gly Val Ile Leu Ser
 835 840 845
 Leu Val Tyr Gly Trp Gln Leu Thr Leu Leu Leu Val Val Ile Ile Pro
 850 855 860
 Leu Ile Val Leu Gly Gly Ile Ile Glu Met Lys Leu Leu Ser Gly Gln
 865 870 875 880
 Ala Leu Lys Asp Lys Lys Gln Leu Glu Ile Ser Gly Lys Ile Ala Thr
 885 890 895
 Glu Ala Ile Glu Asn Phe Arg Thr Ile Val Ser Leu Thr Arg Glu Gln
 900 905 910
 Lys Phe Glu Thr Met Tyr Ala Gln Ser Leu Gln Val Pro Tyr Arg Asn
 915 920 925
 Ala Met Lys Lys Ala His Val Phe Gly Ile Thr Phe Ser Phe Thr Gln
 930 935 940
 Ala Met Met Tyr Phe Ser Tyr Ala Ala Cys Phe Arg Phe Gly Ala Tyr
 945 950 955 960
 Leu Val Ala Gln Gln Leu Met Thr Phe Glu Asn Val Met Leu Val Phe
 965 970 975
 Ser Ala Val Val Phe Gly Ala Met Ala Ala Gly Asn Thr Ser Ser Phe
 980 985 990
 Ala Pro Asp Tyr Ala Lys Ala Lys Val Ser Ala Ser His Ile Ile Arg
 995 1000 1005
 Ile Ile Glu Lys Thr Pro Glu Ile Asp Ser Tyr Ser Thr Glu Gly
 1010 1015 1020
 Leu Lys Pro Thr Leu Leu Glu Gly Asn Val Lys Phe Asn Gly Val
 1025 1030 1035
 Gln Phe Asn Tyr Pro Thr Arg Pro Asn Ile Pro Val Leu Gln Gly
 1040 1045 1050
 Leu Ser Leu Glu Val Lys Lys Gly Gln Thr Leu Ala Leu Val Gly
 1055 1060 1065

Ser Ser Gly Cys Gly Lys Ser Thr Val Val Gln Leu Leu Glu Arg
 1070 1075 1080

Phe Tyr Asp Pro Met Ala Gly Ser Val Phe Leu Asp Gly Lys Glu
 1085 1090 1095

Ile Lys Gln Leu Asn Val Gln Trp Leu Arg Ala His Leu Gly Ile
 1100 1105 1110

Val Ser Gln Glu Pro Ile Leu Phe Asp Cys Ser Ile Ala Glu Asn
 1115 1120 1125

Ile Ala Tyr Gly Asp Asn Ser Arg Ala Val Ser His Glu Glu Ile
 1130 1135 1140

Val Arg Ala Ala Lys Glu Ala Asn Ile His Gln Phe Ile Asp Ser
 1145 1150 1155

Leu Pro Asp Lys Tyr Asn Thr Arg Val Gly Asp Lys Gly Thr Gln
 1160 1165 1170

Leu Ser Gly Gly Gln Lys Gln Arg Ile Ala Ile Ala Arg Ala Leu
 1175 1180 1185

Val Arg Gln Pro His Ile Leu Leu Leu Asp Glu Ala Thr Ser Ala
 1190 1195 1200

Leu Asp Thr Glu Ser Glu Lys Val Val Gln Glu Ala Leu Asp Lys
 1205 1210 1215

Ala Arg Glu Gly Arg Thr Cys Ile Val Ile Ala His Arg Leu Ser
 1220 1225 1230

Thr Ile Gln Asn Ala Asp Leu Ile Val Val Ile Glu Asn Gly Lys
 1235 1240 1245

Val Lys Glu His Gly Thr His Gln Gln Leu Leu Ala Gln Lys Gly
 1250 1255 1260

Ile Tyr Phe Ser Met Val Gln Ala Gly Ala Lys Arg Ser
 1265 1270 1275

<210> 7 <211> 4788 <212> DNA <213> Mus musculus <400> 7
 atggaacttg aagaggacct taagggaaga gcagacaaga acttctcaaa gatgggcaaa 60

aagagtaaaa aggagaagaa agaaaagaaa ccagcagtca gtgtgcttac aatgtttcgt 120

tatgcagggtt ggctagacag gttgtacatg ctggtgggaa ctctggctgc tattatccat 180

ggagtggcgc tcccacttat gatgctgac tttggtgaca tgacagatag ctttgcaagt 240

gtaggaaacg tctctaaaaa cagtactaat atgagtgagg ccgataaaag agccatgttt 300

gcaaactgg aggaagaaat gaccacgtac gcctactatt acaccgggat tgggtgctggt 360

gtgctcatag ttgcctacat ccagggtttca ttttggtgcc tggcagctgg aagacagata 420

cacaagatca ggcagaagtt ttttcatgct ataataatc aggagatagg ctggtttgat 480

gtgcatgacg ttggggagct caacacccgg ctacagatg atgtttccaa aattaatgaa 540

ggaattggtg acaaaatcgg aatgttcttc caggcaatgg caacattttt tgggtggttt 600

ataataggat ttaccctggtg ctggaagcta acccttgtga ttttgccat cagccctggt 660

cttggactgt cagctggtat ttgggcaaag atattgtctt catttactga taaggaaactc	720
catgcttatg caaaagctgg agcagttgct gaagaagtct tagcagccat cagaactgtg	780
attgcgtttg gaggacaaaa gaaggaaactt gaaaggtaca ataacaactt ggaagaagct	840
aaaaggctgg ggataaagaa agctatcacg gccaacatct ccatgggtgc agcttttctc	900
cttatctatg catcatatgc tctggcattc tggatatggga cttccttggc catctccaaa	960
gaatactcta ttggacaagt gctcactgtc ttcttttccg tgttaattgg agcattcagt	1020
gttggacagg catctccaaa tattgaagcc ttcgccaatg cacgaggagc agcttatgaa	1080
gtcttcaaaa taattgataa taagcccagt atagacagct tctcaaagag tgggcacaaa	1140
ccagacaaca tacaaggaaa tctggaattt aagaatatct acttcagtta cccatctcga	1200
aaagaagttc agatcttgaa gggcctcaat ctgaaggtga agagcggaca gacggtggcc	1260
ctggttggca acagtggctg tggaaaaagc acaactgtcc agctgatgca aaggctctac	1320
gacccctag atggcatggt cagtatcgac ggacaggaca tcagaacct caatgtgagg	1380
tatctgaggg agatcattgg tgtggtgagt caggaacctg tgctgtttgc caccacgatc	1440
gccgagaaca ttcgctatgg ccgagaagat gtcaccatgg atgagattga gaaagctgtc	1500
aaggaagcca atgcctatga cttcatcatg aaactgcccc accaatttga caccctgggt	1560
ggtgagagag gggcgcacgt gagtggggga cagaaacaga gaatcgccat tgcccgggcc	1620
ctggtccgca atcccaagat ctttttgttg gacgaggcca cctcagccct ggatacagaa	1680
agtgaagctg tggttcaggc cgcactggat aaggctagag aaggccggac caccattgtg	1740
atagctcatc gcttgtctac cgttcgtaat gctgacgtca ttgctggttt tgatggtggt	1800
gtcatttgtg agcaaggaaa tcatgatgag ctcatgagag aaaagggcat ttacttcaaa	1860
cttgtcatga cacagacagc aggaaatgaa attgaattag gaaatgaagc ttgtaaatct	1920
aaggatgaaa ttgataattt agacatgtct tcaaaagatt caggatccag tctaataaga	1980
agaagatcaa ctgcgaaaag catctgtgga ccacatgacc aagacaggaa gcttagtacc	2040
aaagaggccc tggatgaaga tgtacctcca gcttcctttt ggcggtacct gaagttgaat	2100
tcaactgaat ggccttattt tgtggttggc atattctgtg ccataataaa tggaggctta	2160
cagccagcat tctccgtaat attttcaaaa gttgtagggg tttttacaaa tgggtggcccc	2220
cctgaaaccc agcggcagaa cagcaacttg ttttccttgc tgtttctgat ccttgggatc	2280
atttctttca ttacattttt tcttcagggc ttacatttg gcaaagctgg agagatcctc	2340
accaagcgac tccgatacat ggttttcaaa tccatgctga gacaggatgt gagctggttt	2400
gatgacccta aaaacaccac cggagcactg accaccaggc tcgccaacga tgctgctcaa	2460
gtgaaagggg ctacagggtc taggcttgct gtgattttcc agaacatagc aaatcttggg	2520
acaggaatca tcatatccct aatctatggc tggcaactaa cacttttact cttagcaatt	2580
gtacccatca ttgcgatagc tggagtgggt gaaatgaaaa tgttgtctgg acaagcactg	2640

aaagataaga aggaactaga aggttctgga aagattgcta cggaagcaat tgaaaacttc	2700
cgcactgttg tctctttgac tcgggagcag aagtttgaaa ccatgtatgc ccagagcttg	2760
cagataccat acagaaatgc gatgaagaaa gcacacgtgt ttgggatcac gttctccttc	2820
accaggcca tgatgtattt ttcttatgct gcttgtttcc gggtcgggtgc ctacttgggtg	2880
acacaacaac tcatgacttt tgaaaatggt ctgttagtat tctcagctat tgtctttggt	2940
gccatggcag tggggcaggt cagttcattc gtcctgact atgcgaaagc aacagtgtca	3000
gcatcccaca tcatcaggat cattgagaaa acccccgaga ttgacagcta cagcacgcaa	3060
ggcctaaagc cgaatatggt ggaaggaaat gtgcaattta gtggagtcgt gttcaactat	3120
cccacccgac ccagcatccc agtgcttcag gggctgagcc ttgaggtgaa gaagggccag	3180
acgctggccc tgggtggcag cagtggctgc ggaagagca cagtggcca gctgctcgag	3240
cgttctacg accccatggc tggatcagtg tttctagatg gcaaagaaat aaagcaactg	3300
aatgtccagt ggctccgagc acagctgggc attgtgtccc aagagcccat tctctttgac	3360
tgcagcatcg cagagaacat tgcctacgga gacaacagcc gggtcgtgtc ttatgaggag	3420
attgtgaggg cagccaagga ggccaacatc caccagttca tcgactcgct acctgataaa	3480
tacaacacca gagtaggaga caaaggcact cagctgtcgg gtgggcagaa gcagcgcac	3540
gccatcgcac gcgccctcgt cagacagcct cacattttac ttctggacga agcaacatca	3600
gctctggata cagaaagtga aaaggttgtc caggaagcgc tggacaaagc caggggaaggc	3660
cgcacctgca ttgtgatcgc tcaccgctg tccaccatcc agaacgcgga cttgatcgtg	3720
gtgattcaga acggcaaggt caaggagcac ggcacccacc agcagctgct ggcgcagaag	3780
ggcatctact tctcaatggt cagtgtgcag gctggagcaa agcgtcatg aactgtgacc	3840
atgtaagatg ttaagtattt ttattgtttg tattcatata tgggtgttta tccaagtcaa	3900
aaggaaaaca cttactaaaa tagccagtta tctattttct gccacagtgg aaagcattta	3960
gtttggttta gagtcttcag aggctttgta attaaaaaaa caaaaataga tacagcatca	4020
aatggagatt aatgctttta aatgcactat aaaatttata aaagggttaa aagtgaatgt	4080
ttgataatat atacttttat ttatactttc tcatttgtaa ctataactga tttctgctta	4140
acaaattatg tatgtatcaa aaattactga aatgtttgta taaagtatat atagtgaac	4200
tgagcattca tttttttgag ttattttgct caaatgcatg cgaaattata tattgtccca	4260
actgggatat tgtacataat tttagccttt aaaaaacagt ccattactgg ggggaggggg	4320
catcactcta tgggcaaagt gttactcaga catgggcacc tgagttcaga tccctaccac	4380
ctaagtaagc agacaagggtg tgggtgttttt gtaatgccag tgctagaggc agaaaagaca	4440
gatcctgcag gctcagtggc tggccaaaca gcctagccaa catagcgcgt tccaggttca	4500
gtgagaaaac ttgtctcaa aatcagaggg aaaagcaa at gaggtgtcag ccatgtgcac	4560
tcatgcaaat gccatacatg cagaagtatg tgcacacaca cgcacacatt aaccaacgac	4620

tagcaaggaa aatgaaggtg gataagaggg gtgggactgg gacaaaggag ggtacctgga 4680
 tgaatatgac tgaaggacgt tatgtacaca tatgaaaacg tcgtactgaa actcactaca 4740
 atgtatactt aatatattgc taataaaata ttttttaaag aaaaaaat 4788

<210> 8 <211> 1276 <212> PRT <213> Mus musculus <400> 8

Met Glu Leu Glu Glu Asp Leu Lys Gly Arg Ala Asp Lys Asn Phe Ser
 1 5 10 15
 Lys Met Gly Lys Lys Ser Lys Lys Glu Lys Lys Glu Lys Lys Pro Ala
 20 25 30
 Val Ser Val Leu Thr Met Phe Arg Tyr Ala Gly Trp Leu Asp Arg Leu
 35 40 45
 Tyr Met Leu Val Gly Thr Leu Ala Ala Ile Ile His Gly Val Ala Leu
 50 55 60
 Pro Leu Met Met Leu Ile Phe Gly Asp Met Thr Asp Ser Phe Ala Ser
 65 70 75 80
 Val Gly Asn Val Ser Lys Asn Ser Thr Asn Met Ser Glu Ala Asp Lys
 85 90 95
 Arg Ala Met Phe Ala Lys Leu Glu Glu Glu Met Thr Thr Tyr Ala Tyr
 100 105 110
 Tyr Tyr Thr Gly Ile Gly Ala Gly Val Leu Ile Val Ala Tyr Ile Gln
 115 120 125
 Val Ser Phe Trp Cys Leu Ala Ala Gly Arg Gln Ile His Lys Ile Arg
 130 135 140
 Gln Lys Phe Phe His Ala Ile Met Asn Gln Glu Ile Gly Trp Phe Asp
 145 150 155 160
 Val His Asp Val Gly Glu Leu Asn Thr Arg Leu Thr Asp Asp Val Ser
 165 170 175
 Lys Ile Asn Glu Gly Ile Gly Asp Lys Ile Gly Met Phe Phe Gln Ala
 180 185 190
 Met Ala Thr Phe Phe Gly Gly Phe Ile Ile Gly Phe Thr Arg Gly Trp
 195 200 205
 Lys Leu Thr Leu Val Ile Leu Ala Ile Ser Pro Val Leu Gly Leu Ser
 210 215 220
 Ala Gly Ile Trp Ala Lys Ile Leu Ser Ser Phe Thr Asp Lys Glu Leu
 225 230 235 240
 His Ala Tyr Ala Lys Ala Gly Ala Val Ala Glu Glu Val Leu Ala Ala
 245 250 255
 Ile Arg Thr Val Ile Ala Phe Gly Gly Gln Lys Lys Glu Leu Glu Arg
 260 265 270
 Tyr Asn Asn Asn Leu Glu Glu Ala Lys Arg Leu Gly Ile Lys Lys Ala
 275 280 285
 Ile Thr Ala Asn Ile Ser Met Gly Ala Ala Phe Leu Leu Ile Tyr Ala
 290 295 300

Ser Tyr Ala Leu Ala Phe Trp Tyr Gly Thr Ser Leu Val Ile Ser Lys
 305 310 315 320
 Glu Tyr Ser Ile Gly Gln Val Leu Thr Val Phe Phe Ser Val Leu Ile
 325 330 335
 Gly Ala Phe Ser Val Gly Gln Ala Ser Pro Asn Ile Glu Ala Phe Ala
 340 345 350
 Asn Ala Arg Gly Ala Ala Tyr Glu Val Phe Lys Ile Ile Asp Asn Lys
 355 360 365
 Pro Ser Ile Asp Ser Phe Ser Lys Ser Gly His Lys Pro Asp Asn Ile
 370 375 380
 Gln Gly Asn Leu Glu Phe Lys Asn Ile His Phe Ser Tyr Pro Ser Arg
 385 390 395 400
 Lys Glu Val Gln Ile Leu Lys Gly Leu Asn Leu Lys Val Lys Ser Gly
 405 410 415
 Gln Thr Val Ala Leu Val Gly Asn Ser Gly Cys Gly Lys Ser Thr Thr
 420 425 430
 Val Gln Leu Met Gln Arg Leu Tyr Asp Pro Leu Asp Gly Met Val Ser
 435 440 445
 Ile Asp Gly Gln Asp Ile Arg Thr Ile Asn Val Arg Tyr Leu Arg Glu
 450 455 460
 Ile Ile Gly Val Val Ser Gln Glu Pro Val Leu Phe Ala Thr Thr Ile
 465 470 475 480
 Ala Glu Asn Ile Arg Tyr Gly Arg Glu Asp Val Thr Met Asp Glu Ile
 485 490 495
 Glu Lys Ala Val Lys Glu Ala Asn Ala Tyr Asp Phe Ile Met Lys Leu
 500 505 510
 Pro His Gln Phe Asp Thr Leu Val Gly Glu Arg Gly Ala His Val Ser
 515 520 525
 Gly Gly Gln Lys Gln Arg Ile Ala Ile Ala Arg Ala Leu Val Arg Asn
 530 535 540
 Pro Lys Ile Leu Leu Leu Asp Glu Ala Thr Ser Ala Leu Asp Thr Glu
 545 550 555 560
 Ser Glu Ala Val Val Gln Ala Ala Leu Asp Lys Ala Arg Glu Gly Arg
 565 570 575
 Thr Thr Ile Val Ile Ala His Arg Leu Ser Thr Val Arg Asn Ala Asp
 580 585 590
 Val Ile Ala Gly Phe Asp Gly Gly Val Ile Val Glu Gln Gly Asn His
 595 600 605
 Asp Glu Leu Met Arg Glu Lys Gly Ile Tyr Phe Lys Leu Val Met Thr
 610 615 620
 Gln Thr Ala Gly Asn Glu Ile Glu Leu Gly Asn Glu Ala Cys Lys Ser
 625 630 635 640
 Lys Asp Glu Ile Asp Asn Leu Asp Met Ser Ser Lys Asp Ser Gly Ser
 645 650 655

Ser Leu Ile Arg Arg Arg Ser Thr Arg Lys Ser Ile Cys Gly Pro His
 660 665 670
 Asp Gln Asp Arg Lys Leu Ser Thr Lys Glu Ala Leu Asp Glu Asp Val
 675 680 685
 Pro Pro Ala Ser Phe Trp Arg Ile Leu Lys Leu Asn Ser Thr Glu Trp
 690 695 700
 Pro Tyr Phe Val Val Gly Ile Phe Cys Ala Ile Ile Asn Gly Gly Leu
 705 710 715 720
 Gln Pro Ala Phe Ser Val Ile Phe Ser Lys Val Val Gly Val Phe Thr
 725 730 735
 Asn Gly Gly Pro Pro Glu Thr Gln Arg Gln Asn Ser Asn Leu Phe Ser
 740 745 750
 Leu Leu Phe Leu Ile Leu Gly Ile Ile Ser Phe Ile Thr Phe Phe Leu
 755 760 765
 Gln Gly Phe Thr Phe Gly Lys Ala Gly Glu Ile Leu Thr Lys Arg Leu
 770 775 780
 Arg Tyr Met Val Phe Lys Ser Met Leu Arg Gln Asp Val Ser Trp Phe
 785 790 795 800
 Asp Asp Pro Lys Asn Thr Thr Gly Ala Leu Thr Thr Arg Leu Ala Asn
 805 810 815
 Asp Ala Ala Gln Val Lys Gly Ala Thr Gly Ser Arg Leu Ala Val Ile
 820 825 830
 Phe Gln Asn Ile Ala Asn Leu Gly Thr Gly Ile Ile Ile Ser Leu Ile
 835 840 845
 Tyr Gly Trp Gln Leu Thr Leu Leu Leu Leu Ala Ile Val Pro Ile Ile
 850 855 860
 Ala Ile Ala Gly Val Val Glu Met Lys Met Leu Ser Gly Gln Ala Leu
 865 870 875 880
 Lys Asp Lys Lys Glu Leu Glu Gly Ser Gly Lys Ile Ala Thr Glu Ala
 885 890 895
 Ile Glu Asn Phe Arg Thr Val Val Ser Leu Thr Arg Glu Gln Lys Phe
 900 905 910
 Glu Thr Met Tyr Ala Gln Ser Leu Gln Ile Pro Tyr Arg Asn Ala Met
 915 920 925
 Lys Lys Ala His Val Phe Gly Ile Thr Phe Ser Phe Thr Gln Ala Met
 930 935 940
 Met Tyr Phe Ser Tyr Ala Ala Cys Phe Arg Phe Gly Ala Tyr Leu Val
 945 950 955 960
 Thr Gln Gln Leu Met Thr Phe Glu Asn Val Leu Leu Val Phe Ser Ala
 965 970 975
 Ile Val Phe Gly Ala Met Ala Val Gly Gln Val Ser Ser Phe Ala Pro
 980 985 990
 Asp Tyr Ala Lys Ala Thr Val Ser Ala Ser His Ile Ile Arg Ile Ile
 995 1000 1005

Glu Lys Thr Pro Glu Ile Asp Ser Tyr Ser Thr Gln Gly Leu Lys
 1010 1015 1020
 Pro Asn Met Leu Glu Gly Asn Val Gln Phe Ser Gly Val Val Phe
 1025 1030 1035
 Asn Tyr Pro Thr Arg Pro Ser Ile Pro Val Leu Gln Gly Leu Ser
 1040 1045 1050
 Leu Glu Val Lys Lys Gly Gln Thr Leu Ala Leu Val Gly Ser Ser
 1055 1060 1065
 Gly Cys Gly Lys Ser Thr Val Val Gln Leu Leu Glu Arg Phe Tyr
 1070 1075 1080
 Asp Pro Met Ala Gly Ser Val Phe Leu Asp Gly Lys Glu Ile Lys
 1085 1090 1095
 Gln Leu Asn Val Gln Trp Leu Arg Ala Gln Leu Gly Ile Val Ser
 1100 1105 1110
 Gln Glu Pro Ile Leu Phe Asp Cys Ser Ile Ala Glu Asn Ile Ala
 1115 1120 1125
 Tyr Gly Asp Asn Ser Arg Val Val Ser Tyr Glu Glu Ile Val Arg
 1130 1135 1140
 Ala Ala Lys Glu Ala Asn Ile His Gln Phe Ile Asp Ser Leu Pro
 1145 1150 1155
 Asp Lys Tyr Asn Thr Arg Val Gly Asp Lys Gly Thr Gln Leu Ser
 1160 1165 1170
 Gly Gly Gln Lys Gln Arg Ile Ala Ile Ala Arg Ala Leu Val Arg
 1175 1180 1185
 Gln Pro His Ile Leu Leu Leu Asp Glu Ala Thr Ser Ala Leu Asp
 1190 1195 1200
 Thr Glu Ser Glu Lys Val Val Gln Glu Ala Leu Asp Lys Ala Arg
 1205 1210 1215
 Glu Gly Arg Thr Cys Ile Val Ile Ala His Arg Leu Ser Thr Ile
 1220 1225 1230
 Gln Asn Ala Asp Leu Ile Val Val Ile Gln Asn Gly Lys Val Lys
 1235 1240 1245
 Glu His Gly Thr His Gln Gln Leu Leu Ala Gln Lys Gly Ile Tyr
 1250 1255 1260
 Phe Ser Met Val Ser Val Gln Ala Gly Ala Lys Arg Ser
 1265 1270 1275

<210> 9 <211> 2719 <212> DNA <213> Homo sapiens <400> 9
 ttttaggaacg caccgtgcac atgcttggtg gtcttggttaa gtggaaactg ctgctttaga 60
 gtttggttgg aaggtccggg tgactcatcc caacatttac atccttaatt gttaaagcgc 120
 tgcctccgag cgcacgcac ctgagatcct gagccttttg ttaagaccga gctctattaa 180
 gctgaaaaga taaaaactct ccagatgtct tccagtaatg tcgaagtttt tatcccagtg 240
 tcacaaggaa acaccaatgg cttccccgcg acagtttcca atgacctgaa ggcatttact 300
 gaaggagctg tgtaagtttt tcataacatc tgctatcgag taaaactgaa gagtggcttt 360

ctaccttgctc gaaaaccagt tgagaaagaa atattatcga atatcaatgg gatcatgaaa	420
cctgggtctca acgccatcct gggacccaca ggtggaggca aatcttcgtt attagatgctc	480
ttagctgcaa ggaaagatcc aagtggatta tctggagatg ttctgataaa tggagcaccg	540
cgacctgccca atttcaaatg taattcaggt tacgtgggtac aagatgatgt tgtgatgggc	600
actctgacgg tgagagaaaa cttacagttc tcagcagctc ttcggcttgc aacaactatg	660
acgaatcatg aaaaaaacga acggattaac agggtcattg aagagttagg tctggataaa	720
gtggcagact ccaaggtttg aactcagttt atccgtgggtg tgtctggagg agaaagaaaa	780
aggactagta taggaatgga gcttatcact gatccttcca tcttgctcctt ggatgagcct	840
acaactggct tagactcaag cacagcaa at gctgtccttt tgcctctgaa aaggatgtct	900
aagcagggac gaacaatcat cttctccatt catcagcctc gatattccat cttcaagttg	960
tttgatagcc tcaccttatt ggctcagga agacttatgt tccacggggc tgctcaggag	1020
gccttgggat actttgaatc agctggttat cactgtgagg cctataataa ccctgcagac	1080
ttcttcttgg acatcattaa tggagattcc actgctgtgg cattaaacag agaagaagac	1140
tttaaagcca cagagatcat agagccttcc aagcaggata agccactcat agaaaaatta	1200
gcgagatgtt atgtcaactc ctcttctac aaagagacaa aagctgaatt acatcaactt	1260
tccgggggtg agaagaagaa gaagatcaca gtcttcaagg agatcagcta caccacctcc	1320
ttctgtcatc aactcagatg ggtttccaag cgttcattca aaaacttgct gggtaatccc	1380
caggcctcta tagctcagat cattgtcaca gtcgtactgg gactggttat aggtgccatt	1440
tactttgggc taaaaaatga ttctactgga atccagaaca gagctggggg tctcttcttc	1500
ctgacgacca accagtgttt cagcagtgtt tcagccgtgg aactctttgt ggtagagaag	1560
aagctcttca tacatgaata catcagcgga tactacagag tgtcatctta tttccttgga	1620
aaactgttat ctgatttatt acccatgagg atgttaccaa gtattatatt tacctgtata	1680
gtgtacttca tgttaggatt gaagccaaag gcagatgcct tcttcgttat gatgtttacc	1740
cttatgatgg tggcttattc agccagttcc atggcactgg ccatagcagc aggtcagagt	1800
gtgggttctg tagcaacact tctcatgacc atctgttttg tgtttatgat gattttttca	1860
gggtctgttg tcaatctcac aaccattgca tcttggctgt catggcttca gtacttcagc	1920
attccacgat atggatttac ggctttgcag cataatgaat ttttgggaca aaacttctgc	1980
ccaggactca atgcaacagg aaacaatcct tgtaactatg caacatgtac tggcgaagaa	2040
tatttggtaa agcagggcat cgatctctca ccctggggct tgtggaagaa tcacgtggcc	2100
ttggcttgta tgattgttat tttcctcaca attgcctacc tgaaattggt atttcttaaa	2160
aaatattctt aaatttcccc ttaattcagt atgatttatc ctcacataaa aaagaagcac	2220
tttgattgaa gtattcaatc aagttttttt gttgttttct gttcccttgc catcacactg	2280
ttgcacagca gcaattgttt taaagagata cattttttaga aatcacaaca aactgaatta	2340

aacatgaaag aacccaagac atcatgtatc gcatattagt taatctcctc agacagtaac 2400
 catggggaag aaatctgggc taatttatta atctaaaaaa ggagaattga attctggaaa 2460
 ctctgacaa gttattactg tctctggcat ttgtttcctc atctttaaaa tgaataggta 2520
 ggtagtagc ccttcagtct taatacttta tgatgctatg gtttgccatt atttaataata 2580
 tgacaaatgt attaattgcta tactggaaat gtaaaattga aaatatgttg gaaaaaagat 2640
 tctgtcttat agggtaaaaa aagccaccgg tgatagaaaa aaaatctttt tgataagcac 2700
 attaaagtta atagaactt 2719

<210> 10 <211> 655 <212> PRT <213> Homo sapien <400> 10

Met Ser Ser Ser Asn Val Glu Val Phe Ile Pro Val Ser Gln Gly Asn
1 5 10 15

Thr Asn Gly Phe Pro Ala Thr Val Ser Asn Asp Leu Lys Ala Phe Thr
20 25 30

Glu Gly Ala Val Leu Ser Phe His Asn Ile Cys Tyr Arg Val Lys Leu
35 40 45

Lys Ser Gly Phe Leu Pro Cys Arg Lys Pro Val Glu Lys Glu Ile Leu
50 55 60

Ser Asn Ile Asn Gly Ile Met Lys Pro Gly Leu Asn Ala Ile Leu Gly
65 70 75 80

Pro Thr Gly Gly Gly Lys Ser Ser Leu Leu Asp Val Leu Ala Ala Arg
85 90 95

Lys Asp Pro Ser Gly Leu Ser Gly Asp Val Leu Ile Asn Gly Ala Pro
100 105 110

Arg Pro Ala Asn Phe Lys Cys Asn Ser Gly Tyr Val Val Gln Asp Asp
115 120 125

Val Val Met Gly Thr Leu Thr Val Arg Glu Asn Leu Gln Phe Ser Ala
130 135 140

Ala Leu Arg Leu Ala Thr Thr Met Thr Asn His Glu Lys Asn Glu Arg
145 150 155 160

Ile Asn Arg Val Ile Glu Glu Leu Gly Leu Asp Lys Val Ala Asp Ser
165 170 175

Lys Val Gly Thr Gln Phe Ile Arg Gly Val Ser Gly Gly Glu Arg Lys
180 185 190

Arg Thr Ser Ile Gly Met Glu Leu Ile Thr Asp Pro Ser Ile Leu Ser
195 200 205

Leu Asp Glu Pro Thr Thr Gly Leu Asp Ser Ser Thr Ala Asn Ala Val
210 215 220

Leu Leu Leu Leu Lys Arg Met Ser Lys Gln Gly Arg Thr Ile Ile Phe
225 230 235 240

Ser Ile His Gln Pro Arg Tyr Ser Ile Phe Lys Leu Phe Asp Ser Leu
245 250 255

Thr Leu Leu Ala Ser Gly Arg Leu Met Phe His Gly Pro Ala Gln Glu
 260 265 270
 Ala Leu Gly Tyr Phe Glu Ser Ala Gly Tyr His Cys Glu Ala Tyr Asn
 275 280 285
 Asn Pro Ala Asp Phe Phe Leu Asp Ile Ile Asn Gly Asp Ser Thr Ala
 290 295 300
 Val Ala Leu Asn Arg Glu Glu Asp Phe Lys Ala Thr Glu Ile Ile Glu
 305 310 315 320
 Pro Ser Lys Gln Asp Lys Pro Leu Ile Glu Lys Leu Ala Glu Ile Tyr
 325 330 335
 Val Asn Ser Ser Phe Tyr Lys Glu Thr Lys Ala Glu Leu His Gln Leu
 340 345 350
 Ser Gly Gly Glu Lys Lys Lys Lys Ile Thr Val Phe Lys Glu Ile Ser
 355 360 365
 Tyr Thr Thr Ser Phe Cys His Gln Leu Arg Trp Val Ser Lys Arg Ser
 370 375 380
 Phe Lys Asn Leu Leu Gly Asn Pro Gln Ala Ser Ile Ala Gln Ile Ile
 385 390 395 400
 Val Thr Val Val Leu Gly Leu Val Ile Gly Ala Ile Tyr Phe Gly Leu
 405 410 415
 Lys Asn Asp Ser Thr Gly Ile Gln Asn Arg Ala Gly Val Leu Phe Phe
 420 425 430
 Leu Thr Thr Asn Gln Cys Phe Ser Ser Val Ser Ala Val Glu Leu Phe
 435 440 445
 Val Val Glu Lys Lys Leu Phe Ile His Glu Tyr Ile Ser Gly Tyr Tyr
 450 455 460
 Arg Val Ser Ser Tyr Phe Leu Gly Lys Leu Leu Ser Asp Leu Leu Pro
 465 470 475 480
 Met Arg Met Leu Pro Ser Ile Ile Phe Thr Cys Ile Val Tyr Phe Met
 485 490 495
 Leu Gly Leu Lys Pro Lys Ala Asp Ala Phe Phe Val Met Met Phe Thr
 500 505 510
 Leu Met Met Val Ala Tyr Ser Ala Ser Ser Met Ala Leu Ala Ile Ala
 515 520 525
 Ala Gly Gln Ser Val Val Ser Val Ala Thr Leu Leu Met Thr Ile Cys
 530 535 540
 Phe Val Phe Met Met Ile Phe Ser Gly Leu Leu Val Asn Leu Thr Thr
 545 550 555 560
 Ile Ala Ser Trp Leu Ser Trp Leu Gln Tyr Phe Ser Ile Pro Arg Tyr
 565 570 575
 Gly Phe Thr Ala Leu Gln His Asn Glu Phe Leu Gly Gln Asn Phe Cys
 580 585 590
 Pro Gly Leu Asn Ala Thr Gly Asn Asn Pro Cys Asn Tyr Ala Thr Cys
 595 600 605

Thr Gly Glu Glu Tyr Leu Val Lys Gln Gly Ile Asp Leu Ser Pro Trp
610 615 620

Gly Leu Trp Lys Asn His Val Ala Leu Ala Cys Met Ile Val Ile Phe
625 630 635 640

Leu Thr Ile Ala Tyr Leu Lys Leu Leu Phe Leu Lys Lys Tyr Ser
645 650 655

<210> 11 <211> 502 <212> DNA <213> Mus musculus <400> 11
ttcggcctag gggccgaggc ttatacggcc agttccatgg cactggccat agccacaggc 60
caaagtgtgg tgtctgtagc aacactactc atgacaatcg cttttgtatt tatgatgctc 120
ttttctggcc tcttgggtgaa tctcagaacc attgggcctt ggctgtcctg gcttcagtac 180
tttagcattc ctcgatatgg cttcacagct ttgcagtata atgaattctt gggacaagag 240
ttttgtccag gattcaatgt aacggacaac agcacttgtg ttaacagcta tgcaatatgt 300
actggtaacg agtacttgat aaatcagggc atcgaactgt caccttgggg actgtggaag 360
aatcatgtgg ccctggcttg tatgattatt atcttcctca caattgccta cctgaaattg 420
ttgtttctta aaaagtattc ttaatttccc ctttaacgga ctattaattg tactccaatt 480
aaatatgggc actttgatta cc 502

<210> 12 <211> 147 <212> PRT <213> Mus musculus <400> 12
Phe Gly Leu Gly Ala Glu Ala Tyr Thr Ala Ser Ser Met Ala Leu Ala
1 5 10 15
Ile Ala Thr Gly Gln Ser Val Val Ser Val Ala Thr Leu Leu Met Thr
20 25 30
Ile Ala Phe Val Phe Met Met Leu Phe Ser Gly Leu Leu Val Asn Leu
35 40 45
Arg Thr Ile Gly Pro Trp Leu Ser Trp Leu Gln Tyr Phe Ser Ile Pro
50 55 60
Arg Tyr Gly Phe Thr Ala Leu Gln Tyr Asn Glu Phe Leu Gly Gln Glu
65 70 75 80
Phe Cys Pro Gly Phe Asn Val Thr Asp Asn Ser Thr Cys Val Asn Ser
85 90 95
Tyr Ala Ile Cys Thr Gly Asn Glu Tyr Leu Ile Asn Gln Gly Ile Glu
100 105 110
Leu Ser Pro Trp Gly Leu Trp Lys Asn His Val Ala Leu Ala Cys Met
115 120 125
Ile Ile Ile Phe Leu Thr Ile Ala Tyr Leu Lys Leu Leu Phe Leu Lys
130 135 140
Lys Tyr Ser
145

<210> 13 <211> 2025 <212> DNA <213> Mus musculus <400> 13
aaaggcataa atcctaaaga tgtcttccag taatgaccac gtgtagtac caatgtcgca 60
gagaaacaac aacggccttc ctaggatgaa ctccagagcc gtaggacgc tcgcagaagg 120

```

agatgtgttg agttttcatc acatcaccta tcgagtgaag gtaaagagtg ggtttctagt 180
ccggaaaaca gttgagaaag aaatactatc agatatcaat gggatcatga aacctggcct 240
taatgctatt ctgggaccca caggcgagg caagtcttcg ttgctagatg tcttagcagc 300
aaggaaagat ccaaagggat tatctggaga tgttttgata aatggagcac ctcaacctgc 360
ccatttcaaa tgctgttcag gttatgtggt tcaagatgac gttgtgatgg gcaccctgac 420
agtgaagaaa aacttacagt tctcagcagc tcttcgactt ccaacaacta tgaagaatca 480
tgaaaaaaat gaacggatta acacaatcat taaagagtta ggtctggaaa aagtagcaga 540
ttctaaggtc ggaactcagt ttatccgtgg catctctgga ggagaaagaa aaaggacaag 600
catagggatg gagctgatca ctgacccttc catcctcttc ctggatgagc ccacgactgg 660
tttgactca agcacagcga atgctgtcct ttgctcctg aaaaggatgt ctaaacaggg 720
tcgaacaatc atcttctcca ttcatcagcc tcggtattcc atctttaagt tgtttgacag 780
cctcacctta ctggcttccg ggaaactcgt gttccatggg ccagcacaga aggccttgga 840
gtactttgca tcagcagggt accactgtga gccctacaac aacctgcgg attttttctt 900
tgatgtcatc aatggagatt cttctgctgt gatgttaaat agagaggaac aagacaatga 960
agcaaacaag actgaagagc cttccaaggg agagaagcca gtaatagaaa atttatctga 1020
gttttatatc aactctgcca tctatggaga aacaaaagct gaattagatc aacttccagg 1080
agctcaggaa aagaaaggaa catcggcctt caaagagcca gtctatgtta cctctttctg 1140
tcaccagctc cgatggattg ccaggcgctc atttaaaac ttgctcggga accctcaagc 1200
ttctgttgct cagttaattg ttacagtcac actggggctt attattggtg ccatttactt 1260
tgatctgaaa tatgatgccg ctggaatgca aaatagagct ggagttttgt ttttcctgac 1320
taccaaccag tgtttttcca gtgtgtcagc tgtggagctg ttcgtagtgg agaagaaact 1380
cttcatacat gagtacatca gtggatatta cagagtgtct tcttacttct ttggaaagg 1440
gatgtctgat ttactcccca tgaggttctt gccaaagtgt atattcactt gtatattata 1500
cttcatgtta ggactgaaga agacgggtga tgcttttttc atcatgatgt ttacccttat 1560
aatggtggct tatacggcca gttccatggc actggccata gccacaggcc aaagtgtggt 1620
gtctgtagca acacttctca tgacaatcgc ttttgtatct atgatgtct tttctggcct 1680
cttgggtgaat ctcaagaacca ttgggccttg gctgtcctgg cttcagtact ttagcattcc 1740
tcgatatggc ttcacagctt tgcagtataa tgaattcttg ggacaagagt tttgtccagg 1800
attcaatgta acggacaaca gcaattgtgt taacagctat gcaatatgta ctggtaacga 1860
gtacttgata aatcagggca tcgaactgtc accttgggga ctgtggaaga atcatgtggc 1920
cctggcttgt atgattatta tcttcctcac aattgcctac ctgaaattgt tgtttcttaa 1980
aaagtattct taatttcccc tttaacggac tattaattgt actcc 2025

```

Met	Ser	Ser	Ser	Asn	Asp	His	Val	Leu	Val	Pro	Met	Ser	Gln	Arg	Asn	
1				5					10					15		
Asn	Asn	Gly	Leu	Pro	Arg	Met	Asn	Ser	Arg	Ala	Val	Arg	Thr	Leu	Ala	
		20						25					30			
Glu	Gly	Asp	Val	Leu	Ser	Phe	His	His	Ile	Thr	Tyr	Arg	Val	Lys	Val	
		35					40					45				
Lys	Ser	Gly	Phe	Leu	Val	Arg	Lys	Thr	Val	Glu	Lys	Glu	Ile	Leu	Ser	
	50					55					60					
Asp	Ile	Asn	Gly	Ile	Met	Lys	Pro	Gly	Leu	Asn	Ala	Ile	Leu	Gly	Pro	
65					70					75					80	
Thr	Gly	Gly	Gly	Lys	Ser	Ser	Leu	Leu	Asp	Val	Leu	Ala	Ala	Arg	Lys	
				85					90					95		
Asp	Pro	Lys	Gly	Leu	Ser	Gly	Asp	Val	Leu	Ile	Asn	Gly	Ala	Pro	Gln	
		100						105					110			
Pro	Ala	His	Phe	Lys	Cys	Cys	Ser	Gly	Tyr	Val	Val	Gln	Asp	Asp	Val	
		115					120					125				
Val	Met	Gly	Thr	Leu	Thr	Val	Arg	Glu	Asn	Leu	Gln	Phe	Ser	Ala	Ala	
	130					135					140					
Leu	Arg	Leu	Pro	Thr	Thr	Met	Lys	Asn	His	Glu	Lys	Asn	Glu	Arg	Ile	
145					150					155					160	
Asn	Thr	Ile	Ile	Lys	Glu	Leu	Gly	Leu	Glu	Lys	Val	Ala	Asp	Ser	Lys	
				165					170					175		
Val	Gly	Thr	Gln	Phe	Ile	Arg	Gly	Ile	Ser	Gly	Gly	Glu	Arg	Lys	Arg	
		180						185					190			
Thr	Ser	Ile	Gly	Met	Glu	Leu	Ile	Thr	Asp	Pro	Ser	Ile	Leu	Phe	Leu	
		195					200					205				
Asp	Glu	Pro	Thr	Thr	Gly	Leu	Asp	Ser	Ser	Thr	Ala	Asn	Ala	Val	Leu	
	210					215					220					
Leu	Leu	Leu	Lys	Arg	Met	Ser	Lys	Gln	Gly	Arg	Thr	Ile	Ile	Phe	Ser	
225					230					235					240	
Ile	His	Gln	Pro	Arg	Tyr	Ser	Ile	Phe	Lys	Leu	Phe	Asp	Ser	Leu	Thr	
				245					250					255		
Leu	Leu	Ala	Ser	Gly	Lys	Leu	Val	Phe	His	Gly	Pro	Ala	Gln	Lys	Ala	
		260						265					270			
Leu	Glu	Tyr	Phe	Ala	Ser	Ala	Gly	Tyr	His	Cys	Glu	Pro	Tyr	Asn	Asn	
		275					280					285				
Pro	Ala	Asp	Phe	Phe	Leu	Asp	Val	Ile	Asn	Gly	Asp	Ser	Ser	Ala	Val	
	290					295					300					
Met	Leu	Asn	Arg	Glu	Glu	Gln	Asp	Asn	Glu	Ala	Asn	Lys	Thr	Glu	Glu	
305					310					315					320	
Pro	Ser	Lys	Gly	Glu	Lys	Pro	Val	Ile	Glu	Asn	Leu	Ser	Glu	Phe	Tyr	
				325					330					335		
Ile	Asn	Ser	Ala	Ile	Tyr	Gly	Glu	Thr	Lys	Ala	Glu	Leu	Asp	Gln	Leu	
			340					345					350			

Pro Gly Ala Gln Glu Lys Lys Gly Thr Ser Ala Phe Lys Glu Pro Val
 355 360 365
 Tyr Val Thr Ser Phe Cys His Gln Leu Arg Trp Ile Ala Arg Arg Ser
 370 375 380
 Phe Lys Asn Leu Leu Gly Asn Pro Gln Ala Ser Val Ala Gln Leu Ile
 385 390 395 400
 Val Thr Val Ile Leu Gly Leu Ile Ile Gly Ala Ile Tyr Phe Asp Leu
 405 410 415
 Lys Tyr Asp Ala Ala Gly Met Gln Asn Arg Ala Gly Val Leu Phe Phe
 420 425 430
 Leu Thr Thr Asn Gln Cys Phe Ser Ser Val Ser Ala Val Glu Leu Phe
 435 440 445
 Val Val Glu Lys Lys Leu Phe Ile His Glu Tyr Ile Ser Gly Tyr Tyr
 450 455 460
 Arg Val Ser Ser Tyr Phe Phe Gly Lys Val Met Ser Asp Leu Leu Pro
 465 470 475 480
 Met Arg Phe Leu Pro Ser Val Ile Phe Thr Cys Ile Leu Tyr Phe Met
 485 490 495
 Leu Gly Leu Lys Lys Thr Val Asp Ala Phe Phe Ile Met Met Phe Thr
 500 505 510
 Leu Ile Met Val Ala Tyr Thr Ala Ser Ser Met Ala Leu Ala Ile Ala
 515 520 525
 Thr Gly Gln Ser Val Val Ser Val Ala Thr Leu Leu Met Thr Ile Ala
 530 535 540
 Phe Val Phe Met Met Leu Phe Ser Gly Leu Leu Val Asn Leu Arg Thr
 545 550 555 560
 Ile Gly Pro Trp Leu Ser Trp Leu Gln Tyr Phe Ser Ile Pro Arg Tyr
 565 570 575
 Gly Phe Thr Ala Leu Gln Tyr Asn Glu Phe Leu Gly Gln Glu Phe Cys
 580 585 590
 Pro Gly Phe Asn Val Thr Asp Asn Ser Thr Cys Val Asn Ser Tyr Ala
 595 600 605
 Ile Cys Thr Gly Asn Glu Tyr Leu Ile Asn Gln Gly Ile Glu Leu Ser
 610 615 620
 Pro Trp Gly Leu Trp Lys Asn His Val Ala Leu Ala Cys Met Ile Ile
 625 630 635 640
 Ile Phe Leu Thr Ile Ala Tyr Leu Lys Leu Leu Phe Leu Lys Lys Tyr
 645 650 655
 Ser

<210> 15 <211> 20 <212> DNA <213> Artificial <220> <223> primer

<400> 15
 ccacgtcagc cttggacaca

<210> 16 <211> 20 <212> DNA <213> Artificial <220> <223> primer
 <400> 16
 gccgcttggg gaggatctct 20

<210> 17 <211> 20 <212> DNA <213> Artificial <220> <223> primer
 <400> 17
 ccatagccac aggccaaagt 20

<210> 18 <211> 20 <212> DNA <213> Artificial <220> <223> primer
 <400> 18
 gggccacatg attcttccac 20

<210> 19 <211> 20 <212> DNA <213> Artificial <220> <223> primer
 <400> 19
 ggcctcagga agacttatgt 20

<210> 20 <211> 20 <212> DNA <213> Artificial <220> <223> primer
 <400> 20
 aaggaggtgg tgtagctgat 20

<210> 21 <211> 19 <212> DNA <213> Artificial <220> <223> primer
 <400> 21
 agctggagag atcctcacc 19

<210> 22 <211> 19 <212> DNA <213> Artificial <220> <223> primer
 <400> 22
 agccggagag atcctcacc 19

<210> 23 <211> 20 <212> DNA <213> artificial <220> <223> primer
 <400> 23
 ctgtagctgt caatctcggg 20

<210> 24 <211> 20 <212> DNA <213> Artificial <220> <223> primer
 <400> 24
 ctgtagctgt caatctcagg 20

<210> 25 <211> 20 <212> DNA <213> Artificial <220> <223> primer
 <400> 25
 ctgtagctgt caatcagagg 20

<210> 26 <211> 2247 <212> DNA <213> Homo sapiens <400> 26
 accgtgcaca tgcttgggtg tcttgtaag tggaaactgc tgcttttagag tttgtttgga 60
 aggtccgggt gactcatccc aacatttaca tccttaattg ttaaagcgct gcctccgagc 120

gcacgcatcc tgagatcctg agcctttggt taagaccgag ctctattaag ctgaaaagat	180
aaaaactctc cagatgtctt ccagtaatgt cgaagttttt atcccagtggt cacaaggaaa	240
caccaatggc ttccccgcga cagcttccaa tgacctgaag gcattttactg aaggagctgt	300
gttaagtttt cataacatct gctatcgagt aaaactgaag agtggctttc taccttgtcg	360
aaaaccagtt gagaaagaaa tattatcgaa tatcaatggg atcatgaaac ctggtctcaa	420
cgccatcctg ggaccacag gtggaggcaa atcttcgtta ttagatgtct tagctgcaag	480
gaaagatcca agtggattat ctggagatgt tctgataaat ggagcaccgc gacctgccaa	540
tttcaaagtgt aattcagggtt acgtgggtaca agatgatggt gtgatgggca ctctgacggt	600
gagagaaaac ttacagttct cagcagctct tcggcttgca acaactatga cgaatcatga	660
aaaaaacgaa cggattaaca gggtcattca agagttaggt ctggataaag tggcagactc	720
caaggttgga actcagttta tccgtgggtgt gtctggagga gaaagaaaaa ggactagtat	780
aggaatggag cttatcactg atccttccat cttgttcttg gatgagccta caactggctt	840
agactcaagc acagcaaag ctgtcctttt gctcctgaaa aggatgtcta agcagggacg	900
aacaatcatc ttctccattc atcagcctcg atattccatc ttcaagttgt ttgatagcct	960
caccttattg gcctcaggaa gacttatggt ccacgggcct gctcaggagg ccttgggata	1020
ctttgaatca gctggttatc actgtgaggc ctataataac cctgcagact tcttcttgga	1080
catcattaat ggagattcca ctgctgtggc attaaacaga gaagaagact ttaaagccac	1140
agagatcata gagccttcca agcaggataa gccactcata gaaaaattag cggagattta	1200
tgtcaactcc tccttctaca aagagacaaa agctgaatta catcaacttt ccgggggtga	1260
gaagaagaag aagatcacag tcttcaagga gatcagctac accacctcct tctgtcatca	1320
actcagatgg gtttccaagc gttcattcaa aaacttgctg ggtaatcccc aggctctat	1380
agctcagatc attgtcacag tcgtactggg actggttata ggtgccattt actttgggct	1440
aaaaaatgat tctactggaa tccagaacag agctgggggt ctcttcttcc tgacgaccaa	1500
ccagtgtttc agcagtgttt cagccgtgga actctttgtg gtagagaaga agctcttcat	1560
acatgaatac atcagcggat actacagagt gtcattctat ttcccttgga aactgttatc	1620
tgatttatta cccatgagga tgttaccaag tattatattt acctgtatag tgtacttcat	1680
gttaggattg aaggcaaagg cagatgcctt cttcgttatg atgtttacc ttatgatggt	1740
ggcttattca gccagttcca tggcactggc catagcagca ggtcagagtg tggtttctgt	1800
agcaaacatt ctcatgacca tctgttttgt gtttatgatg attttttcag gtctgttggt	1860
caatctcaca accattgcat cttggctgtc atggcttcag tacttcagca ttccacgata	1920
tggatttacg gctttgcagc ataataaatt tttgggacaa aacttctgcc caggactcaa	1980
tgcaacagga aacaatcctt gtaactatgc aacatgtact ggcaagaat atttggtaaa	2040
gcagggcac gatctctcac cctggggctt gtggaagaat cacgtggcct tggcttgtat	2100

gattgttatt ttcctcaciaa ttgcctacct gaaattgtta tttcttaaaa aatattctta 2160
aatttcccct taattcagta tgatttatcc tcacataaaaa aagaagcact ttgattgaag 2220
tattcaaaaa aaaaaaaaaa aaaaaaa 2247

<210> 27 <211> 655 <212> PRT <213> Homo sapien <400> 27

Met Ser Ser Ser Asn Val Glu Val Phe Ile Pro Val Ser Gln Gly Asn
1 5 10 15

Thr Asn Gly Phe Pro Ala Thr Ala Ser Asn Asp Leu Lys Ala Phe Thr
20 25 30

Glu Gly Ala Val Leu Ser Phe His Asn Ile Cys Tyr Arg Val Lys Leu
35 40 45

Lys Ser Gly Phe Leu Pro Cys Arg Lys Pro Val Glu Lys Glu Ile Leu
50 55 60

Ser Asn Ile Asn Gly Ile Met Lys Pro Gly Leu Asn Ala Ile Leu Gly
65 70 75 80

Pro Thr Gly Gly Gly Lys Ser Ser Leu Leu Asp Val Leu Ala Ala Arg
85 90 95

Lys Asp Pro Ser Gly Leu Ser Gly Asp Val Leu Ile Asn Gly Ala Pro
100 105 110

Arg Pro Ala Asn Phe Lys Cys Asn Ser Gly Tyr Val Val Gln Asp Asp
115 120 125

Val Val Met Gly Thr Leu Thr Val Arg Glu Asn Leu Gln Phe Ser Ala
130 135 140

Ala Leu Arg Leu Ala Thr Thr Met Thr Asn His Glu Lys Asn Glu Arg
145 150 155 160

Ile Asn Arg Val Ile Gln Glu Leu Gly Leu Asp Lys Val Ala Asp Ser
165 170 175

Lys Val Gly Thr Gln Phe Ile Arg Gly Val Ser Gly Gly Glu Arg Lys
180 185 190

Arg Thr Ser Ile Gly Met Glu Leu Ile Thr Asp Pro Ser Ile Leu Phe
195 200 205

Leu Asp Glu Pro Thr Thr Gly Leu Asp Ser Ser Thr Ala Asn Ala Val
210 215 220

Leu Leu Leu Leu Lys Arg Met Ser Lys Gln Gly Arg Thr Ile Ile Phe
225 230 235 240

Ser Ile His Gln Pro Arg Tyr Ser Ile Phe Lys Leu Phe Asp Ser Leu
245 250 255

Thr Leu Leu Ala Ser Gly Arg Leu Met Phe His Gly Pro Ala Gln Glu
260 265 270

Ala Leu Gly Tyr Phe Glu Ser Ala Gly Tyr His Cys Glu Ala Tyr Asn
275 280 285

Asn Pro Ala Asp Phe Phe Leu Asp Ile Ile Asn Gly Asp Ser Thr Ala
290 295 300

Val Ala Leu Asn Arg Glu Glu Asp Phe Lys Ala Thr Glu Ile Ile Glu
 305 310 315 320
 Pro Ser Lys Gln Asp Lys Pro Leu Ile Glu Lys Leu Ala Glu Ile Tyr
 325 330 335
 Val Asn Ser Ser Phe Tyr Lys Glu Thr Lys Ala Glu Leu His Gln Leu
 340 345 350
 Ser Gly Gly Glu Lys Lys Lys Lys Ile Thr Val Phe Lys Glu Ile Ser
 355 360 365
 Tyr Thr Thr Ser Phe Cys His Gln Leu Arg Trp Val Ser Lys Arg Ser
 370 375 380
 Phe Lys Asn Leu Leu Gly Asn Pro Gln Ala Ser Ile Ala Gln Ile Ile
 385 390 395 400
 Val Thr Val Val Leu Gly Leu Val Ile Gly Ala Ile Tyr Phe Gly Leu
 405 410 415
 Lys Asn Asp Ser Thr Gly Ile Gln Asn Arg Ala Gly Val Leu Phe Phe
 420 425 430
 Leu Thr Thr Asn Gln Cys Phe Ser Ser Val Ser Ala Val Glu Leu Phe
 435 440 445
 Val Val Glu Lys Lys Leu Phe Ile His Glu Tyr Ile Ser Gly Tyr Tyr
 450 455 460
 Arg Val Ser Ser Tyr Phe Leu Gly Lys Leu Leu Ser Asp Leu Leu Pro
 465 470 475 480
 Met Arg Met Leu Pro Ser Ile Ile Phe Thr Cys Ile Val Tyr Phe Met
 485 490 495
 Leu Gly Leu Lys Ala Lys Ala Asp Ala Phe Phe Val Met Met Phe Thr
 500 505 510
 Leu Met Met Val Ala Tyr Ser Ala Ser Ser Met Ala Leu Ala Ile Ala
 515 520 525
 Ala Gly Gln Ser Val Val Ser Val Ala Thr Leu Leu Met Thr Ile Cys
 530 535 540
 Phe Val Phe Met Met Ile Phe Ser Gly Leu Leu Val Asn Leu Thr Thr
 545 550 555 560
 Ile Ala Ser Trp Leu Ser Trp Leu Gln Tyr Phe Ser Ile Pro Arg Tyr
 565 570 575
 Gly Phe Thr Ala Leu Gln His Asn Glu Phe Leu Gly Gln Asn Phe Cys
 580 585 590
 Pro Gly Leu Asn Ala Thr Gly Asn Asn Pro Cys Asn Tyr Ala Thr Cys
 595 600 605
 Thr Gly Glu Glu Tyr Leu Val Lys Gln Gly Ile Asp Leu Ser Pro Trp
 610 615 620
 Gly Leu Trp Lys Asn His Val Ala Leu Ala Cys Met Ile Val Ile Phe
 625 630 635 640
 Leu Thr Ile Ala Tyr Leu Lys Leu Leu Phe Leu Lys Lys Tyr Ser
 645 650 655